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Theranostic radiopharmaceuticals enable diagnostic imaging and radionuclide therapy in patients 
using a single molecular agent labeled with a diagnostic-therapeutic pair (e.g., 68Ga/177Lu) or a 
theranostic radionuclide (e.g., 131I). This theranostic approach can help inform patient-specific 
treatment plans and improve clinical outcomes. Radionuclide pairs used in theranostic agents fall 
into two categories: pseudo matched-pairs (e.g., 68Ga/177Lu) and matched-pairs (e.g., 124I/131I). 
Pseudo matched-pair radionuclides have similar chemistries and pharmacokinetics when bound to 
the same bioconjugate molecule. In contrast, identical chemistries and pharmacokinetics can be 
obtained by using the matched-pair radionuclides.  
 The isotopes of Sc include two diagnostic radioisotopes, 43Sc & 44Sc, and one theranostic 
radioisotope, 47Sc, that have nuclear properties well-suited for use with bioconjugate molecules 
that target disease. These novel Sc radioisotopes can be produced using Ca or Ti nuclei; however, 
the optimal route for their production is still being actively investigated. Thus, the aim of this work 
was to investigate the production of 43Sc, 44Sc, and 47Sc using proton- and photon-induced nuclear 
reactions at energies up to 24 MeV on Ti nuclei, the digestion of Ti target material, and the 
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purification of Sc radioisotopes from radioactive and non-radioactive impurities. Additional 
studies were carried out to investigate the in vitro properties of PSMA-617 labeled with these 
radioisotopes. 
 Solid target holders fabricated from Al, Nb, and Ta were designed and tested for use on a 
negative-ion cyclotron and medical electron linear accelerator. These targets mounted metal foil 
and metal oxide materials for irradiation and were tested at varying conditions (beam energy and 
current) to determine their durability and the best parameters for maximizing radionuclide yield. 
These targets were used to experimentally validate the predicted yields from the 
natTi(p,x)43,44g,44m,47Sc, 48Ti(γ,p)47Sc, 46Ti(p,α)43Sc, 47Ti(p,α)44g,44mSc, 48Ti(p,2p)47Sc, and 
50Ti(p,α)47Sc nuclear reactions. Methods to digest Ti foil and TiO2 were developed that combined 
pressure, heat, and the in situ generation of HF in a closed-vessel. The typical digestion times for 
these methods were 45 min (Ti foil) and 75 min (TiO2) and the average digestion efficiencies were 
(98 ± 3)% and (95 ± 1)%, respectively. The purification of aqueous Sc was investigated using three 
cation exchange resins, branched N,N,N’,N’-tetra-2-ethylhexyldiglycolamide (BDGA) and two 
styrene divinylbenzene copolymer lattices functionalized with either sulphonic acid (AG MP-50) 
or iminodiacetic acid (CHELEX 100). Average Sc recoveries of (77 ± 7)% and (94 ± 3)% were 
realized using either a two-step purification (AG MP-50 followed by CHELEX 100) or a single-
step purification using BDGA, respectively. After purification, the concentrations of common 
trace metal contaminants (e.g., Fe, Cu, and Zn) that can interfere with Sc chemistry were 
approximately 1 mg/L or less. Enriched Ti target materials (i.e., 46Ti, 47Ti, 48Ti, and 50Ti) were 
irradiated and recovered via alkali precipitation at pH 8 using ammonia solution as a titrant. 
Recovered precipitant was combusted to regenerate the enriched TiO2 for iterative use. The 
average percent recoveries of Ti from digested natTi foil and natTiO2 collected after precipitation 
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and combustion were (108 ± 8)% and (104 ± 5)%, respectively. High-purity Sc radioisotopes were 
used to label two bioconjugates: DOTATOC and PSMA-617, and the in vitro properties of these 
radiolabeled compounds were investigated using AR42J or LNCaP cells. The radiochemical yield 
of DOTATOC labeled with 47Sc (1.28 mg/mL) was greater than 99.9%. A blocking study with the 
somatostatin receptor subtype 2 (SSTR2) agonist Octreotide showed receptor-mediated uptake of 
[47Sc]Sc-DOTATOC in AR42J (SSTR2+) cells. Similarly, the radiochemical yields of PSMA-617 
labeled with 43Sc and 47Sc were greater than 99.9% at molar activities between 32-74 MBq/nmol. 
The stability of [43Sc/47Sc]Sc-PSMA-617 was greater than 95% at 168 h in PBS, human serum, 
and mouse serum. The percentages of [43Sc/47Sc]Sc-PSMA-617 associated with LNCaP (PSMA+) 
and PC3 (PSMA-) cells after 4 h of incubation at 37 °C were (22 ± 1)% and (0.30 ± 0.01)%, 
respectively. 
 These results demonstrated a robust method for the cyclotron production of Sc radioisotopes 
via proton-induced reactions that could be used with natural or enriched TiO2 target material. In 
turn, DOTATOC and PSMA-617 were labeled with high-purity Sc radioisotopes produced via 
these methods and their in vitro properties were investigated. The strategies developed in this work 
and data from initial studies will be used to support future work to compare the in vitro and in vivo 





Chapter 1: Introduction 
1.1 Research Focus 
The purpose of this research is to investigate the production of different Sc radioisotopes via 
nuclear reactions on titanium targets, the development of different separation techniques to purify 
these radionuclides, the preparation of different radiolabeled bioconjugate molecules, and the in 
vitro properties of these radiolabeled compounds. Ultimately, this research aims to produce 
medically relevant radionuclides, which can be used to diagnose and treat disease. Moreover, as 
no consensus exists on the best route to produce and supply Sc radioisotopes, this research 
developed methods that could be easily adopted for the production of research quantities of high-
purity 43Sc, 44Sc, and 47Sc. 
 The role of radionuclides in medicine, a select history of their development, and the chart of 
nuclides are presented in Section 1.2 to lay a foundation for the importance of this work. The 
different modes of radioactive decay (see Section 1.3) are presented along with a description of 
the techniques used for molecular imaging in nuclear medicine (see Section 1.4). The application 
of targeted radionuclide therapy to treat disease is discussed in Section 1.5. Two examples of 
theranostic agents that combine diagnostic imaging and radionuclide therapy are given in Section 
1.6 to highlight recent successes of this theranostic approach. These successes have motivated 
research directed at developing new methods of production and supply of novel medical 
radionuclides. 
 In Chapter 2, the nuclear properties of different radioisotopes of Sc (see Section 2.1) and V 
(see Section 2.2) are presented. The means and techniques to produce radionuclides are discussed 
in Section 2.4. The production of the radioisotopes of interest investigated in this work is presented 
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in Section 2.5 (Sc radioisotopes) and Section 2.6 (44Ti). The digestion of solid target materials and 
techniques for chemical purification of radionuclides are presented in Section 2.7.  
 Findings from the photonuclear production, purification, and in vitro evaluation of the 
theranostic radionuclide 47Sc (Chapter 3) and the cyclotron production and separation of Sc 
radioisotopes from natTi metal and natTiO2 (Chapter 4) are presented and discussed. Results from 
in vitro studies carried out using Sc radionuclides produced in this work are presented in Chapter 
5. Lastly, opportunities for future work, and a brief concluding summary that details how the 
findings in this work contribute to knowledge pertinent to the production and supply of these 
important Sc radionuclides are outlined in Chapter 6. 
1.2 Radionuclides in Medicine 
High-energy rays from radioactive substances were used as early as 1899 to treat rodent ulcer and 
epithelioma; however, at the time the mechanism of action was unknown.1 The invention of a 
stationary gamma camera (Anger camera) in 1957 and subsequent work in the 1960s and 1970s to 
develop platforms for tomographic imaging laid a foundation for modern nuclear medicine.2, 3 
Today, modern nuclear medicine employs different strategies to deliver radioactive compounds in 
a targeted manner to localized and non-localized disease for treatment or diagnostic imaging.4 In 
the field of theranostics, these two applications are combined such that treatment of disease is 
guided by diagnostic imaging. The production of new radionuclides and study of their nuclear 
properties plays an important role in the development of new radiopharmaceuticals, which are 
becoming increasingly used in personalized medicine.5 This work investigates the production and 





The history of radionuclides in medicine began with the Nobel Laureates Wilhelm Konrad 
Roentgen (Nobel Prize in Physics, 1901)6, Antoine Henri Becquerel, Marie and Pierre Curie 
(Nobel Prize in Physics, 1903)7, and Frédéric Joliot and Iréne Joliot-Curie (Nobel Prize in 
Chemistry, 1935). In particular, the work by Frédéric Joliot and Iréne Joliot-Curie was the first 
demonstration of radionuclides produced via particle-induced reactions.8 Inspired by this work, 
Lauritsen et al. (1934) bombarded LiF, Be, H3BO3, C, Mg and Al with deuterons and reported the 
characteristics of the produced radionuclides.9, 10 Similarly, John Cockcroft and Ernest Walton 
bombarded C, N, and O nuclei using protons (p), deuterons (d), and alpha (α) particles, to produce 
radionuclides, including medically relevant 11C (t1/2 = 20.36 min) and 13N (t1/2 = 9.97 min).11, 12 
The production of artificial radionuclides was further advanced by the work of Ernest Lawrence, 
which included the construction of a series of cyclotrons at the University of California at Berkeley 
capable of delivering different particles of increasing energy and intensity.13, 14 It was these efforts 
that led to the discovery of the element technetium, and 131I (t1/2 = 8.02 d) by Carlo Perrier and 
Emilio Segré (1937) and Glenn Seaborg and John Livingood (1938), respectively. 15-17 Today, 
99mTc (t1/2 = 6.01 h) is the most widely used diagnostic radionuclide in nuclear medicine and 131I, 
a theranostic radionuclide, is still used to diagnose and treat differentiated cancer of the thyroid.15 
1.2.2 The Chart of the Nuclides 
The proliferation and application of different particle sources led to the discovery of thousands of 
distinct nuclides over the last 120 years.18 The chart of nuclides (Figure 1-1) is a visual map of all 





Figure 1-1. The chart of the nuclides20 
The nuclides are organized with the neutron number (N) on the abscissa and the proton number 
(Z) on the ordinate. In this representation, the coloring of each box (nuclide) denotes the observed 
type of radioactive decay: stable (black), alpha decay (yellow), positron decay/electron capture 
(red), beta decay (blue), and spontaneous fission (green).19 Nuclides that appear along the same 
row are isotopes (constant Z) and nuclides that have the same mass number (N + Z) are isobars. 
The isobars form 45° lines that have a negative slope. Stable nuclides at low Z have approximately 
equal numbers of protons and neutrons. This is evidenced by a line at N = Z of stable nuclides 
(black). However, nuclides with larger Z values require more neutrons (N > Z) to be stable. This 
trend is observed in Figure 1-1 as the line of stable nuclides becomes non-linear as Z increases.  
 This line through the stable nuclides can be described as the line of beta stability. Moreover, 
the line of stability can be further visualized as a valley of stability based on the binding energy 
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(BE) of each nuclide. The BE is the energy required to break apart a nuclide into its proton and 
neutron components. If the mass is set as a third dimension than stable nuclides (with the lowest 
mass at a certain isobar) will lie towards the valley and unstable nuclides (with combinations of N 
and Z that lie off the N = Z line) will lie further up the sides of the valley of stability. 
 Characteristics of these nuclides which lie off the valley of stability, like their radioactive decay 
and nuclear structure, can determine their potential use in medicine to diagnostically image and 
treat disease. Some of these radionuclides, like 131I, have been developed for use in medicine to 
diagnose and treat disease based on their unique nuclear characteristics. Others, like 60Co (t1/2 = 
5.27 y), are used for gamma sterilization (irradiation of material to kill microorganisms) and 
industrial radiography (non-destructive testing using γ-rays to verify internal structure).  
1.3 Radioactive Decay 
The nucleus of an atom consists of a densely packed arrangement of nucleons (i.e. protons and 
neutrons). Radionuclides are atoms with a nucleus that contains an unstable arrangement of 
nucleons in a state of excess energy. The process of radioactive decay occurs when a nucleus emits 
radiation (i.e., releases energy) spontaneously to arrive at a less energetic and more stable state. 
Radioactive decay can be grouped into four general modes that include alpha (α), beta (β), electron 
capture (EC) and gamma (γ) decay. In α, β, and EC decay, the mass-energy equivalence between 
the reactant (parent nuclide) and products (daughter nuclide and particles) is conserved by a Q-
value. During spontaneous radioactive decay, the Q-value will always be positive. 
1.3.1 Units of Radioactive Decay 
Radioactivity refers to the amount of ionizing radiation emitted by a material, which represents 
how many atoms in the material decay in a given period of time. The initial unit for measuring the 
amount of radioactivity was defined by Ernest Rutherford (1910) as the curie (Ci).21 A Ci was 
6 
 
defined as the amount of radioactivity in one gram of 226Ra (t1/2 = 1600 y), which is now fixed at 
3.7 × 1010 decays per second. The becquerel (Bq), defined as one nuclear decay per second, was 
given official status as the SI unit of activity in 1975.22 Thus, 1 Ci is equal to 3.7 × 1010 Bq 
(approximately the number of decays per second that occur in one gram of 226Ra).  
1.3.2 Alpha Decay 
The first mode, α decay, occurs when a heavy nucleus emits a 4He2+ nucleus (i.e., an α particle). 
Alpha particles are monoenergetic and their loss by parent nuclei result in transmutation to a 
daughter with four fewer nucleons (two protons and two neutrons), represented by Equation 1-1. 
Equation 1-2 shows the α decay of the therapeutic radionuclide 211At (t1/2 = 7.2 h).23 
  XZA  → Y(N−2)2−(Z−2)
(A−4) +  He22+24 + Qα   (1-1) 
  At83211  → Bi2−81207 + He2+ + Qα24    (1-2) 
The emitted heavy α particle travels in a relatively straight path and produces intense ionization 
due to its 2+ charge. It is stopped in 2-10 cm of air depending upon its energy, and has an 
approximate range of 30-50 μm in body tissues.24 Due to their short range in body tissues, α 
particles can deposit cell-killing ionizing radiation in a small region, and are used for treatment of 
small nonlocalized neoplasms and micrometastases.25 
1.3.3 Beta Decay 
The second mode, β decay, can occur via two different mechanisms, electron decay (β-) and 
positron decay (β+). These types of decay result in no change in the total number of nucleons (A). 
Decay by β- and β+ is accompanied by emission of an antineutrino (ῡe) or a neutrino (υe), 
respectively. The energy and momentum associated with β- and β+ decay is conserved and shared 
between the recoiling daughter (due to particle emission), the emitted electron (or positron), and 
the emitted antineutrino (or neutrino). Electron and β+ decay end in a three-body final state where 
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the decay energies are shared between the daughter nucleus and the emitted particles. Beta particles 
(i.e., electrons and positrons) are released with a continuous energy distribution that ranges from 
zero to the maximum decay energy (Figure 1-2). 
 
Figure 1-2. The beta spectrum of 210Bi26 
In Figure 1-2, the width of the region defined by the dotted lines define the energy of a single 
emitted antineutrino (Eυ = 0.76 MeV) and electron (Eel = 0.4 MeV). For each decay, the particle 
energies can vary as long as their combined energy does not exceed the maximum decay energy 
of 1.16 MeV. 
 Neutron-rich nuclei (right of the valley of beta stability, Figure 1-1) typically undergo β- decay 
along an isobaric line. A nucleus that undergoes β- decay converts a neutron to a proton by emitting 
an electron and antineutrino (Equation 1-3). The mass number of the parent remains unchanged, 
but the atomic number of the daughter increases by one. Equation 1-4 shows the β- decay of the 
therapeutic radionuclide 177Lu (t1/2 = 6.7 d). 
  XZA  → Y(Z+1)A +  β−10 + υ� + Qβ−   (1-3) 
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  Lu71177  → Hf72177 + β−10 + υ� + Qβ−   (1-4) 
 Proton-rich nuclei (left of the line of beta stability, Figure 1-1) that have decay energies that 
exceed 1.02 MeV can undergo β+ decay along an isobaric line. A nucleus that undergoes β+ decay 
converts a proton to a neutron by emitting a positron and neutrino (Equation 1-5). The mass 
number of the parent remains unchanged, but the atomic number of the daughter decreases by one 
(the opposite of β- decay). Equation 1-6 shows the β+ decay of the diagnostic radionuclide 68Ga 
(t1/2 = 68 min). 
  XZA  → Y+(Z−1)A +  β+10 + υ + Qβ+   (1-5) 
  Ga3168  → Zn+3068 +  β+10 + υ + Qβ+   (1-6) 
An important aspect of β+ decay is the emission of a positron (β+), an electron with a positive 
charge. As the kinetic energy of the emitted positron is reduced via thermalization in its medium, 
it will eventually undergo positron-electron annihilation (Equation 1-7) and produce two 
annihilation photons. These photons are emitted in opposite directions in a collinear fashion 
(approximately 180° apart). 
  β− + β+  → γ1 +  γ2    (1-7) 
Both the positron and electron have a rest energies of 0.511 MeV; thus, the photons have a total 
combined energy of 1.022 MeV. The rest energy of both β particles (β- and β+) illustrate why only 
proton-rich nuclei with decay energies exceeding 1.02 MeV can undergo β+ decay.  
 Beta particles have less mass than α particles and as a result experience different electronic 
and nuclear interactions. They can be deflected multiple times in their medium due to their mass 
and charge, and are stopped in tens to hundreds of centimeters of air depending upon the β particle 
energy. In human tissues, β particles have an approximate range of 3 to 12 mm.25, 27 Lutetium-177 
and other radionuclides that undergo β- decay (emitting low-energy electrons) are used for targeted 
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radionuclide therapy. Unlike α particles, these electrons deposit their energy throughout a much 
greater region and can deposit cell-killing ionizing radiation to medium and large heterogeneous 
tumors. However, the long-range of these particles can result in damage to healthy tissue that 
surrounds a targeted disease.25 Radionuclides that undergo β+ decay and emit positrons (like 68Ga) 
have been clinically used for decades in nuclear medicine to diagnose diseases like cancer. 
1.3.4 Electron Capture 
The third mode involves proton-rich nuclei (left of the line of beta stability, Figure 1-1) that have 
a decay energy of less than 1.02 MeV. Further, EC decay competes with β+ decay for these nuclei 
when decay energies exceed 1.02 MeV. These proton-rich nuclei undergo decay by EC along an 
isobaric line. Decay by EC involves the capture of an orbital electron by a nucleus that results in 
the conversion of a proton into a neutron (Equation 1-8). Equation 1-9 shows the EC decay of 
the cosmogenic radionuclide 7Be (t1/2 = 53.3 d). 
  X+ZA + e−10 → Y(Z−1)A +  υ + QEC   (1-8) 
  Be+47 + e−10 → Li37 +  υ + QEC   (1-9) 
The mass number of the parent remains unchanged, but the atomic number of the daughter 
decreases by one (like β+ decay). This process ends in a two-body final state and results in the 
emission of a monoenergetic neutrino. Further, the orbital shell vacancy is filled by a higher shell 
electron. The difference in shell energy can be emitted as a characteristic x-ray or mediated by the 
Auger effect. The Auger effect involves the transfer of the excess energy to an orbital electron, 
which is ejected.28 In general, Auger electrons have energies of only a few eV. Auger electrons at 
these energies have a range of a few nm to 100 μm in human tissues.29 The short range of Auger 
electrons limits their ability to deposit cell-killing ionizing radiation to DNA and cells; thus, 
therapeutic agents that incorporate Auger-emitting radionuclides require localization of the 
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radioactivity proximal to the cell nucleus.30  
1.3.5 Isomeric Transition and Gamma Rays 
After a nucleus undergoes α, β, or EC decay, the daughter nucleus may be in an excited state. The 
final mode involves a nucleus in this intermediate state that undergoes an isomeric transition (IT) 
to emit excess energy as a photon. Photons emitted during ITs (approximately 8 keV to 8 MeV) 
are known as gamma rays (γ-rays). Typically, nuclei undergo prompt IT; however, some nuclei 
remain in an intermediate state for longer periods that are known as metastable states. The nuclear 
isomer 99mTc (see Section 1.2.1) has branched radioactive decay, undergoing β- decay to stable 
99Ru (0.004%) or IT (99.99%) to its ground state 99Tc (t1/2 = 2.1 × 105 y) that results in a 140.5 
keV (Iγ = 89%) γ-ray. Figure 1-3 shows a simplified decay scheme (i.e. energy level diagram) for 
the IT of 99mTc to 99Tc. 
 
Figure 1-3. The isomeric transition of 99mTc 
This critical isomer of Tc is the most widely used radioisotope in medicine and is employed in 
approximately 80% of all nuclear medicine procedures.31  
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 When the excess energy of the excited nucleus exceeds the binding energy of an orbital 
electron, internal conversion (IC) competes with IT. In IC, the excess energy is transferred to an 
orbital electron that is ejected with an energy equal to the excess energy minus the electron binding 
energy. The electron shell vacancy is filled by higher-shell electrons, resulting in the emission of 
characteristic x-rays and Auger electrons. In both cases, IT and IC, the number of nucleons does 
not change. Isomeric transitions allow some radionuclides to be used in nuclear medicine for both 
therapy (via particles emitted during radioactive decay of the parent) and diagnosis (via γ-rays).  
1.4 Molecular Imaging Techniques 
Diagnostic radiopharmaceuticals are molecular agents that incorporate a radionuclide to probe 
physiological processes. These agents often have selectivity for a distinct biomarker. After 
administration, the gamma rays emitted during decay of the radionuclide escape the body and can 
be imaged externally. These techniques are sensitive and non-invasive. They require only small 
masses of a radiopharmaceutical (pmol—nmol) to obtain data that is either difficult or impossible 
to obtain with other imaging modalities such as radiography, optical imaging, fluoroscopy, 
computed tomography, and magnetic resonance imaging. They can be used to screen for disease 
at its earliest stages, and in some cases can pinpoint the exact location of a tumor well before it 
can be detected by other diagnostic tests. Molecular imaging with radiopharmaceuticals can also 
provide individualized care by profiling a patient’s response to treatment, providing critical data 
to inform treatment plans, assessing disease progression, and identifying recurrence of disease.32 
Two different nuclear molecular imaging modalities are widely used in nuclear medicine.  
1.4.1 Positron Emission Tomography 
Positron emission tomography (PET) is a tomographic imaging technique. The basis for PET relies 
on the two 511 keV annihilation photons resultant from β+ decay (see Section 1.3.3). The 
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annihilation photons escape the subject and can be detected using an array of γ-ray detectors.33 
These detectors use scintillation crystals (e.g. bismuth germanium oxide, lutetium yttrium 
orthosilicate, or lutetium oxyorthosilicate) coupled with photomultiplier tubes.34 In a PET scanner, 
many detectors are positioned around a patient and configured to detect pairs of annihilation 
photons in coincidence. The line of intersection (also called the line of response, LOR) determined 
by the position of each coincident photon (in the detectors) can then be used to map their origin 
(Figure 1-4).  
 
Figure 1-4. A simplified PET scanner schematic 
Using an array of detectors, a set of two-dimensional (2D) slices (composed of many coincident 
photon pairs) can be collected that map electron-positron annihilation sites. These 2D slices 
represent cross-sectional images of a patient. These raw data (contained in each slice) are stored 
in a sinogram that captures all LORs as a function of angle relative to a reference point. The set of 
sinograms can be reorganized into a three-dimensional (3D) projection image (tomographic view) 
that displays all slices at a particular projection angle. 
 The spatial resolution of modern clinical PET imaging and small animal imaging is 4-6 mm 
13 
 
and approximately 1 mm, respectively.35 This resolution can be limited by two physics-related 
factors, namely annihilation photon non-collinearity and the positron range.36 The first factor, non-
collinearity of annihilation photons, can be explained by non-zero momentum of electron-positron 
annihilation. The non-collinearity increases uncertainty in the origin of the annihilation event. The 
second factor, the positron range, is dependent on the positron energy and is the distance a positron 
travels after β+ decay. Due to the three-body nature of β+ decay, a positron has a mean energy, 
(Eβ+mean) at approximately one-third of the Emax. Thus, positrons at or near Emax can limit (along 
with non-collinearity) resolution since they travel further from the site of β+ decay before 
thermalization leads to annihilation (Figure 1-5). 
 
Figure 1-5. The dependence of PET resolution on positron energy (i.e., range) 
Figure 1-5 illustrates the longer range of higher-energy positrons (left) and shows how the smaller 
region defined by the lower-energy positrons (right) could afford an improved resolution in a PET 
scanner. This impact on resolution is most often observed when using small-animal PET scanners 
based on their spatial resolution. Even though these two phenomena (non-collinearity and positron 
range) can limit PET imaging resolution, their effects can be taken into account during 
reconstruction of raw PET data to improve resolution in a projection image.37  
14 
 
 There are several FDA-approved (Food and Drug Administration) PET radiopharmaceuticals 
used clinically. The most commonly used radionuclide in PET imaging is 18F (t1/2 = 110 min), 
which is widely used to label deoxy-glucose ([18F]FDG, Figure 1-6), a glucose analogue, for the 
imaging of glucose metabolism. The upregulation of glucose metabolism is a widely used 
biomarker. 
 
Figure 1-6. The chemical structure of deoxy-glucose and [18F]FDG 
Imaging of this biomarker occurs after transport of [18F]FDG into the cell followed by 
phosphorylation. The presence of 18F at the C-2 position prevents participation in the standard 
metabolic pathway. For example, 18F accumulates in neoplastic cells and disease that has increased 
glycolytic activity. Beyond its use to assess glucose metabolism in heart, lungs, and brain, it may 
also be used in oncology for screening, staging, pre-surgical planning, radiotherapy planning, and 
monitoring treatment of cancers (and reoccurrence of disease). It has clinically been used with 
breast cancer, colorectal cancer, head and neck cancer, lung cancer, esophageal cancer, and 
lymphoma.38 
1.4.2 Single Photon Emission Computed Tomography 
Single photon emission computed tomography (SPECT) is a tomographic imaging technique with 
some similarities to PET imaging. The basis for SPECT is detection of γ-rays using nuclear 
detectors that contain scintillation crystals (e.g. thallium doped sodium iodide or cesium iodide 
and cerium doped lanthanum chloride) coupled with photomultiplier tubes.39 In a SPECT scanner, 
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one or more detectors, is rotated around the patient (Figure 1-7) to acquire a 2-D slice at multiple 
angles.  
 
Figure 1-7. A simplified SPECT scanner schematic 
Similar to PET, the raw data included in a set of 2D slices can be reorganized into a 3D projection 
image that displays all slices at a particular projection angle. The spatial resolution of the latest 
clinical SPECT imaging systems vary from 3 mm to 8 mm.40 
 The main limitation of SPECT imaging arises due to the use of γ-rays that emit at all angles 
(Figure 1-7). To extract data on the γ-ray origin, a collimator must be used to restrict the γ-ray 
acceptance angle. In practice, these collimators are composed of a high Z material (e.g., tungsten), 
capable of attenuating γ-rays outside of the acceptance angle (Figure 1-7). Position information is 
extracted from γ-rays that pass through a collimator and interact with the detector (orthogonal to 
the collimator face) while γ-rays that would otherwise degrade resolution and contrast are absorbed 
by the high Z material.41 Generally, radionuclides suitable for use in SPECT emit low-energy γ-
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rays (<160 keV). Higher-energy γ-rays require larger collimators and the increased material 
needed between the collimating holes (i.e., septa) to absorb γ-rays lead to a reduction in sensitivity. 
Thus, radionuclides that emit high-energy γ-rays require larger quantities of the radioactive 
compound to acquire usable image data compared to the greater sensitivity of a PET scanner. 
 Historically, the most important radionuclide in SPECT imaging is the nuclear isomer 99mTc 
(see Section 1.2.1). For example, [99mTc]Tc-sestamibi is indicated for imaging myocardial 
perfusion, identification of parathyroid adenomas, and is also used for radioguided surgery of the 
parathyroid. Imaging agents, like [99mTc]Tc-sestamibi that incorporate 99mTc, are clinically used 
in SPECT imaging for successful patient management with at least twenty-three different 99mTc 
radiopharmaceuticals in wide use.42 
1.5 Targeted Radionuclide Therapy 
Targeted radionuclide therapy (TRNT) uses molecular compounds labeled with therapeutic 
radionuclides (e.g., α and β- emitters). These radiolabeled compounds target disease by having 
high affinities for specific biomarkers of disease that are overexpressed relative to healthy tissue. 
Targeted radionuclide therapy can be coupled with other types of cancer treatment (e.g., surgery, 
external beam radiation therapy, brachytherapy, chemotherapy, hormonal therapy, and biological 
therapy) to form a personalized multimodal treatment plan. Therapeutic radionuclides, unlike PET 
and SPECT radionuclides, emit ionizing radiation with short path lengths like a β- particle, α 
particle, or Auger electrons. As these ionizing particles slow, they transfer energy to their local 
environment in the form of ionizations and excitations. 
 The primary mechanism of action for TRNT is direct or indirect damage to DNA induced by 
the ionizing particles that can lead to cell cycle delay and cell death.43 Moreover, multiple reports 
support the existence of bystander responses (cell-to-cell signaling) mediated by radiation-induced 
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DNA damage, which may improve efficacy of treatment; however, the mechanisms underpinning 
bystander signaling in TRNT are not fully understood.44-46 An additional feature of TRNT is the 
crossfire effect that occurs when a β- or α particle causes DNA damage as it crosses multiple 
cells.47 The crossfire effect leads to greater therapeutic efficacy as one radioactive decay can lead 
to DNA damage in multiple cells. 
 Many TRNT compounds have been approved for human use or are in development for clinical 
use. For example, the FDA-approved treatment of thyroid carcinoma with the β- emitting 
radionuclide 131I is used after thyroidectomy to ablate any remaining cancerous remnants. In a 
retrospective study of 261 patients given 131I ablation therapy between 2012 and 2015 had a 
success rate of 65.9% after their first treatment.48 
 Several compounds that incorporate radionuclides that emit α particles are in clinical 
development and the effort to develop these radiopharmaceuticals has been motivated by the 
success of 223RaCl2, the first FDA-approved α emitting radionuclide. Radium-223 dichloride is 
indicated for the treatment of patients with metastatic castration resistant prostate cancer 
(mCRPC). It preferentially targets areas of increased bone turnover in in bone metastases and its 
emitted α particles have an average range that is less than 100 µm in tissue. The development of 
new α particle emitting radiopharmaceuticals include phase I clinical trials with monoclonal 
antibodies labeled with 213Bi (t1/2 = 45.6 min) and 211At (t1/2 = 7.2 h), and the initial evaluation of 
223Ra (t1/2 = 11.4 d) to treat breast cancer.49,50 
1.6 Theranostics 
The theranostic approach uses a combination of diagnostic and therapeutic techniques to identify 
and treat disease in the same patient. In nuclear medicine, molecular compounds are labeled with 
a theranostic radionuclide (suitable for both diagnostic imaging and radionuclide therapy) or a 
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combination of two different diagnostic and therapeutic radionuclides. These theranostic 
compounds can be used to identify disease, stage progression, and predict patient response to 
treatment by profiling the concentration or presence of a targeted biomarker. 
 The first widely used theranostic radiopharmaceutical was 131I, a theranostic radionuclide that 
undergoes β- decay to 131Xe, followed by emission of 284.3 keV (Iγ = 6.12%) and 364.5 keV (Iγ 
= 81.5%) γ-rays. Iodine-131 was first used to treat thyroid cancer in 1946.51 Its emitted β- particles 
have a Eβ-mean of 181.9 keV and their max range in tissue can reach 2.4 mm.52 The β- particles 
deliver ionizing radiation to targeted cells. Additionally, the γ-rays emitted during nuclear decay 
of 131Xe to its ground state can be imaged with a gamma camera (via SPECT). Therefore, 131I is a 
theranostic radionuclide.  
1.6.1 Targeting Neuroendocrine Tumors with Somatostatin Analogues 
Neuroendocrine tumors (NET) are a rare group of neoplasms with an incidence of approximately 
7 cases per 100,000 people in the United States (2012).53 These tumors can overexpress 
somatostatin receptors (SSTR), primarily subtype two (SSTR2). Somatostatin receptors are a G 
protein-coupled receptor (GPCR) that detect molecules outside the cell and activate internal signal 
transduction. When activated, SSTR transit the cell membrane and offer a pathway to transport 
radioactive agents into the cell nucleus. Approximately 34% of all FDA-approved drugs target 
GPCRs and exploit this mechanism.54 Three examples of recently FDA-approved 
radiopharmaceuticals, [68Ga]Ga-DOTATOC and [68Ga/177Lu]Ga/Lu-DOTATATE, allow PET 
imaging and treatment of NETs. These molecular agents target SSTR, with high affinity and 
specificity for SSTR2.55 
 DOTATOC (Figure 1-8) was approved for use with 68Ga (see Section 1.3.3) as a PET 




Figure 1-8. The chemical structure of DOTATOC. 
In Figure 1-8, the central 12 membered tetraaza ring (DOTA) has a high affinity for chelating di- 
and trivalent cations. For La and most lanthanide-like elements including Ga(III), DOTA functions 
as an octadentate ligand and binds the metal through its four amine N atoms and four carboxylate 
O atoms. In most cases, DOTA coordinates an additional water ligand yielding an overall 
coordination number of nine.56 In contrast, DOTA binds Sc(III) yielding an overall coordination 
number of eight. Similar coordination by DOTA to Lu(III) and Y(III) has been reported.57 
 DOTATATE (Figure 1-9) was approved for use with 68Ga and 177Lu (see Section 1.3.3) in 




Figure 1-9. The chemical structure of DOTATATE. 
It forms two compounds which can be used in a theranostic fashion.  
 Diagnostic imaging with [68Ga]Ga-DOTATATE identified NET recurrence in 26 of 29 patients 
(sensitivity, 90%) and excluded recurrent NET in 28 of 34 patients (specificity, 82%).58 Targeted 
radionuclide therapy with [177Lu]Lu-DOTATATE in 116 patients with advanced, progressive, 
SSTR-positive midgut NETS showed markedly longer progression-free survival and significantly 
higher response rates versus a control group of 113 patients given non-radioactive DOTATATE.59 
These results contributed to the FDA approval of [68Ga]Ga-DOTATATE and [177Lu]Lu-
DOTATATE to detect NETs, monitor NETs progression, and determine patient response to 
TRNT. 
 The coordination of DOTA in DOTATATE (Figure 1-9) is similar to that reported in 
DOTATOC for 68Ga. For 177Lu, the change in coordination number (9 → 8) affects the 
pharmacokinetics of the radiopharmaceutical and increases the lipophilicity of the radiolabeled 
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compound. In fact, reports have shown a four to fivefold increase in the IC50 value for DOTATOC 
coordinated to Y (which is coordinated similarly to Lu-DOTATOC).57, 60 The similarities in 
coordination number between Sc(III), Y(III), and Lu(III) present a case where DOTATATE 
labeled with the Sc radionuclides investigated in this work would yield similar (e.g., 43,44Sc/177Lu) 
or identical (e.g., 43,44Sc/47Sc) pharmacokinetic profiles when screening for and treating NETs. 
1.6.2 Targeting Prostate Cancer with PSMA Agonists 
Prostate cancer is the second leading cause of cancer-related death in men in the United States. 
From 1999 to 2005, disseminated and advanced forms of prostate cancer had an approximate 5-
year survival rate of 31% for all races.61 Prostate cancer overexpresses prostate-specific membrane 
antigen (PSMA). This biomarker is expressed at greater levels in castration-resistant and de-
differentiated (i.e., disseminated) disease. The bioconjugate PSMA-617 (Figure 1-10) combines 
the DOTA chelator with a urea-derived targeting agent that has high affinity for PSMA was 




Figure 1-10. The chemical structure of PSMA-617. 
After PSMA-binding, PSMA-617 is internalized into the cell nucleus via clathrin-coated pits.63 
Similar to targeting SSTR, PSMA is a favorable biomarker as it will transport PSMA-617 labeled 
with a radionuclide into the cell. Many recent clinical studies have showed excellent safety and 
efficacy. Based on these studies, a randomized phase 3 study of 177Lu-PSMA-617 for the treatment 
of patients with progressive PSMA-positive mCRPC is currently underway. A theranostic 
approach to mCRPC can be pursued by using the bioconjugate PSMA-11 (Figure 1-11) labeled 
with 68Ga or 18F. Gallium-68 and 18F-labeled PSMA-targeting bioconjugates like PSMA-11 and 
PSMA-1007 are increasingly being used to detect and monitor progression of prostate cancer. For 
example, [68Ga]Ga-PSMA-11 has shown a sensitivity and specificity of 77% and 97%, 




Figure 1-11. The chemical structure of PSMA-11. 
Similar to DOTATATE, interest exists in advancing PSMA-617 due to its ability to coordinate 
Ga(III), Sc(III), and Lu(III). It would allow a theranostic approach using the same bioconjugate 
molecule, and its use would provide a more accurate pharmacokinetic profile that could inform 
treatment. Thus, investigating the in vitro properties of PSMA-617 labeled with 43Sc, 44Sc, and 
47Sc represents another case where the Sc radionuclides investigated in this work could play an 
important role. 
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Chapter 2: Cyclotron Production of 
Radioscandium 
2.1 Nuclear Properties of Radioscandium 
The element Sc has one naturally-occurring stable isotope, 45Sc, and several medically relevant 
radioisotopes.1 Figure 2-1 shows the five radioisotopes of Sc (including isomeric states) that have 
ground state half-lives greater than 60 minutes: 43Sc, 44Sc, 46Sc, 47Sc, and 48Sc.  
 
Figure 2-1. The isotopes of Sc with mass numbers from 43 to 481 
Three of these radioisotopes (43Sc, 44Sc, and 47Sc) were investigated in this work for their use as 
diagnostic, therapeutic, and theranostic radioisotopes. The remaining two isotopes (46Sc and 48Sc), 
have properties that are less advantageous for medical use. The properties of all five radioisotopes 
are noted below because most 43Sc, 44Sc, and 47Sc production methods will result in the co-
production of 46Sc and 48Sc, which are considered radionuclidic impurities that lower the 
radioisotopic purity of the desired 43Sc, 44Sc, or 47Sc.  
2.1.1 Scandium-43 
Scandium-43 (t1/2 = 3.90 h) decays by β+ decay (Iβ+ = 88.1%) and EC decay (IEC+ = 11.9%) to 43Ca 





Figure 2-2. A simplified 43Sc decay scheme1 
Scandium-43 has nuclear properties that make it an excellent PET radionuclide. First, its half-life 
is similar to the biological half-lives of many compounds such as peptides (1-10 kDa), peptidic 
proteins (10-50 kDa) and mAbs (150 kDa) commonly used in diagnostic imaging.2 Next, its mean 
positron energy is 476 keV; thus, a better image resolution would be predicted compared to 68Ga, 
which has a mean positron energy of 830 keV.3 Lastly, it has a low intensity 373 keV γ-ray emitted 
by the excited daughter.  
2.1.2 Scandium-44 
Scandium-44 (t1/2 = 3.93 h) decays by β+ decay (Iβ+ = 94.3%) and EC decay (IEC+ = 5.7%) to an 





Figure 2-3. A simplified 44Sc decay scheme1 
Scandium-44 has a similar decay mode and half-life as 43Sc, and emits a positron with a mean 
energy of 632 keV during decay. Its excited daughter, 44Ca, emits an 1157 keV γ-ray. The high-
energy γ-ray will lead to an increased γ-ray dose to patients and clinical staff. Moreover, the higher 
energy positron will have an increased range relative to 43Sc (potentially leading to loss of PET 
resolution). Scandium-44 produced by particle-induced nuclear reactions results in a mixture of its 
ground state and nuclear isomer (44mSc). Scandium-44m (t1/2 = 58.61 h) decays by EC (IEC = 1.2%) 
to an excited state of 44Ca with emission of a 1.002 (Iγ = 1.2%), 1.126 (Iγ = 1.2%), and 1.157 MeV 
γ-ray (Iγ = 1.2%). It also undergoes decay by IT (IIT = 98.8%) to the ground state of 44Sc with 





Figure 2-4. A simplified 44mSc decay scheme showing the branched decay of 44mSc1 
A mixture of the 44Sc ground state and excited state can increase the patient dose when this 
radionuclide is used for diagnostic imaging. To simplify patient dosimetry, 44Sc in its ground state 
(with no isomer) would be the best scenario for clinical use of this PET radionuclide.  
 The long-lived radionuclide 44Ti could serve as a reliable source of 44Sc in only its ground state 
(Figure 2-5). 
 
Figure 2-5. Titanium-44 and Sc radioisotopes are shown1 
Multiple groups have investigated the production of 44Ti and the design of a system that would 
allow harvesting of 44Sc from the decay of 44Ti.4, 5 Thus, the nuclear properties of 44Ti are an 
important element of this work. Titanium-44 decays by electron capture decay (IEC = 100%) to an 




depicted in Figure 2-6.1 
 
Figure 2-6. A simplified 44Ti decay scheme1 
2.1.3 Scandium-47 
Scandium-47 (t1/2 = 3.34 d) decays by β- decay (Iβ- = 100%) to 47Ti (Figure 2-7) with emission of 
a 159.4 keV γ-ray (Iγ = 68.3%).1 
 
Figure 2-7. A simplified 47Sc decay scheme1 
Scandium-47 has properties similar to the theranostic radionuclide 177Lu (see Section 1.6). Its 
moderate half-life, β- particle energies, and imageable 159.4 keV γ-ray make 47Sc well suited for 
use as a theranostic radionuclide. Targeted delivery of 47Sc-labeled compounds to cancer cells 





2.1.4 Scandium-46 & Scandium-48 
Scandium-46 (t1/2 = 83.79 d) decays by β- decay (Iβ- = 100%) to an excited state of 46Ti (Figure 
2-8). Similarly, 48Sc (t1/2 = 43.67 h) decays by β- decay (Iβ- = 100%) to an excited state of 48Ti 
(Figure 2-9). The decay products (46Ti and 48Ti) emit multiple high-energy γ-rays during nuclear 
decay. 
 
Figure 2-8. A simplified 46Sc decay scheme1 
 
Figure 2-9. A simplified 48Sc decay scheme1 




The relatively long half-life of 46Sc is not compatible with the shorter biological half-life of most 
diagnostic and therapeutic agents, and both radionuclides decay to daughters that emit several 
high-energy γ-rays that cause unnecessary radiation exposure to patients and clinical staff (shown 
in Figure 2-8 and Figure 2-9). 
2.2 Nuclear Properties of Radiovanadium 
The element V has one naturally-occurring stable isotope and several predicted or known 
radioisotopes.1 Figure 2-10 shows the three radioisotopes of V that have half-lives greater than 1 
minute: 47V, 48V, and 49V. 
 
Figure 2-10. The isotopes of V with mass numbers from 47 to 511 
Two of these radioisotopes, 47V (t1/2 = 32.6 min) and 48V (t1/2 = 15.97 d), were co-produced in this 
work as contaminants. The properties of both radioisotopes are noted below because the chemical 
separation of Sc from these V contaminants was a significant focus of this work. 
 Vanadium-47 and 48V decay by β+ decay (Iβ+ = 96.5% and 49.9%) and EC decay (IEC+ = 3.46% 





Figure 2-11. A simplified 47V decay scheme1 
 
Figure 2-12. A simplified 48V decay scheme1 
The EC decay of 47V to 47Ti results in the emission of a 159.8 keV and 1.793 MeV γ-ray (Iγ = 
0.11% and 0.19%).1 The remaining γ-rays that are emitted during the de-excitation of 47Ti have 
intensities <0.01%. Similarly, the decay of 48V results in an excited state of 48Ti that emits a 928.3 
keV (Iγ = 0.78%), 983.5 keV (Iγ = 99.98%), 1.3121 MeV (Iγ = 98.2%), and 2.240 MeV (Iγ = 




2.3 Nuclear Reactions 
Each of the radionuclides discussed in Section 2.1 and Section 2.2 are produced by bombarding 
target material (nuclei) using different particle sources to induce nuclear reactions. Nuclear 
reactions can be described as a change in the identity or characteristic of a nucleus when it is 
bombarded with a particle of sufficient energy. These reactions can be categorized into many types 
such as elastic scattering, inelastic scattering, fission, fusion, spallation, and transmutation. This 
work investigated the production of Sc radioisotopes and 44Ti produced by inducing transmutation 
reactions with protons and photons.  
 Nuclear reactions are represented in a manner similar to a balanced chemical reaction. For 
example, Equation 2-1 details the reaction that produces the PET radionuclide 43Sc using protons 
incident on 46Ti nucleus.  
  Ti2246 + p11 → Sc2143 + 𝛼𝛼24     (2-1) 
This reaction can be represented in shorthand by writing the target nucleus, projectile particle, 
ejected particle, and product nucleus in sequence for a two-body reaction (Equation 2-2). The 
comma represents the reaction arrow, and the incident and ejected particles are housed within 
parentheses. 
  Ti2246 (p,α) Sc2143     (2-2) 
 These transmutation reactions are best described as an event where a projectile merges with a 
target (nucleus) by striking it. If the nucleus retains the proton then its kinetic energy is distributed 
among all available nucleons leading to formation of a compound nucleus. The compound nucleus 
can undergo different processes by which it de-excites (i.e., evaporates particles) to assume a more 
stable configuration of nucleons. This process of de-excitation to the final products depends only 




parity of the compound nucleus. The spin of a nuclear state is an intrinsic property and the parity 
can be determined by studying the behavior of its wave function under the reflection of its space 
coordinates through the origin. For instance, a 24 MeV proton incident on a 48Ti nucleus may 
produce one of several probable reaction products (Figure 2-13). 
 
Figure 2-13. Potential nuclear reactions on a 48Ti nucleus 
 Each nuclear reaction has a distinct thermodynamic threshold energy that can be expressed as 
a Q-value. The Q-value is the enthalpy (-ΔHrxn) of a chemical reaction and, in the T=0 limit, a Q-
value > 0 indicates a spontaneous decay. The Q-value is determined by subtracting the mass excess 
(∆) of the products from the reactants. The mass excess of a nuclide in atomic mass units (u) is the 
difference between its actual mass and mass number (A). For example, the mass excess of 43Sc is 
shown in Equation 2-3. 
  ∆43Sc= M( Sc21
43 ) − A = (42.96115 − 43) =  −0.03885 u (2-3) 
Thus, the difference in the total mass excess of the products from the reactants can be used to 
calculate the Q-value for the general reaction A(a,b)B (Equation 2-4).  
  Q = [(Δa +  ΔA) − (Δb + ΔB)]   (2-4) 




0.0033 u. This mass excess can be expressed in units of MeV (after multiplying by u = 931.478 
MeV/c2), making the Q-value for 46Ti(p,α)43Sc equal to -3.07 MeV. The sign on the Q-value (-) 
indicates that the mass of the products is more than that of the reactants. Thus, an incident proton 
must have an energy above 3.07 MeV to overcome the thermodynamic threshold. 
 In some cases, the Q-value may not fully describe the particle energy required for a reaction to 
occur due to Coulombic forces. The positively charged proton in Figure 2-13 will experience 
repulsion due to the positive charge of the 48Ti nucleus. Thus, the proton must overcome the 
Coulomb barrier. Equation 2-5 can be used to approximate the energy required to overcome the 
Coulomb barrier were Z1 and Z2 are the atomic numbers of the incident particle and target nucleus, 
respectively, and R is the radius of the combined incident particle and target nucleus. If the atomic 
radii are expressed in fermis (fm) then VC has units of MeV. The radius (R) can be obtained in fm 
using Equation 2-6. 
  VC =
1.44 × Z1 × Z2
R
    (2-5) 




3 �    (2-6) 
For the 46Ti(p,α)43Sc reaction, the energy required for a proton to overcome the Coulomb barrier 
is 3.1 MeV. Thus, the magnitude of the Coulomb barrier imposes a kinetic threshold (in contrast 
to the thermodynamic limit imposed by a negative Q-value) that must be overcome in order for 
the reaction to occur. The actual threshold energy for a reaction to occur is the value (negative Q-
value or Coulomb barrier) with the greatest magnitude. For the 46Ti(p,α)43Sc reaction, the kinetic 
threshold (3.1 MeV) is the proton energy required for the reaction to occur. 
 For particles above the threshold energy, the probability of inducing a reaction is determined 




(cm2/nucleus), or more commonly in units of barns (1 barn = 10-24 cm2/nucleus), which have been 
adopted for convenience. Figure 2-14 illustrates the cross section for a reaction where the particle 
strikes the target nucleus. 
 
Figure 2-14. The geometric probability for a particle striking a target nucleus8 
In this case, particles in the beam may “miss” the target nuclei. However, a fraction will experience 
an electrostatic interaction with the nuclei that results in scattering with no loss of energy. A subset 
of this fraction may interact with the target nuclei via a direct collision, and will merge to form a 
compound nucleus. The excitation energy of the compound nucleus, which is dependent on the 
energy of the incident particle, will determine the different final products that may occur via de-
excitation. Thus, the cross section for each reaction is dependent on the incident particle energy 




function. It should be noted that this simplified geometric view (Figure 2-14) does not represent 
all variables that determine the magnitude of the nuclear reaction cross section. Instead, the cross 
section of a nuclear reaction is a prediction of its probability to occur. Thus, the magnitude of the 
actual cross section can be larger or smaller than the geometrical cross sectional area of a target 
nucleus. 
 The magnitude of a nuclear reaction cross section (i.e., excitation function) may be measured 
experimentally, and can be used to determine the optimal particle energies for maximizing 
radionuclide yield. The excitation function for the 48Ti(p,x)48V reaction is shown in Figure 2-15. 
 
Figure 2-15. The 48Ti(p,x)48V excitation function9-11 
Figure 2-15 indicates that the peak cross section is approximately 380 mb at 12 MeV for the 
48Ti(p,x)48V reaction. Thus, bombarding a thin 48Ti target with 12 MeV protons will capture the 
portion of the excitation function with the greatest cross section magnitude. The total yield could 
be further increased by bombarding a thick target with 20 MeV protons. An appropriately thick 




excitation function peak would be utilized. In that case, the envelope of proton energies occurring 
within the target would span a larger region of the excitation function peak and increase the 
probability of the reaction occurring.  
 The proton and photon energies used in this work range from 0-24 MeV. Reactions induced at 
these energies such as (γ,n), (γ,p), (γ,n+p), (p,n), (p,xn), (p,α), (p,n+α), and (p,xn+α) are 
commonly observed. In these reactions, the “x” accounts for the emission of multiple nucleons 
(often neutrons at these energies). 
2.4 Radionuclide Production 
Radionuclides are produced using nuclear reactors12, 13, cyclotrons14, 15, and linear accelerators16-
19, or are obtained from a nuclear generator via the radioactive decay of a long-lived parent 
radionuclide.20, 21 This work investigated radionuclide production using an H- (i.e., negative ion) 
cyclotron and an electron linear accelerator (eLINAC).  
2.4.1 Cyclotron 
The acceleration of a proton in a negative ion cyclotron starts with an external ion source, which 
generates H- ions and injects them into the center of a strong magnetic field. The magnetic field 
moves the ions in a circular path over large electrodes (i.e., dees) in a vacuum chamber. The radius 
of this path depends on the charge and velocity of the ion as well as the strength of the magnetic 
field. The radius can be modeled by Equation 2-7 where m is the ion mass in kg, v is the ion 
velocity in m/s, q is the particle charge in C, and B is the magnitude of the magnetic field in kg•s-
1•C-1 . 
  R = mv
qB
     (2-7) 




an alternating fashion, attracts and repels the ions, which causes them to accelerate across a gap 
between each dee. As the protons gain more energy, their radius increases until they reach the 
outer edge of the dees. At the outer edge of the vacuum chamber, the excess electrons can be 
stripped by impinging them onto a thin carbon foil (Figure 2-16).  
 
Figure 2-16. Diagram of a negative ion cyclotron 
The newly formed H+ ions are deflected down a vacuum beam line until they reach a target, where 
the energetic positive ions (i.e., protons) are used to induce nuclear reactions in a target material.  
2.4.2 Electron Linear Accelerator 
The acceleration of an electron in a linear accelerator (eLINAC) starts with an electron gun, which 
uses a hot cathode that emits electrons. The emitted electrons are accelerated towards an anode 
and collimated to produce an electron beam. In an eLINAC, the electron beam is injected into a 
linear accelerator structure. Inside this structure, a wave-guide delivers high-frequency 
microwaves that are reflected to form standing waves that accelerate the electrons via an effective 
electric field (i.e., sum of incident and reflected wave). The accelerated electrons (traveling as a 
beam organized into bunches of electrons) are directed down a flight tube and their horizontal 




where a downward focused electron beam is well suited for external beam therapy. In this work, a 
downward focused electron beam was used to generate bremsstrahlung radiation. 
 Bremsstrahlung radiation is electromagnetic radiation that is produced by the deceleration of 
a charged particle (i.e., electron) when it is deflected by an atomic nucleus. The electrostatic 
attraction between the moving electron and the atomic nucleus causes the particle to lose energy, 
which is converted into a photon. Bremsstrahlung photons have a continuous spectrum and the 
peak of the spectrum occurs at approximately one-third of Emax. To obtain bremsstrahlung photons 
in this work the electron beam was made incident on a high Z converter made of W (Figure 2-16). 
 
Figure 2-17. Bremsstrahlung photons generated by a converter material 
Figure 2-16 shows the conversion of an electron beam to a beam of forward-directed 
bremsstrahlung photons that were used to induce nuclear reactions in a target material. 
2.4.3 Production Rates and Yields 
The production rate of reaction products produced during an irradiation is dependent on several 
parameters, including the magnitude of the reaction cross section in cm2, the energy of the incident 
particle in MeV, the thickness of the target material in nuclei/cm2, and the flux of the incoming 




thin 48Ti target bombarded with 11-12 MeV protons (Figure 2-15). For a reaction with a constant 
cross section (dσ/dE = 0), the production rate (nuclei formed/s) is given by Equation 2-8 where 
Nt is the target thickness, φparticle is the beam intensity in particles per second, and σ is the cross 
section. 
  R = Ntϕparticleσ    (2-8) 
 Since the cross section varies as the energy of the incident particle drops due to energy 
attenuation in the target material, a more exact production rate can be obtained by integrating 
Equation 2-7 from the initial energy to the final energy of the incident particle. This integral 
(Equation 2-9) extracts the magnitude of the cross section in cm2 via the σ(E) term. The particle 
energy at each infinitely thin slice is accounted for by the dE/dx term.  






dE   (2-9) 
The integrated yield for a finite time bombardment must account for the decay of the produced 
activity during bombardment. Accounting for decay yields Equation 2-10, where NA is 
Avogadro’s number, At is the molecular weight of the target material in g/mol, λ is the decay 
constant of the reaction product in s-1, t is the time of irradiation in s, σ(E) is the cross section as a 
function of energy in cm2, and S(E) is the total stopping power in units of MeV•cm2•g-1. 







dE  (2-10) 
A physical yield rate in units of Bq/µA•h can be obtained by evaluating Equation 2-10 for 1 h at 
1 µA over any given energy range. When the initial and final particle energies are known, these 





2.4.4 General Targetry 
Several methods to produce traditional PET radionuclides using a low-energy cyclotron have been 
optimized.22 In most cases, these methods involve the use of gas or liquid targets containing non-
metal target material (e.g., H2O, N2, and Ne) that allow for rapid heat exchange. These targets 
enable prompt transfer of the radionuclide after production via pressurized tubing to automated 
radiosynthesis modules.  
 In contrast, novel radionuclides are often produced using solid targets that contain metal or 
metal oxide target materials. Unlike gas or liquid targets, the most limiting factor in solid targets 
is heat dissipation.23 Energy deposition (heat) occurs as particles pass through a material. The 
majority of energy loss takes place as the particles decelerate due to stopping power. The stopping 
power is the incremental loss of energy E per unit distance traveled, x (Equation 2-11) in a 
medium.  
  S(E) =  −dE
dx
     (2-11) 
The stopping power of a material is dependent on the material properties, the particle energy, and 
the particle type. In this work, the software The Stopping and Range of Ions in Matter (SRIM) was 
used to model the energy loss of ions in matter and their range.24 For solid targets and their target 
material, the stopping power will increase as the traveling particle decelerates and loses energy 
before reaching a maximum and dropping to zero. This maximum, known as the Bragg peak, is 
the region with the greatest heat deposition. Thus, solid targets are often designed using materials 




Table 2-1. Material Properties25 
Property Aluminum Niobium Tantalum 
Thermal Conductivity (W⋅m-1⋅K-1) 237 53.7 57.5 
Heat Capacity (J⋅mol-1⋅K-1) 21.5 10.6 3.34 
Melting Point (°C) 660 2470 2996 
 
 To increase cooling of the solid target and target material, the heat can be drawn from the 
conductive target by forced convective heat transfer. This is often accomplished using flowing 
water driven by a pump. Other factors that affect radionuclide production with solid targets include 
cost and availability of the target material, complexity of the chemical separation, and recycling 
of enriched target material (if necessary). In most cases, production with solid targets will increase 
material handling and require development of technologies for automating the production (to limit 
worker exposure to strong radiation fields), digestion, and purification of an irradiated target 
(which are different from those reported with gas and liquid targets).14  
2.4.5 Radionuclide Production on the TR-24 Cyclotron 
The TR-24 cyclotron at UAB can deliver proton beams with energies of 17-24 MeV with a 1 cm 
diameter at currents up to 0.3 mA. These protons can be used to produce various radioisotopes. 
For example, protons accelerated by the TR-24 under 20 MeV are used to produce 18F (see Section 
1.4.1), 11C (see Section 1.2.1), 13N (see Section 1.2.1) 15O (t1/2 = 122.2 s), 89Zr (t1/2 = 78.4 h), and 
64Cu (t1/2 = 12.7 h).1 Unlike lower-energy cyclotrons, the TR-24 also allows production of 
radionuclides via intermediate energy nuclear reactions that have low cross section values at 
energies below 20 MeV. Generally, the majority of cyclotrons producing medical radionuclides 
employ protons with an energy below 20 MeV to produce PET radionuclides.22 The TR-24 was 




lines and the capability to irradiate two targets simultaneously (Figure 2-18). 
 
Figure 2-18. The TR-24 cyclotron and vault schematic 
It currently has three target stations that were designed to mount solid targets and irradiate them at 
energies up to 24 MeV (Figure 2-18). The three target stations are configured to mount target 
material at a grazing angle of 7°and 20°, or orthogonal to the horizontal beam. Target assemblies 
mounted onto target stations are cooled by flowing water that contacts the back of the target. For 
targets mounted onto the 20° and 90° target stations, the target face is cooled using helium gas. 
The configuration of each target station constrains the design of the entire target assembly (also 
referred to as the target), which houses the target material (i.e., the material that is irradiated to 
produce the radionuclide of interest) in a fixed position on the TR-24. These constraints are 
detailed below. 
 The 90° target station accepts circular targets that have a maximum target thickness of 2 mm 




and services all components of the cyclotron including the target stations. To avoid affecting 
cyclotron performance, protons must fully stop in the target during target irradiation to prevent 
activation of the cooling water. At 24 MeV, the maximum range of a proton in aluminum is 
approximately 3 mm.24 Thus, the combination of target material and the choice of metal housing 
material for each target were carefully considered to prevent the exit of low-energy protons. 
Targets designed to mount powders or poorly densified material included features that fully 
contained the target material to avoid radiological contamination. 
 The 7° and 20° target stations, due to their slant relative to the proton beam, will stop protons 
in the target. The stations accept maximum target thicknesses of 5.7 mm and 3 mm, respectively. 
Due to the incident angle of the beam, the beam profiles for both stations are elliptical, which leads 
to a more diffuse deposition of beam power. The stock ACSI high power targets (7° station) were 
designed to allow greater water flow rates that improve cooling efficiencies and the 20° station has 
water flow rates similar to the 90° station. Like the 90° target station, target material mounted onto 
either slant target station must be secured, and powders or poorly densified material must be 
contained to avoid radiological contamination. 
 Solid target assemblies were developed and tested in this work using materials shown in Table 
2-1. These targets were designed based on the desired target material and physical constraints 
levied by the solid target end-stations on the TR-24 (Figure 2-18). Each target was also designed 
to promote heat transfer via conductive and forced convective cooling. 
Aluminum Target Holder 
An Al (ρAl = 2.7 g/cm3) solid target was designed by Dr. Tommaso S. Carzaniga and Dr. Saverio 
Braccini at the University of Bern at the Laboratory for High Energy Physics. The 2 mm thick 





Figure 2-19. Cross section drawing of Al target assembly 
The solid target had a base and cap that were secured by radially positioned SmCo (samarium-
cobalt) magnets. These magnets lay outside the beam strike area. The circular 500 μm bore 
centered in the base had a diameter of 7 mm. It contained up to 60 mg of pressed TiO2. A 1 mm 
diameter Viton O-ring created a seal between the base and cap that enclosed the target material. 
Based on the TR-24 constraints, these Al targets were tested at proton energies and beam currents 
of up to 17 MeV and 20 μA, respectively. 
Niobium Target Holder 
A Nb (ρNb = 8.57 g/cm3) solid target was designed at UAB. The 2 mm thick circular assembly had 
a 24 mm diameter (Figure 2-20).  
 
Figure 2-20. Cross section drawing of Nb target assembly 
The solid target base had a centered 600 μm circular bore with a 10 mm diameter. It contained a 
250 μm thick Ti foil with a 10 mm diameter. Direct contact (heat conduction) between the foil and 
Nb was achieved using a single-turn stainless steel spiral internal retaining ring with a 10.1 mm 
outer diameter. After each irradiation, the retaining rings were removed, radionuclides produced 




energies and beam currents of up to 24 MeV and 40 μA, respectively. 
Tantalum Target holder 
A Ta (ρTa = 16.69 g/cm3) solid target was designed at UAB. The 2mm thick circular two-piece 
assembly had a 24 mm diameter (Figure 2-21).  
 
Figure 2-21. Cross section drawing of Ta target assembly 
The solid target base had a centered 400 μm circular bore with a 10 mm diameter. It contained up 
to 120 mg of pressed TiO2. A 0.5 mm diameter Viton O-ring created a seal between the base and 
a 100 μm thin cap that enclosed the target material (similar to the Al target design). Direct contact 
between the pressed TiO2, Ta base, and thin cap (Ti or Ta) was achieved using a single-turn 
stainless steel spiral internal retaining ring with a 10.1 mm outer diameter. After each irradiation, 
the retaining rings were removed, allowed to decay, and discarded. These Ta targets were tested 
at proton energies and beam currents up to 24 MeV and 35 μA, respectively. 
2.5 Production of Sc Radioisotopes from Titanium 
2.5.1 Nuclear Reactions on Natural Titanium 
Titanium (Z = 22) is a low-density (4.5 g/cm3) lustrous-silver transition metal with five stable 
isotopes.25 It is known for its corrosion resistance and strength-to-density ratio and is primarily 
used as an alloy with other metals (e.g. Fe or Al) to produce strong and lightweight alloys. In 2016, 
170,000 tons of Ti was produced. It most often adopts a +4 oxidation state and octahedral 




2-1).25 It is not a refractory metal but has many of the common refractory metal characteristics 
(e.g. m.p. = 1660 °C).25 Titanium nuclei (Figure 2-22) bombarded with protons and photons at 
energies that range from 0-24 MeV will induce nuclear reactions that produce 43Sc, 44mSc, 44gSc, 
46Sc, 47Sc, and 48Sc and other radionuclides. 
 
Figure 2-22. A select region of the Chart of the Nuclides (Z = 21 to 23)1 
A summary of the different reactions that can occur when bombarding natural titanium with 




Table 2-2. Proton- and photon-induced nuclear reactions on Ti nuclei9, 26 
Radionuclide Nuclear Reaction Q-value (MeV) Threshold (MeV) 
43Sc 46Ti(p,α) -3.07 3.14 
 47Ti(p,n+α) -11.95 12.21 
44mSc/44gSc 47Ti(p,α) -2.25 2.30 
 48Ti(p,n+α) -13.88 14.17 
 49Ti(p,2n+α) -22.02 22.47 
46Sc 47Ti(p,2p) -10.46 10.69 
 48Ti(γ,n+p) -2.21 2.21 
 49Ti(p,α) -14.37 14.67 
 50Ti(p,n+α) -1.94 1.98 
47Sc 48Ti(p,2p) -11.44 11.68 
 48Ti(γ,p) -1.14 1.14 
 49Ti(γ,n+p) -1.96 1.96 
 50Ti(p,α) -2.23 2.28 
48Sc 49Ti(γ,p) -1.13 1.13 
 49Ti(p,2p) -11.35 11.59 
47V 47Ti(p,n) -3.71 3.79 
 48Ti(p,2n) -15.34 15.66 
48V 47Ti(p,γ) 6.83 0.0 
 48Ti(p,n) -4.79 4.89 
 49Ti(p,2n) -12.93 13.20 
 
The proton-induced reactions on naturally isotopic Ti (natTi) have been described and these 
reactions on natTi were initially investigated using Ti foils to develop targetry and target processing 
strategies.9 Developing this expertise allowed the use of more expensive isotopically enriched Ti 
target material to produce 43Sc, 44Sc, and 47Sc. 




Reaction Data (EXFOR) database and used to predict (Equation 2-9) the approximate end-of-
bombardment (EOB) yields of reaction products. In parallel, these predicted yields were verified 
using the TR-24 (90° target station) to bombard natTi foils with protons at energies up to 24 MeV. 
The natTi foils were mounted onto disc shaped Nb target holders (see Section 2.4.5), irradiated, 
dissolved in mineral acid, and their EOB yields were determined by measuring small aliquots of 
each digestant with a gamma detector. The measured and predicted yields are shown in Figure 
2-23. 
 
Figure 2-23. Plot showing predicted EOB yield and experimental EOB yield for natTi(p,x) 
reactions 
The yields (determined by γ-ray measurement) agreed with the predicted yields based on EXFOR 
data. These results from early experiments showed that significant quantities of Sc radioisotopes 




target processing strategies and radiosynthesis of nuclear molecular imaging agents. The key 
limitation of this production route (with natTi) is the low radioisotopic and radionuclidic purity of 
43Sc, 44Sc, and 47Sc. Thus, production using enriched 46Ti, 47Ti, and 50Ti was investigated in order 
to obtain radiopure mixtures of 43Sc, 44Sc, and 47Sc. 
2.5.2 Nuclear Reactions on Enriched Titanium 
Enriched Ti material (46Ti, 47Ti, 48Ti, and 50Ti) can be used to produce 43Sc, 44Sc, and 47Sc while 
minimizing the co-production of 46Sc and 48Sc and other radionuclidic impurities. Due to the cost 
of enriched Ti ($3-30/mg), irradiated target material must be recovered during target processing 
so that it can be recycled. After recovery, this material can be precipitated and combusted as TiO2. 
The recovered TiO2 can be directly converted to Ti metal via reduction but this process can be 
difficult due to a large and positive Gibbs energy (e.g., >350 kJ⸱mol-1). The direct reduction of 
TiO2 to Ti metal can occur via a metallothermic reaction. Metallothermic reactions are 
displacement reactions that use reactive metals to reduce compounds so that metals, alloys, 
nonmetal elementary substances, and composites are produced.27 For example, metallic calcium, 
which is air reactive and requires handling in inert atmosphere, can be used to reduce TiO2 to Ti 
at temperatures above 1000°C.3 Due to the stability of TiO2 (positively large Gibbs energy) the 
reduction to Ti using hydrogen is not feasible.  
 In this work, direct reduction was avoided due to the many handling steps and likely loss of 
enriched target material that would occur during iterative use (i.e., recycling target material). 
Instead, target holders were developed to contain and mount TiO2 such that it could be irradiated 
with protons. The Al target holder (see Section 2.4.5) and Ta target holder (see Section 2.4.5) were 
used for irradiation of TiO2 at energies up to 17 MeV and 24 MeV, respectively.  




47V and 48V (from reactions on 47Ti and 48Ti) due to the magnitude of their cross sections (Figure 
2-24).  
 
Figure 2-24. Reactions that produce 48V and 47V on Ti nuclei28-32 
Figure 2-24 shows that as proton energies drop below 20 MeV increasing quantities of 47V and 
48V will be produced. The EOB yields for these contaminants will depend on the amount of 46Ti, 
47Ti, and 48Ti present in the target material. Fortunately, co-produced 47V and 48V can be separated 
from radioscandium during target processing to improve radionuclidic purity of the desired 
product.  
 In contrast, co-produced contaminant radioisotopes of Sc cannot be chemically separated from 
the desired Sc product; thus, their excitation functions should be used to define proton energies 
that limit their production. Likewise, the excitation functions for the desired 46Ti(p,α)43Sc, 
47Ti(p,α)44m,44gSc, 48Ti(p,2p)47Sc and 50Ti(p,α)47Sc reactions can be used to maximize the 
production of the 43Sc, 44Sc, or 47Sc radioisotope of interest. Unfortunately, few measurements of 




out and so cross section quantities predicted by the nuclear reaction code TALYS have been 
included in the plots below.29 
Production of Scandium-43 
Scandium-43 can be produced via the 46Ti(p,α)43Sc reaction (Figure 2-25) using enriched 46Ti. 
 
Figure 2-25. The 46Ti(p,α)43Sc excitation function28, 33 
Figure 2-25 indicates that proton energies from 24 MeV to 10 MeV span the excitation function 
peak. Titanium-46 can be obtained at enrichment levels up to 97%. The likely isotopic impurities 
are 47Ti and 48Ti, the latter due to its high natural abundance. Figure 2-26 shows the excitation 





Figure 2-26. Excitation functions of contaminant reactions on 47Ti and 48Ti28 
If the proton energy range is reduced to 18 MeV or less, the predicted radioisotopic contaminants 
will be 44mSc and 44gSc (Figure 2-26). 
Production of Scandium-44 
Scandium-44 in its ground state and its nuclear isomer, can be produced via the 47Ti(p,α)44m,44gSc 





Figure 2-27. The 47Ti(p,α)44m,44gSc excitation function28, 29 
Figure 2-27 indicates that proton energies from 24 MeV to 10 MeV span the excitation function 
peak. Titanium-47 can be obtained at enrichment levels up to 95%. The most likely isotopic 
contaminants are 48Ti and 49Ti due to similar mass numbers and natural abundance. Figure 2-28 






Figure 2-28. Excitation functions of contaminant reactions on 47Ti, 48Ti and 49Ti28, 29 
If the proton energy range is narrowed (approximately 20 MeV to 10 MeV), the primary 
radioisotopic contaminants will be 46Sc and 47gSc (Figure 2-28). 
Production of Scandium-47 
Scandium-47 can be produced via the 48Ti(p,2p)47Sc and 50Ti(p,α)47Sc reactions (Figure 2-29) 





Figure 2-29. The 48Ti(p,2p)47Sc and 50Ti(p,α)47Sc excitation functions28, 29, 32 
Figure 2-29 indicates that proton energies from 24 MeV to 17 MeV and 24 MeV to 8 MeV span 
portions of the excitation function peak for the 48Ti(p,2p)47Sc and 50Ti(p,α)47Sc reactions, 
respectively. These enriched isotopes can be obtained at enrichment levels up to 99% and 80%, 
respectively. Titanium-48 can be obtained with the highest enrichment factor (due to its natural 
abundance); however, 48Ti is the likely isotopic impurity in enriched 50Ti. Enriched 50Ti that 
contains mostly 48Ti as an isotopic contaminant allows 47Sc production via both reaction pathways. 
Figure 2-30 shows the excitation function for the reactions on these impurities (i.e., 48Ti, 49Ti, and 





Figure 2-30. Excitation functions of contaminant reactions on 48Ti and 50Ti28, 29 
Figure 2-30 indicates that a thick target could be used with 24 MeV protons and the predicted 
radioisotopic contaminants will be 46Sc, 44mSc, 44gSc, and 48Sc (Figure 2-30). However, in both 
cases (enriched 48Ti and 50Ti), due to the long half-life of 46Sc, a maximum proton energy of 24 
MeV can be used without significant co-production of 46Sc. 
 The above excitation functions illustrate that production of Sc radionuclides with enriched Ti 
target material will result in complex mixtures that include radioisotopic contaminants that will 
affect radionuclidic purity. Further, in most cases, experimental measurements are needed to 
determine the optimal proton energies to maximize 43Sc, 44Sc, and 47Sc yield while minimizing co-
production of radioisotopic contaminants. 
2.6 Production of Titanium-44 from Scandium 
Scandium (Z = 21) is a low-density (2.99 g/cm3), naturally occurring silvery-white metal with 1 
stable isotope 45Sc.25 It develops a yellowish hue when oxidized by air. It is extracted as Sc2O3 




thermal conductivity (relative to Al) of 15.8 W⋅m-1⋅K-1.25 It is a soft metal that can be easily 
machined and has a melting point of 1541°C.25 Sc nuclei bombarded with protons at energies from 
0 – 30 MeV will produce 44mSc, 44gSc, 45Ti (t1/2 = 184.8 min), and 44Ti.  
Table 2-3. Proton-induced nuclear reactions on Sc nuclei9, 26 
Radionuclide Nuclear Reaction Q-value (MeV) Threshold (MeV) 
44mSc/44gSc 45Sc(p,n+p) -11.33 11.58 
45Ti 45Sc(p,n) -2.84 2.91 
44Ti 45Sc(p,2n) -12.38 12.65 
 
Titanium-44, which is of interest for its use in a 44Ti/44Sc generator, can be produced via the 
45Sc(p,2n)44Ti reaction using monoisotopic 45Sc (Figure 2-31).  
 
Figure 2-31. The 45Sc(p,2n)44Ti excitation functions28, 29, 34, 35 
Figure 2-31 indicates that a proton energy from 24 MeV to 13 MeV will span a large portion of 
the excitation function peak (at energies up to 24 MeV) for the 45Sc(p,2n)44Ti reaction. Scandium-




function for the reactions on 45Sc that will co-produce radionuclides.  
 
Figure 2-32. Excitation functions of contaminant reactions on 45Sc28, 29, 34, 36 
Due to the long half-life of 44Ti (see Section 2.1), co-production of 45Ti, 44mSc, and 44gSc do not do 
not need to be taken into account when selecting the irradiation parameters, such as proton energy. 
In this case, the irradiated 45Sc can be stored for 30 days to allow decay of 44mSc. The short-lived 
45Ti will mostly decay 30 h after EOB. 
2.7 Post-Irradiation Target Processing 
The radionuclides produced via irradiation of a target must be chemically separated from the target 
material and purified from both stable and radioactive contaminants. In this work, approximately 
10 kBq to 3 GBq (10-15 to 10-8 g) of 43Sc, 44Sc, or 47Sc was produced in Ti (0.05 to 0.12 g) along 
with elemental impurities like Fe and Zn (10-7 to 10-5 g) that lead to contaminant radionuclides 
(via unwanted nuclear reactions). In general, techniques that are utilized for purification and 
isolation of target radionuclides include solvent extraction, electro-deposition, precipitation, 
distillation, and ion-exchange chromatography. This work uses ion-exchange chromatography, 




electrostatic interactions with functional groups fixed to a chromatographic support. The nature of 
this technique requires that irradiated target materials be digested to obtain the target radionuclide 
in a stable solvated form.  
2.7.1 Target Digestion 
The digestion (i.e., dissolution) of irradiated Ti metal and TiO2 is an essential part of the production 
and purification of 43Sc, 44Sc, and 47Sc. Titanium is known to have excellent corrosion resistance 
due to a stable and strongly adherent oxide film (TiO2) that spontaneously forms when it is exposed 
to air. The formation of this film can be accelerated by heating or by exposure to oxidizing agents 
(e.g., HNO3). Thus, a successful digestion method must be able to attack the TiO2 film. 
 Historically, hydrofluoric acid (HF) has been the most effective acid for breaking the strong 
Si-O bond (Average bond enthalpy = 798 kJ/mol) that prevents or complicates extraction of metals 
from geological samples.37 Likewise, It can be used to rapidly attack (i.e., break) the strong Ti-O 
bond (Average bond enthalpy = 662 kJ/mol).37 In aqueous HF, the digestion of TiO2 occurs via 
Equation 2-12 to form the colorless hydrogen hexafluorotitanate(IV). 
  TiO2 + 6HF → H2TiF6 + 2H2O   (2-12) 
The digestion of Ti metal in aqueous HF occurs via two steps (Equation 2-13 and Equation 2-
14).37, 38 
  2Ti (s) + 6HF (aq) → 2TiF3 (aq) + 3H2 (g)  (2-13) 
  4TiF3 (aq) + 4HF (aq) + O2 (g) → 4TiF4(aq) + 2H2O (l) (2-14) 
Thus, Ti digested by HF, results in solutions containing Ti(III) and Ti(IV) that have an intense 
dark-violet color.  
 Alternatively, mixtures of HF-HCl can be used in place of concentrated HF. These systems at 




colored solution.39 The use of HF-HCl systems were investigated in this work to digest Ti metal 
and TiO2. 
2.7.2 Ion-exchange Chromatography 
Ion-exchange chromatography, like other liquid chromatography techniques, involves a mobile 
phase and a stationary phase. In this application, the mobile phase contains the dissolved target 
material, the desired radionuclide, and any impurities. The stationary phase is a chromatographic 
support (inert organic matrix) fixed with ionizable functional groups that can carry displaceable 
ions. Equation 2-16 models the interaction of a cationic radionuclide (M+) and a mobile phase 
cation (C+) carried by an anionic functional group (F-) bound to a solid support (S).  
 S − F−C+ + M+  ↔  S − F−M+ + C+   (2-16) 
If the magnitude of the electrostatic interactions between M+ and F- are greater than C+ and F- then 
the cationic radionuclide (present as a complex ion in solution) will be retained by the functional 
group. This action displaces the mobile phase cation. Subsequently, the mobile phase composition 
can be adjusted to displace the retained M+.  
 The three chromatographic resins (Figure 2-33) used in this work were branched N,N,N’,N’-
tetra-2-ethylhexyldiglycolamide (BDGA) and two styrene divinylbenzene copolymer lattices 





Figure 2-33. Three cation exchange resins used in this work 
The magnitude of the electrostatic interaction at different mobile phase compositions with these 
resins can be measured to determine selectivity for one cation over another. These data can be used 
to develop selective gradients that separate one cationic species from another. This same process 
could be used with anionic species when the ionizable functional groups are capable of carrying 
displaceable anions.  
2.8 Summary 
The medically relevant radioisotopes of Sc (43Sc, 44Sc, and 47Sc) can be produced using natTi and 
enriched Ti (46Ti, 47Ti, 48Ti, and 50Ti) as a target material. Further, an alternative production route 
for 44Sc (which yields only the ground state of this isotope) involves the cyclotron production of 
44Ti via the 45Sc(p,2n)44Ti reaction. Titanium-44 via its decay to 44Sc could be used in a 44Ti/44Sc 
radioisotope generator. These radioisotopes can be produced using energetic protons and photons 
to induce nuclear reactions; however, in some cases the probabilities of these reactions (i.e., cross 
sections) are not well studied. In each case, the radioisotope of interest will be contained in a Ti 
metal, TiO2, or Sc matrix. After irradiation, these materials must be digested and aqueous 
analytical techniques employed to purify 43Sc, 44Sc, 47Sc, and 44Ti from the irradiated target 




the photonuclear production of 47Sc using natTi metal using a 22 MeV medical eLINAC that was 
repurposed for basic physics research. 
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Chapter 3: Photonuclear Production, 
Chemistry, and In Vitro Evaluation of the 
Theranostic Radionuclide 47Sc 
3.1 Introduction 
Theranostic applications in molecular imaging and therapy involve the use of a radionuclide or 
radionuclide pairs with nuclear, physical and biological characteristics that allow tailored imaging 
and therapy in the same patient.1 This personalized approach to nuclear medicine offers the 
possibility of matching the properties of different theranostic radionuclides with a targeting vector 
for distinct tumor types. Important parameters considered when selecting suitable radionuclides 
include availability, chemistry, biological properties, half-life and decay properties. Therefore, 
better matching of radionuclide properties to different diseases can be enabled by the development 
of new production routes for hard to obtain theranostic radionuclides. Thus, increasing the number 
of available medical radionuclides will motivate more innovative diagnostic and therapeutic agents 
for use in personalized nuclear medicine.1-3 
 Recently, the development of multiple receptor-targeted radionuclide therapies has highlighted 
the need for the rapid and complete assessment of their pharmacokinetics.4-6 To address this need, 
imaging with a chemically identical diagnostic (labeled with a radionuclide of the same element) 
affords the truest picture of in vivo distribution for the therapeutic agent.7 Therefore, the 
development of matched-pair radionuclides for use in receptor-targeted therapies and imaging is 
an emerging area of research. Unfortunately, the limited availability of a number of the most 




therapeutic agents to the clinic.7 
 The theranostic radionuclide 47Sc (Figure 2-7) is compatible with the biological half-life of 
antibodies or peptide-based radiopharmaceuticals.8, 9 Further, 43Sc (Figure 2-2) and 44Sc (Figure 
2-3) have been proposed as diagnostic radionuclides for PET imaging.10 The mode of decay, 
emitted particles, and emitted γ-rays for each Sc radioisotope were introduced in Chapter 2, Section 
2.1. 
 Reactor production of 47Sc has been investigated using neutron capture on enriched titanium 
via the 47Ti(n,p)47Sc reaction (En > 1 MeV) or neutron capture on enriched 46Ca(n,γ)47Ca (En = 
0.025 eV), resulting in 47Ca (t1/2 = 4.54 d), which may be used for a 47Ca-47Sc generator system.11, 
12 One challenge facing development of a 47Ca-47Sc generator is the natural abundance of 46Ca 
(0.004%). Due to this abundance, it is only available at enrichment levels up to 30%.13 Accelerator 
production and measurement of cross sections for the production of 47Sc have been investigated 
using medium to high energy protons (17 < Ep < 150 MeV) via the natTi(p,2p)47Sc, 48Ti(p,2p)47Sc, 
51V(p,3pn)47Sc, and natCa(p,2n)47Sc reactions.1, 13, 14 Cyclotron production via the above methods 
resulted in co-production of 46Sc (Figure 2-8) and 48Sc (Figure 2-9), decreasing the radionuclidic 
purity of 47Sc. Production with spallation neutrons was also investigated via the 47Ti(n,p)47Sc, 
natV(n,x)47Sc and natTi(n,x)47Sc reactions.15 Based on these data, production routes that afford 
radionuclidic purity suitable for clinical application require costly enriched targets or access to 
nuclear reactors with a high-energy neutron flux (En > 1 MeV). Therefore, the poor availability of 
47Sc, due to the above factors, has hampered preclinical investigation and clinical application of 
the theranostic 47Sc/43Sc and 47Sc/ 44Sc matched-pair radioisotopes. 
 In an effort to address the above challenges, recent work has investigated the use of high-




via photonuclear reactions on titanium nuclei.16, 17 The electrons accelerated by these machines 
emit bremsstrahlung radiation (Figure 2-17) as they pass through matter, resulting in a spectrum 
of photon energies ranging from zero to the electron energy. A high-intensity flux of 
bremsstrahlung photons can be obtained by using a radiator or “converter” made from a high Z 
material, like W. A small fraction of the generated bremsstrahlung photons are energetic enough 
to induce photonuclear reactions such as (γ,n) and (γ,p) for radionuclide production.18, 19 The flux 
of bremsstrahlung photons can be enhanced with the use of a radiator or “converter” made from a 
high Z material, like W. The use of converter does not significantly alter the energy distribution of 
radiated photons, but it enhances the number of radiated photons and hence increases the number 
of radiated photons that are energetic enough to induce photonuclear reactions. For example, 
Rotsch et al. (2018) used natTiO2 targets to demonstrate a 47Sc production rate at 35 MeV and 40 
MeV of 4.25 MBq/g·kW·hr and 6.92 MBq/g·kW·hr, respectively, using bremsstrahlung photons.20 
Belyshev et al. (2015) showed that the integrated cross section of the natTi(γ,p)47Sc reaction, using 
thin titanium foils of natural isotopic composition, was 110 ± 19 mb using a 55 MeV electron 
beam.17 T. R. Sherwood and W. E. Turchinetz (1962) measured the cumulative cross section of 
the natTi(γ,p)47Sc reaction (Figure 3-1), yielding a peak cross section of approximately 28 mb at 





Figure 3-1. Excitation functions for the photon-induced 48,49Ti(γ,p)47Sc nuclear reaction21, 22 
 A high-intensity eLINAC facility capable of photonuclear radionuclide production has many 
advantages in contrast to reactor or other accelerator facilities. These advantages include reduced 
volume of radioactive waste, low cost and operation expense, and fewer nuclear reaction channels, 
which may lead to a higher radionuclidic and radioisotopic purity of the final product. The 
photonuclear production of 47Sc, 99Mo for 99Mo-99mTc generators, 67Cu for the 67Cu/64Cu 
theranostic matched-pair, 225Ac for targeted alpha therapy and 195mPt as a theranostic radionuclide 
has been reported using bremsstrahlung radiation.16, 19, 23-25 These reports show that a number of 
long-lived theranostic radionuclides or radionuclide pairs, including 47Sc, that suffer from lack of 
availability, may be produced by photonuclear reactions at eLINAC facilities. 
 In this work, the photonuclear production of carrier-free 47Sc via the natTi(γ,p)47Sc reaction 
using bremsstrahlung radiation generated by an electron beam (22 MeV Varian CLINAC) was 
investigated. To isolate the produced 47Sc from natTi target material, a separation method using AG 




using CHELEX 100 chelating resin. The purified 47Sc was used to radiolabel 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid-DPhe-c(Cys-Tyr-DTrp-Lys-Thr-Cys)-Thr-ol 
(DOTATOC) and the in vitro binding of [47Sc]Sc-DOTATOC was then established in somatostatin 
receptor subtype 2 (SSTR2)-expressing AR42J cells (Figure 3-2).  
 
Figure 3-2. The methods developed in this work 
These results show that future photonuclear production of 47Sc at a high-intensity eLINAC facility 
could represent a production route capable of producing the quantities needed for pre-clinical 
research and translation to the clinic of this important theranostic radionuclide. 
3.2 Materials & Methods 






All chemicals were analytical or trace metals grade. Deionized 18.2 MΩ⋅cm water (Milli-Q 
System; Millipore, Billerica, MA, USA) was used unless otherwise specified. Ammonium acetate 
(NH4CH3CO2, 99.999%), sodium hydroxide (NaOH, pellets, 99.995%), hydrogen peroxide (H2O2, 
TraceSELECT® Ultra ≥30), hydrochloric acid (HCl, 37 % wt. in water, 99.999%), nitric acid 
(HNO3, 70% wt. in water, 99.999%), and sulfuric acid (H2SO4, 95-98% wt. in water, 99.999%) 
were purchased from Sigma-Aldrich (St. Louis, Missouri, USA). Chelex® 100 chelating resin 
(100-200 mesh, Na+ form) and AG MP-50 cation exchange resin (100-200 mesh, H+ form) were 
purchased from BIO-RAD (Hercules, California, USA). 1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetraacetic acid-DPhe-c(Cys-Tyr-DTrp-Lys-Thr-Cys)-Thr-ol (DOTATOC) and L-Cysteinamide, 
D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-
hydroxy-1-(hydroxymethyl)propyl]-, cyclic (2→7)-disulfide (Octreotide) were purchased from 
Bachem Americas, Inc. (Torrance, CA, USA). Type 4N high-purity, 0.127 mm thick, natural 
titanium foil was purchased from ESPI Metals (Ashland, OR, USA). Scandium(III) nitrate hydrate 
(Sc(NO3)3, FW: 240.97 g/mol, 99.9%) was purchased from Alfa Aesar (Heysharn, Lancashire, 
UK). Stock solutions of 0.25 and 1.0 M ammonium acetate, pH adjusted to 4.7, were purified with 
columns containing Chelex® 100 resin prior to use. All glassware was acid washed in a 50% HNO3 
bath overnight at room temperature. 
Instrumentation 
A modified Varian CLINAC (2100, Palo Alto, CA, USA) located at Indiana University 
(Bloomington, IN, USA) was used for all irradiations. The CLINAC was described in previous 
work by Queern et al. (2018).26 To obtain a high-intensity flux of bremsstrahlung photons, a thin 
high Z material, W, was placed immediately upstream of the Ti target. The average electron beam 




Instrumentation (Saint Genis Pouilly, France). For calibration measurements, the transformer was 
mounted in the same location as the target holder. An electron beam energy of 22 MeV, the top 
setting with this CLINAC, was selected to maximize the photon flux in the region most likely to 
contain the highest photonuclear cross section for natTi(γ,p)47Sc. 
Photonuclear Production 
Scandium-47 was produced via the 48Ti(γ,p)47Sc nuclear reaction by irradiation of a natTi target 
foil-stack (39 foils, 2.0 x 2.0 x 0.135 mm) using bremsstrahlung radiation generated by impinging 
22 MeV electrons onto a 0.762 mm thick W radiator.  
Target Dissolution 
The region where the bremsstrahlung beam struck each foil was determined by imaging select foils 
for several hours with Gafchromic EBT3 radiographic film (Bridgewater, NJ, USA). The exposed 
films were used to create punch templates for foil 1, 5, 10, 15, 20, 25, 30, and 35. The templates 
were used to extract the activated Ti metal in each Ti target foil as discs using a McMaster Carr 
portable lever-operated hole-punch with a 3 to 4 mm punch (Douglasville, GA, USA). The 
extracted discs were split into three sets. Each foil set was placed in a 50 mL round bottom flask 
along with 20 mL of aqueous 2.0 M H2SO4. The flask was fitted with a reflux condenser, and the 
apparatus was heated at 350°C for 4 h using a sand filled mantle heater. During heating, the 
colorless solution became deep-violet and remained clear. After heating, 1.16 mL of 30% H2O2 





Figure 3-3. The method used to digest 3-4 mm Ti discs 
The solution was quantitatively transferred to a 100 mL beaker and the H2SO4 molarity was 
adjusted to 0.5 M by adding 59 mL of water. The final solution contained approximately 0.5% 
H2O2 in 80 mL of 0.5 M H2SO4. 
Resin Conditioning 
AG MP-50 and Chelex-100 resin were treated (to remove contaminants) before use by transferring 
50 g of each to a separate clean 500 mL glass media bottle. First, the resins were mixed with 20 
mL of 5.0 M HNO3. After sedimentation, the supernatant was decanted to remove fine resin 
particles and contaminants. This process was repeated twice. Next, the resins were mixed with 20 
mL of water. Similarly, the supernatant was decanted after sedimentation. This was repeated until 
the water, after mixing, had a pH of 7. The above process was then repeated using 2.0 M HCl. 
Finally, the treated resin was stored under water until use. 
Separation Method 
A separation method previously described by Kolsky et al. was adapted for this work.27 A glass 
column (0.5 x 20 cm) was slurry packed with treated AG MP-50 cation exchange resin to a wet 




through the column at a flow rate of 1.5 mL/min. The resin was equilibrated by passing 15 mL of 
0.5 M H2SO4 containing 2% H2O2 through the column. The digested Ti target material and 47Sc in 
approximately 80 mL of 0.5 M H2SO4 was loaded onto the column. The adsorbed Ti was eluted 
with 40 mL of 2% H2O2 in 2.0 M H2SO4. The resin was equilibrated with 10 mL of water and the 
adsorbed 47Sc was eluted with 20 mL of 1 M ammonium acetate (pH 4-5). This eluate, containing 
47Sc, was loaded onto a column (0.5 x 20 cm) containing Chelex® 100 chelating resin packed and 
prepared under conditions as described above. The adsorbed 47Sc was rinsed with 20 mL of water 
and eluted in 5.0 mL of 12.1 M HCl (Figure 3-4). 
 
Figure 3-4. The two-step purification of 47Sc 
 After elution, the eluate was evaporated to a wet salt by gentle heating under nitrogen gas flow. 
This residue was dissolved in 1 mL of water and evaporated to dryness. This process was 
completed twice, resulting in a final product pH of 7. The final product was dissolved in 400 µL 
of 0.25 M ammonium acetate (pH 4), which was used as the 47Sc solution for subsequent 





Fractions preserved from separations in this work were analyzed via inductively coupled plasma 
mass spectrometry (ICP-MS) to determine the concentration of elements present. Multi-element 
standards in 2% HNO3 at 1, 50, 100, 250, 500, 750, and 1000 mg/L were used for instrument 
calibration. For each collected fraction, an aliquot was diluted in 2% HNO3 and analyzed on an 
Agilent Technologies 7800 ICP-MS (Santa Clara, CA, USA) to determine the presence of 
transition metals. Agilent software, ICP-MS MassHunter v4.3, was used for data acquisition and 
analysis. 
γ-Ray Spectroscopy 
Samples containing radionuclides in this work were characterized and quantified by γ-ray 
spectroscopy using a Canberra GC2018 high-purity germanium (HPGe) detector with a relative 
efficiency of 24.5% (Meriden, CT, USA) connected to a Canberra DSA-100 multichannel analyzer 
(Meriden, CT, USA). Canberra Genie 2000 software was used for all data acquisition and analysis 
(Meriden, CT, USA). An energy and efficiency calibration was performed using a mixed nuclide 
source in a sealed 1.5 mL microcentrifuge vial prepared by Eckert & Ziegler Analytics (Atlanta, 
GA, USA). Efficiency-calibration spectra with a minimum photopeak area of 2 x 105 counts were 
collected and fit to a fourth-order polynomial to determine the detector efficiency.28 For all 
measurements, aliquots of sample material were transferred to a 1.5 mL vial, diluted to 1 mL, and 
suspended in a fixed acrylic holder at a distance of 5 cm from the HPGe detector. This geometry 
was maintained for all samples. The activity of characterized radioisotopes was determined based 
on the net peak area in each photopeak.29 For each photopeak, the activity (A0) at the beginning of 
the decay-counting measurement was determined according to Equation 4-1 where λ is the decay 
constant of the radioisotope in s-1, NA is the net peak area, Iγ is the branching ratio of the γ-ray, ε 




measurement, and tR is the real time of measurement in s. 
  𝐀𝐀𝟎𝟎 =
𝛌𝛌𝐍𝐍𝐀𝐀
𝐈𝐈𝛄𝛄𝛆𝛆(𝟏𝟏−𝐃𝐃𝐃𝐃)(𝟏𝟏−𝐞𝐞−𝛌𝛌𝐭𝐭𝐑𝐑)
    (4-1) 
For all measurements, the average dead time was less than 5%.  
Radiosynthesis of [47Sc]Sc-DOTATOC 
As described by Pruszynski et al., radiolabeling of DOTATOC (1,421.60 g/mol) with 47Sc was 
carried out in pH 4-5 0.25 M ammonium acetate buffer.30 In brief, 60 μL of a 6.4 μg/μl aqueous 
DOTATOC stock solution was added to 40 μL of 0.25 M ammonium acetate buffer in a 1.5 mL 
centrifuge vial. To this vial, 1.7 MBq of 47Sc dissolved in 200 μL of 0.25 M ammonium acetate 
was added. The reaction pH and final concentration of DOTATOC (270 nmol in 300 µL) was pH 
4-5 and 0.9 mM, respectively. The reaction mixture was incubated for 30 minutes at 95°C using 
an Eppendorf Thermomixer set to 800 rpm. 
[47Sc]Sc-DOTATOC Characterization 
Radiochemical analyses were performed using radio thin layer chromatography (radio-TLC) and 
radio high-performance liquid chromatography (radio-HPLC). Radio-TLC analyses were 
performed using Agilent Technologies instant TLC-SA (iTLC) chromatography paper (Santa 
Clara, CA, USA) and were developed using a 1:1 mixture of 1.0 M ammonium acetate and 
methanol. TLC plates were read using an Eckert & Ziegler AR-2000 radio-TLC system 
(Hopkington, MA, USA) and Eckert & Ziegler Winscan 3.0 software (Hopkington, MA, USA) 
was used to define regions of interest (ROI) and integrate peaks. Radio-HPLC analyses were 
performed on an Agilent Technologies HPLC (Infinity 1260, Santa Clara, CA, USA) equipped 
with a multi-wavelength diode-array detector followed by an in-line LabLogic NaI detector (Flow-
RAM Galbi NaI, Brandon, FL, USA) using a Thermo Scientific C18 analytical column (BetaBasic, 




software was used for radio-HPLC data collection and analysis. Before any measurement by radio-
HPLC, solvents (HPLC grade) were degassed and water used for HPLC mobile phase was passed 
through a 0.22 µm filter. The HPLC method involved use of two solvents (A & B). Solvent A was 
acetonitrile (ACN) with 0.1% trifluoroacetic acid (TFA) and Solvent B was water with 0.1% TFA. 
The gradient elution began at 5%(A):95%(B) and changed linearly to 80%(A):20%(B) over 20 
min at 1.0 mL/min.  
Cell Culture 
All cell culture materials were purchased from Fisher Scientific unless otherwise noted. The 
SSTR2 positive rat pancreatic cancer cell line AR42J (ATCC, Manassas, VA, USA) was cultured 
in GibcoTM IMDM media supplemented with 10% fetal bovine serum (FBS) and 0.1% gentamicin. 
Cells were incubated at 37 °C in a 5% CO2 atmosphere and were harvested using 0.05% trypsin-
EDTA. Cells were washed once with supplemented IMDM prior to use. Cells were counted with 
a Nexcelom (Lawrence, MA, USA) auto T4 bright field cell counter. 
Competitive Binding Assay 
AR42J cells were seeded into two 24-well plates (8-wells/plate) in 1 mL of media (1 x 105 
cells/well) and incubated overnight. After incubation, media was discarded, and 1 mL of 75 kBq 
[47Sc]Sc-DOTATOC (12 μM) in IMDM media was transferred into each non-blocking well (4-
wells/plate). For the blocking study, 1 mL of 75 kBq [47Sc]Sc-DOTATOC containing 40 μM 
Octreotide was added into each blocking well (4 wells/plate). Additional 1 mL aliquots of the 
blocking and non-blocking solutions were transferred into empty wells on each plate as a reference. 
One mL of each solution, blocking and non-blocking, was transferred to separate 1.5 mL centrifuge 
tubes and used as reference standards to determine total 47Sc added to each well. Subsequently, 
the two 24-well plates were incubated at 37 °C for 2 h (first plate) or 4 h (second plate). At each 




1.5 mL centrifuge tubes. All centrifuge tubes were counted in a HIDEX 300 SL automatic γ-
counter using a 3” NaI crystal (Turku, Finland). Data is expressed as percentage of added dose 
bound (% Bound) with the standard error of the mean (SEM). A one-way ANOVA test was applied 
to each set of data (blocking and non-blocking) at 2 h and 4 h to determine P values and difference 
between each observed mean. 
3.3 Results 
3.3.1 Scandium-47 Production 
An average 47Sc yield (n = 3 ± 1σ) of 80 MBq/mA·h was obtained using a 22 MeV electron beam 
with an average beam current of 2.5 μA (Table 3-1). 













1 03/29/2017 17:03:00 630 2.5 0.762 39 
2 05/07/2017 11:35:00 680 2.5 0.762 40 
3 10/06/2017 20:51:00 840 2.5 0.762 39 
 
Using radiographic film, the region attributed to 47Sc was mapped in select Ti foils. The beam 
strike, imaged on the film, of the entry (no. 1) and exit (no. 39) foil had an average diameter of 3 
and 4 mm, respectively. Select foils were characterized and the presence of 46Sc (Figure 2-8), 47Sc, 
and 48Sc (Figure 2-9) were confirmed by γ-ray analysis. The EOB radioisotopic purities of 47Sc, 
46Sc, and 48Sc were determined by γ-ray analysis. The average Sc decay-corrected to EOB 
radioisotopic purities (n = 9 ± 1σ) were (90.0 ± 0.1)% 47Sc, (1.2 ± 0.1)% 46Sc, and (8.3 ± 0.1)% 
48Sc. Figure 3-5 shows the post-EOB radioactive decay of 46Sc, 47Sc, and 48Sc and the change in 





Figure 3-5. The decay of Sc radioisotopes and 47Sc radioisotopic purity31 
The maximum 47Sc radioisotopic purity (Figure 3-5) was reached approximately 5.85 d post-EOB. 
Templates fashioned from exposed radiographic films were used to mechanically extract the 
region containing the greatest concentration of 47Sc. The average (n = 3 ± 1σ) extraction efficiency 





Figure 3-6. Scandium-47 extraction efficiencies from irradiated natTi foil31  
3.3.2 Digestion and Purification 
The extracted discs from each irradiation were split into three groups (A, B, and C) and dissolved 
in 2.0 M H2SO4 under reflux conditions. After digestion, the clear and deep-violet solution was 
cooled to room temperature. A 1 mL aliquot was removed from each group and analyzed with an 
HPGe detector to measure the activity associated with each radionuclide. Table 3-2 shows the 
average radioactivities decay-corrected to EOB for 46Sc, 47Sc, and 48Sc (sum of A, B, and C 
radioactivities). 
Table 3-2. The average (n = 3 ± 1σ) 46,47,48Sc radioactivities measured in the 
extracted natTi discs31 
Run 46Sc (kBq) 47Sc (kBq) 48Sc (kBq) 
1 26 (1) 2178 (7) 229 (1) 
2 25 (1) 2111 (124) 210 (17) 
3 32 (1) 2420 (138) 222 (14) 
 
The digestion solution was adjusted to contain two percent of 30% H2O2 dissolved in 0.5 M H2SO4. 
Upon addition of hydrogen peroxide, the solution rapidly changed color to an intense orange but 
remained clear. In previous work, Müller and Schwarzenbach characterized the orange 
peroxytitanium(IV) species in solutions below pH 1, in general form, as Ti(O2)(OH)n-2(4-n)+; 
however, the number of hydroxyl groups has not been shown conclusively.32 The mixture of Sc 
radioisotopes and peroxytitanium species mixture was directly loaded onto a column containing 
AG MP-50 resin.  
 For the final optimized separation and purification (Run 3), an aliquot was taken at each point 
in the separation and analyzed by HPGe and ICP-MS. Due to weak peroxytitanium affinity for AG 




through and 1 M H2SO4 eluate. The average recovery (n = 3 ± 1σ) of bulk natTi target material was 
quantitative as measured by ICP-MS. After the first eluent, the AG MP-50 resin was rinsed with 
10 mL of water to remove hydrogen peroxide from the column. The strongly adsorbed Sc 
radioisotopes were recovered in 20 mL of 1 M ammonium acetate (pH 4.7). The average decay-
corrected EOB radioscandium recovery (n = 3 ± 1σ) was (92.2 ± 4.7)%. The concentration of 
metal contaminants including Cr, Cu, Fe, Ni, and Zn, were measured in the 1 M ammonium acetate 
eluate. The average concentrations (n = 3 ± 1σ) of each trace metal contaminant were 191 ± 15 
μg/L (Cr), 188 ± 36 μg/L (Cu), 414 ± 89 μg/L (Fe), 100 ± 30 μg/L (Ni), and 620 ± 296 μg/L (Zn) 
in 20 mL of eluate.  
 The eluate containing Sc radioisotopes was further purified by loading onto a column 
containing CHELEX 100 resin whereupon the Sc radioisotopes were strongly adsorbed. After 
rinsing with water, these radioisotopes were stripped from the column in 5 mL of 12.1 M HCl with 
an average (n = 3 ± 1σ) recovery of (91 ± 3)% decay-corrected to EOB. The total decay-corrected 
EOB average (n = 3 ± 1σ) recovery was (83 ± 3)%. Similar to the analysis after the first column, 
metal contaminants with a concentration greater than 1 μg/L were measured in the 5 mL of 12.1 
M HCl eluate. The average concentrations (n = 3, 1σ) of Cr, Cu, Fe, Ni, and Zn were 127 ± 6 μg/L 
(Cr), 169 ± 34 μg/L (Cu), 357 ± 154 μg/L (Fe), 107 ± 33 μg/L (Ni) and 189 ± 25 μg/L (Zn) in 5 




Table 3-3. The average (n = 3 ± 1σ) metal mass measured in the digestant and the 
  Sample Cr Cu Fe Ni Zn 
Digestant Mass (μg) 552 (30) 493 (72) 946 (35) 206 (24) 908 (620) 
Post AG MP-50 (μg) 3.9 (0.3) 3.8 (0.7) 8.4 (1.8) 2.0 (0.6) 13 (6) 
Post CHELEX 100 (μg) 0.6 (0.2) 0.8 (0.2) 1.8 (0.8) 0.5 (0.2) 1.9 (0.1) 
 
The overall reductions in Cr, Cu, Fe, Ni, and Zn after separation and purification were 99.9%, 
99.8%, 99.8%, 99.8%, and 99.9%, respectively. 
 For the final irradiation (Run 3), the 12.1 M HCl eluates containing Sc radioisotopes from 
groups A, B, and C were combined and evaporated to a wet residue under nitrogen gas with gentle 
heating (95°C). The residue was dissolved in 1 mL of water and evaporated. This process was 
repeated twice more. After the final evaporation was conducted, the residue was dissolved in 255 
µL of 0.25 M ammonium acetate (pH 4) after which a 10 µL aliquot was taken and analyzed. 





Figure 3-7. γ-ray spectra of the purified 47Sc solution31 
This solution contained a 47Sc concentration of 8.5 ± 0.4 kBq/μL. The average concentration of 
trace metal contaminants in 255 μL of solution were 0.8 ± 0.1 mg/L (Cr), 0.8 ± 0.1 mg/L (Cu), 1.6 
± 0.1 mg/L (Fe), 1.8 ± 0.1 mg/L (Ni), and 6.0 ± 0.3 mg/L (Zn). 
3.3.3 Radiosynthesis of [47Sc]Sc-DOTATOC 
DOTATOC was radiolabeled by adding 200 μL of 0.25 M ammonium acetate (pH 4.7) containing 
1.7 MBq of 47Sc to 100 μL of 0.1 M ammonium acetate (pH 4) containing 0.384 mg of DOTATOC 
(270 nmol). The final concentration of DOTATOC was 0.9 mM with a molar activity of 6.3 
kBq/nmol. The mixture was vortexed and incubated at 95°C for 30 minutes. The radiochemical 
yield was determined by radio-TLC and radio-HPLC (Figure 3-8). 
 
Figure 3-8. Radio-HPLC and radio-TLC chromatograms. Radio-HPLC analysis of DOTATOC 
(A, gray, tR = 8.8 min) and 47Sc (A, black, tR = 1.9 min). Radio-HPLC analysis of DOTATOC 




47Sc (C, Rf = 0) and [47Sc]Sc-DOTATOC (D, Rf = 0.8) in 0.25 M ammonium acetate developed 
in a 1:1 mixture of 1.0 M ammonium acetate and methanol.31 
The radio-TLC analysis of 47Sc, in a 1:1 mixture of 1.0 M ammonium acetate and methanol, had 
a single peak with an Rf value of 0. The same analysis of [47Sc]Sc-DOTATOC had a single peak 
with an Rf value of 0.8. The retention time of 47Sc and DOTATOC determined by HPLC analysis 
was 1.9 min and 8.8 min, respectively. The same analysis of the [47Sc]Sc-DOTATOC solution 
diluted with 0.25 M ammonium acetate showed a peak in the radio and UV/Vis (λ = 280 nm) 
spectra at 8.5 min and 8.8 min, respectively. These analyses showed the radiochemical yield was 
greater than 99.9%. Thus, the compound was used without further purification.  
3.3.4 Competitive Cell Binding Assay 
Binding of [47Sc]Sc-DOTATOC to AR42J cells was determined in vitro at 2 and 4 h. To determine 
if uptake of [47Sc]Sc-DOTATOC was receptor-mediated, the ligand Octreotide was used as a 
blocking agent due to its known affinity for SSTR2.33, 34 At 2 and 4 h (n =4 ) the percentage of 
bound [47Sc]Sc-DOTATOC was significantly decreased (p<0.0001 and p = 0.0071) in cells that 





Figure 3-9. The percentage of cell receptor bound or internalized [47Sc]Sc-DOTATOC is shown 
on the ordinate axis at 2 and 4 h (n = 4±1σ, SEM). Co-incubation (blocked) with SSTR blocking 
agent Octreotide significantly decreased cell uptake.31 
The maximum mean uptake and standard error of [47Sc]Sc-DOTATOC was achieved by 2 h (0.31 
± 0.02)%, as uptake at 4 h (0.32 ± 0.02)% was not significantly increased.  
3.4 Discussion 
Multiple irradiations of a natTi target foil-stack were carried out using a modified Varian CLINAC. 
The radioactivities and the beam dispersion throughout the target foil-stack were measured. The 
diameter of the region activated by the bremsstrahlung radiation increased from 3 to 4 mm 
throughout 39 natTi foils. For each foil, the region containing 47Sc was mechanically extracted, 
reducing the Ti mass involved in the separation. While this method and the use of natural titanium 
metal was suitable for this work, future studies that seek to optimize 47Sc yield will require 
enriched TiO2 (48Ti) target material, well-defined target geometry, target cooling, and optimized 
target mass due to the strong dependence between 47Sc yield and the target nuclei population (mass 




TiO2 target with a profile commensurate to the bremsstrahlung beam diameter will not require 
mechanical extraction. Secondly, the aqueous Ti4+ obtained after purification of 47Sc can be 
recovered as TiO2 at pH 8 by alkali-precipitation; thus, enriched target material could be recycled 
without employing high temperature techniques to reduce TiO2 to Ti metal. The disadvantage of 
this approach and of production methods that use photon-induced reactions are the large target 
masses (grams) required for production of large quantities of the radioisotope of interest. During 
purification, the analytical techniques developed in this work must be able to sequester grams of 
target material from 10-12 to 10-15 g of 47Sc. As future work continues on developing photonuclear 
production of 47Sc, these parameters should be optimized for high-intensity electron beams, as they 
will directly affect the recovery and purity of the chemically purified 47Sc product. 
 A number of Sc radionuclides may be co-produced when using a natTi target, including 44Sc, 
46Sc, 48Sc, and 49Sc. Similar to the photonuclear work previously reported by Mamtimin et al., 46Sc 
and 48Sc were experimentally observed in the Ti foils; however, 44Sc and 49Sc were not observed 
due to their short half-lives and maximum bremsstrahlung photon energy used in this work.18 The 
co-production of 46Sc presents the most significant challenge to using natTi as a target material 
since the 47Sc radionuclidic purity decreases over time due to the longer half-life of 46Sc. The two 
contaminant radionuclides, can, in principle, be produced via the 48Ti(γ,np)46Sc, 47Ti(γ,p)46Sc, 
50Ti(γ,np)48Sc, and 49Ti(γ,p)48Sc reactions and have threshold energies of 22.1 MeV, 10.5 MeV, 
22.3 MeV and 11.3 MeV, respectively. 
 In the work by Mamtimin, using a 22 MeV electron beam, the EOB ratio of 46Sc, 47Sc, and 
48Sc were 0.03, 0.82, and 0.14, respectively.18 In work by Rotsch et al., using a 35 MeV electron 
beam and capturing a larger portion of the natTi(γ,p)47Sc cross section (Figure 4-1), the ratio of 




47Sc, and 48Sc EOB radioactivities in this work using a 22 MeV electron beam were 0.01, 0.90, 
and 0.09. For each study, natTi target material was used and the irradiation times were less than one 
half-life of the three radionuclides. These studies show that the slope (dσ/dE) of the excitation 
functions for each radionuclide was similar, resulting in comparable radioisotopic purity at EOB 
even at different electron beam energies. Furthermore, when using a 22 MeV electron beam in our 
work, which generated photons less than the threshold energies of the (γ,np) channels, no 
improvement in 47Sc radionuclidic purity was observed when compared to the work by Mamtimin 
and Rotsch, suggesting the (γ,p) reactions on 47Ti and 49Ti are the dominant sources of Sc 
impurities. These data agree with the only published measurements of these cross sections (Figure 
3-10) at energies used in this work. 
 
Figure 3-10. Excitation functions for the (γ,p) reactions on 47Ti, 48Ti, and 49Ti21, 22 
 The 47Sc EOB radionuclidic purity was impacted by co-production of 46Sc and 48Sc for each 
study when using natTi target material. Thus, the best case scenario for limiting co-production of 




commercially at enrichment levels up to 99.6%.35 Favorably, the abundant 48Ti (73.8%) may be 
purchased commercially at a relatively low cost (2-3$/mg).35 
 The extracted Ti foils were acid digested and a separation method using AG MP-50 cation 
exchange resin and CHELEX 100 resin was used to isolate the 47Sc. This separation system was 
selected based on previously published work using both resins.27, 36 Initial elemental analysis of 
fractions preserved during separation with AG MP-50 showed varying levels of trace metal 
contamination due to Cr, Cu, Fe, Ni, and Zn. To reduce the concentration of these cations, which 
may compete with radioscandium for DOTA binding or cause transmetallation of the 
radioscandium-DOTA complex, a second separation step was performed to further purify the 
isolated 47Sc.37 For this two-step method, the overall recovery of 47Sc for the separation and 
purification of was (77 ± 7)%. The observed losses during radiochemical separation were due to 
material transfer and loss to both the AG MP-50 and CHELEX 100 resins. The typical masses of 
impurities measured after both steps were less than 1 μg for Cr, Cu, and Ni while Fe and Zn was 
less than 2 μg. These data on overall recovery compares well with recent work by Rotsch et al. 
(2018) and Domnanich et al. (2017) where a 76.3% and 89.7% overall recovery was reported using 
branched DGA cation-exchange resin.20, 38 Further, the mass of Zn and Fe measured in the purified 
47Sc fraction was reduced by 60% and 45%, respectively, compared to the mass reported by Rotsch 
et al. (2018).20 
 As a proof of concept, the purified 47Sc was used to radiolabel DOTATOC, a somatostatin 
analog that when radiolabeled can be used for diagnosis and therapy of neuroendocrine tumors 
that overexpress SSTR2. This small peptide was selected due to its well characterized affinity for 
trivalent radiometals.39 A high radiochemical yield of 99.9% was achieved for the radiosynthesis 




expressing AR42J cells. The maximum uptake was achieved by 2 h, and co-incubation of the 
radiolabeled compound with Octreotide lead to a 70% reduction in uptake at 2 h, indicating 
receptor-mediated uptake. In previous work [43,44Sc]Sc-DOTATOC has been synthesized and 
evaluated for SSTR2-binding, however the work performed in this study illustrates the feasibility 
of performing initial radiosynthetic and pre-clinical screening studies using the moderate 47Sc 
yields obtained from a CLINAC.12, 30, 40, 41 
3.5 Conclusion 
This work demonstrated the photonuclear production of 47Sc using a modified Varian CLINAC, 
tungsten radiator, and targets composed of natTi foil. These results show that CLINACs no longer 
in clinical use may be used to produce small quantities of medically relevant radionuclides for 
small experiments. Moreover, the methods shown in this work could be applied to obtain 47Sc in 
higher yields with potentially higher molar activities from similar targets irradiated using a 
higher intensity eLINAC. Based on this work, future photonuclear production of 47Sc using 
enriched 48Ti targets and high-intensity eLINACs may be a feasible route to developing this 
promising theranostic radionuclide; however, the limited cross section data on the 48Ti(γ,p)47Sc 
reaction must be improved in order to optimize radionuclidic purity and 47Sc yield. 
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Chapter 4: Cyclotron Production and 
Separation of Sc Radionuclides from Natural 
Titanium Metal and Titanium Dioxide 
Targets 
4.1 Introduction 
The element Sc has three radionuclides with properties suitable for diagnostic and therapeutic 
applications in nuclear medicine. Scandium-43 (Figure 2-2) and 44Sc (Figure 2-3) undergo 
positron decay with an overall mean energy of 476.0 keV (88.1%) and 632.0 keV (94.3%), 
respectively, making it well-suited for PET (see Section 1.4.1). Scandium-47 (Figure 2-7) 
undergoes beta decay, with a β-mean energy of 162 keV to 47Ti, followed by emission of a 159 keV 
γ-ray (68.4%). Thus, 47Sc could be used for targeted radionuclide therapy (see Section 1.5) and 
SPECT (see Section 1.4.2). The combined use of these Sc radionuclides in theranostic agents  with 
the same structure allows diagnostic imaging and radiotherapy in the same patient. 
 Interest in these radioisotopes has been motivated by the recent clinical success of DOTA-
(Tyr3)-octreotate (DOTATATE) and findings from multiple clinical trials investigating small-
molecule inhibitors of prostate specific membrane antigen (PSMA). The somatostatin analogue 
DOTATATE labeled with 68Ga (t1/2 = 67.71 min) or 177Lu (t1/2 = 6.647 d) can be used in a 
theranostic manner to diagnose and treat SSTR-expressing neuroendocrine tumors.1, 2 Similarly, 
inhibitors of PSMA like PSMA-11, PSMA-617, DCFPyL and MIP-1072 labeled with 68Ga, 177Lu, 
18F (t1/2 = 109.7 min), 131I (t1/2 = 8.03 d), 123I (t1/2 =13.2 h) or 99mTc (Figure 1-3) can be used for 




radionuclides of different elements can have differences in their in vivo kinetics.4 The selection of 
a matched-pair (e.g., 43Sc/47Sc), guarantees identical pharmacodynamic and pharmacokinetic 
profiles, and provides the truest picture of in vivo distribution prior to radionuclide therapy. 
Further, the half-lives of 43Sc/44Sc could allow imaging at longer time points after injection 
compared to the shorter lived 68Ga.5 Therefore, the development of efficient methods to produce 
43Sc, 44Sc, and 47Sc is an important first step to translating these matched-pair radioisotopes of Sc 
to the clinic. 
 Scandium-43 and 44Sc can be produced via multiple routes. Accelerator production using α 
particles, protons, and deuterons on Ca and Ti nuclei have been investigated for the 
natCa(α,x)43,44,47Sc, 42Ca(d,n)43Sc, 43Ca(p,n)43Sc, 44Ca(p,2n)43Sc, 46Ti(p,α)43Sc, 47Ti(p,α)44Sc, 
44Ca(p,n)44Sc, natCa(p,n)44Sc and 44Ca(d,2n)44Sc nuclear reactions.6-12 The use of Ca and Ti have 
been shown to provide GBqs and hundreds of MBqs of 43Sc and 44Sc depending upon beam current 
and irradiation time; however, 44Sc produced by these reactions will result in the co-production of 
its nuclear isomer, 44mSc (t1/2 = 58.6 h). The presence of this longer-lived metastable state may 
complicate patient dosimetry. Alternatively, 44Sc may be obtained without its nuclear isomer 
(44mSc) from a 44Ti (t1/2 = 59.2 y)/44Sc generator due to the preferred transition from the 0+ excited 
state of 44Ti to the ground state of 44Sc during β- decay (see Figure 2-4 and Figure 2-6).13-15 
 Scandium-47 can also be produced via multiple routes. Reactor production of 47Sc has been 
investigated using fast neutrons on enriched Ti via the 47Ti(n,p)47Sc reaction (En > 1-MeV) or 
thermal neutrons (En = 0.025 eV) on enriched Ca via the 46Ca(n,γ)47Ca→47Sc reaction for a 47Ca-
47Sc (t1/2 = 4.54 d) generator system.16 One challenge facing development of a 47Ca-47Sc generator 
is the low natural abundance of 46Ca (0.004%). Scandium-47 may also be produced by the 




48Ca(p,2n)47Sc reaction was investigated at 18 MeV and resulted in a saturation yield of 12 
GBq/μA.17-20 
 Unlike production routes using Ca, the use of Ti could allow production of 43Sc, 44Sc, and 47Sc 
on a single proton accelerator using a unified separation methodology that takes advantage of 
identical targetry and target processing chemistries, and results in better radionuclidic purity of 
43Sc, 44Sc, and 47Sc. However, the magnitudes of the cross section for reactions on Ti are much 
less than those on Ca at lower energies (16 to 18 MeV). Favorably, the cross section values increase 
at the higher energies (up to 24 MeV) used in this study. Multiple challenges must be addressed to 
produce Sc radioisotopes from stable nuclei of Ti using this unified approach. First, the powdery 
TiO2 targets require a holder that encapsulates the irradiated material to prevent radiological 
contamination. Next, the slow TiO2 digestion kinetics and short half-life of 43,44Sc necessitate 
development of a rapid digestion method. Lastly, 43Sc, 44Sc, and 47Sc with high radionuclidic purity 
can only be obtained using enriched Ti, since 46Ti, 47Ti, and 50Ti have natural abundancies of 
8.25%, 7.44%, and 5.18%, respectively. Thus, efficient recycling chemistry must be developed to 
recover and reuse the enriched target material.  
 To address these challenges, methods were developed to investigate 43Sc, 44Sc, and 47Sc yields 
and purification chemistry using natural Ti and TiO2. The results from this work suggest that 43Sc, 
44Sc, and 47Sc could be produced at energies up to 24 MeV using enriched TiO2 and purified using 
a unified methodology to supply quantities needed for the pre-clinical evaluation of these matched-
pair radioisotopes. 
4.2 Materials and Methods 
Reagents 




System; Millipore, Billerica, MA). Ammonium bifluoride (NH4HF2, 99.999%), hydrochloric acid 
(HCl, 37% wt. in water, 99.999%), 25% ammonia solution (NH4OH, EMSURE), TiO2 (anatase 
form, 99.8%), periodic table analytical standards (Mix 1, 10-mg/L, TraceCERT), ammonium 
acetate (CH3CO2NH4, 99.999%) and nitric acid (HNO3, 70% wt. in water, 99.999%) were 
purchased from Sigma-Aldrich (St. Louis, Missouri). Analytical standards containing Ti (1000 
mg/L) and Sc (1000 mg/L) were purchased from Agilent (Santa Clara, CA). Analytical grade 
branched N,N,N’,N’-tetra-2-ethylhexyldiglycolamide (BDGA) resin was purchased from Eichrom 
Technologies (Lisle, IL). 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) was 
purchased from Macrocyclics (Plano, TX). All glassware was acid washed in a 50% HNO3 bath 
overnight. 
Target Holders 
Multiple target holders were developed to mount and irradiate Ti foil and TiO2 target materials. 
The disc shaped 2 mm thick target holders fabricated from Al, Ta and Nb were described in Section 
2.4.5 (Figure 2-19, Figure 2-20, and Figure 2-21). 
Preparation of Target Material 
Titanium foil targets were prepared using a Precision Brand Products 10 mm punch and die 
(Downers Grove, IL). Prior to pressing, TiO2 was dried overnight at 230°C in a vacuum oven at 
0.3 Pa. Approximately 35 or 70 mg of TiO2 was transferred into a clean 7 or 10 mm die (Specac, 
Kent, United Kingdom) and pressed for 5 min at 4 tons pressure on a manual press (Carver, 
Wabash, Indiana). Additional TiO2 was iteratively added and pressed. This process was repeated 
twice to achieve final target masses of approximately 52 or 110 mg. 
Cyclotron Parameters 
Irradiations were conducted on a TR-24 cyclotron (Advanced Cyclotron Systems, Inc., Richmond, 




and 24 MeV. Ti and TiO2 targets were mounted at an incident angle of 90° and bombarded at beam 
currents up to 40 and 30 μA, respectively. The targets were cooled by high-pressure, low-flow He 
gas (275 to 345 kPa, 1 L/min) on the front and pumped water (2 to 3 L/min) on the back. 
Bombarded targets were allowed to decay for 1 to 5 h, depending upon irradiation parameters to 
allow for the decay of co-produced 47V (Figure 2-11).  
Production Yields 
The radionuclidic yields were determined using a high-purity germanium (HPGe) detector. 
Predicted yields were calculated using nuclear data retrieved from the Experimental Nuclear 
Reaction Data (EXFOR) database.21, 22 The code SRIM was used to model the entrance and exit 
proton energies. End-of-bombardment (EOB) yields were determined using Mathcad 14.0 and 
Equation 1, where NA is Avogadro’s constant (atoms/mol), I is incident particle flux (particles/s), 
At is atomic weight (g/mol), λ is the decay constant (1/s), t is irradiation time (s), E0 is the initial 
proton energy (MeV), Ee is the exit proton energy (MeV), σ(E) is the energy-dependent reaction 




(1 − e−λt)∫ σ(E) dES(E)
E0
Ee
    (4-1) 
Determination of Equilibrium Dissociation Constant. 
A mixture of 100 mg BDGA resin, 990 μL of HCl (0.1 to 10 M) and 10 μL of 48V (100 kBq/mL), 
47Sc (500 kBq/mL) or 45Ti (222 MBq/mL) were prepared in quadruplicate to determine the average 
(n = 4 ± 1σ) equilibrium dissociation constant (Kd). Each sample was equilibrated on a rocker for 
24 h after which the supernatant was removed and filtered with a 0.22 μm hydrophilic membrane 
filter. A 100 uL aliquot of the filtered supernatant was diluted to 1 mL with water for each sample 
and measured with an HPGe detector. At an HCl concentration of 6 to 10 M, no photopeak was 




a 2 h measurement of the supernatant. The Kd coefficients were calculated using equation 2, where 
Ai is the initial activity in Bq, Aeq is the activity in filtered supernatant in Bq, V is the volume of 








    (5-2) 
Digestion of Ti foil and TiO2 
Irradiated Ti was transferred into a conical 15 mL screw-cap perfluoroalkoxy alkane (PFA) vial 
(Savillex, Eden Prairie, MN) containing approximately 200 mg of NH4HF2 dissolved in 3 mL of 
12.1 M HCl. The vial was capped and heated at 230°C for 45 min. Irradiated TiO2 was transferred 
into a conical 15 mL screw-cap vial and mixed with NH4 HF2 (1:3 ratio). The vial was capped and 
heated to 230°C for 45 min. After heating, the dry residue was dissolved by adding 5 mL of 12.1 
M HCl and heating the closed vessel for 45 min in a Si-oil bath at 160°C. Both digestion methods 
were validated using non-radioactive Ti. For these validation experiments, samples were taken in 
triplicate, filtered, and diluted in 2% HNO3 for trace metal analyses. The digestion methods are 





Figure 4-1. Methods for the digestion of Ti foil and TiO2 
BDGA Separation 
Approximately 110 mg of BDGA resin was vortexed with 5 mL of 7 M HNO3. The mixture was 
transferred into a Biorad 0.8 x 9 cm polypropylene column (Hercules, CA) and the HNO3 was 
eluted at a flow rate of 1.0 mL/min To protect the packed resin (7 mm height), a glass wool plug 
was placed on top of the resin bed. The resin was washed with 5 mL each of 7.0 M HNO3, water, 
0.1 M HCl and 7.0 M HCl. The digestant was loaded onto the column in approximately 7 8 M HCl 
at a flow rate of 1 mL/min Eluent 1 (20 mL, 7.0 M HCl), eluent 2 (10 mL, 7.0 M HNO3) and eluent 
3 (10 mL, 0.1 M HCl) were passed through the column and collected at a flow rate of 1.0 mL/min 
The final eluate containing the Sc radionuclides was collected into a 10 mL v-shaped vial and 
evaporated to dryness under vacuum at 100°C. After evaporation, the purified Sc was digested in 






Figure 4-2. The 43Sc, 44Sc, and 47Sc separation. 
The elution profile of stable Ti, V and Sc on BDGA resin was determined by taking 1 mL fractions 
of each eluate. Samples were prepared in triplicate and measured with an HPGe detector and by 
ICP-MS to determine the recovery. The decontamination factor, a measure of the Sc purification, 
was determined using Equation 3, where DA,B is the factor giving the change in ratio of constituent 
1 (A) to constituent 2 (B).24 





     (5-3) 
Alkali Precipitation of Ti  
Eluate containing Ti was diluted to 500 mL with water and heated for 45 min at 160 °C. While 
stirring on a stir plate, the pH was adjusted to 8 by dropwise addition of 19 mL 25% ammonia 
solution. The stir bar was removed after precipitation at pH 8. The precipitate was allowed to settle 




(Pittsburgh, PA) filter paper and rinsed twice with 10 mL 1% ammonia solution in water. The 
precipitate was dried by rinsing with 10 mL of acetone. The filter paper was transferred to a 
zirconia crucible and combusted in a tube furnace at 1000 °C for 24 h. 
High Purity Germanium Spectroscopy 
Radioactive samples were characterized by gamma-ray spectroscopy using a Canberra GC2018 
HPGe detector with a relative efficiency of 24.5% (Meriden, CT). Canberra Genie 2000 software 
was used for data acquisition and analysis. Energy and efficiency calibrations were performed 
using a mixed nuclide source in a sealed 1.5 mL microcentrifuge vial prepared by Eckert & Ziegler 
Analytics (Atlanta, GA). Efficiency-calibration spectra with a minimum photopeak area of 2 x 105 
counts were collected and fit to determine the detector efficiency. For all measurements, aliquots 
of sample material were transferred into a 1.5 mL vial, diluted to 1 mL, and suspended in a fixed 
acrylic holder at a distance of 5 or 25 mm from the HPGe detector. This geometry was maintained 
for all sample measurements. 
Inductively Coupled Plasma Mass Spectrometry 
Samples containing stable elements were preserved and analyzed via ICP-MS. Multi-element 
standards in 2% HNO3 at 0.1, 1, 10, 100 and 1000 μg/L were used for instrument calibration. Each 
sample was diluted in 2% HNO3 and measured on an Agilent Technologies 7700 ICP-MS (Santa 
Clara, CA). Agilent Technologies MassHunter (version 4.3) was used for data acquisition and 
analysis. 
4.3 Results 
4.3.1 Target Irradiations 
The Nb target holder was used to irradiate 250 μm thick metallic Ti foils (ρ = 4.506 g/cm3) at 




target holders tolerated beam currents up to 40 μA. A two-piece Al target holder was used to 
irradiate a 400 μm thick pressed TiO2 (ρ = 4.23 g/cm3) disc at approximately 17 MeV. The average 
(n = 3 ± 1σ) mass of the disc target was (52.2 ± 0.4) mg. The magnetization of the SmCo magnets 
was confirmed after each irradiation (n = 6). At a beam current of 20 μA, thermal damage was 
observed on the Al cap and base; thus, future irradiations were limited to 15 μA. The Ta target 
holder was used to irradiate a 400 μm thick pressed TiO2 disc at approximately 24 MeV. The 
average (n = 3 ± 1σ) mass of the disc target was (110.1 ± 0.5) mg. The Ta target holder allowed 
for irradiation at beam currents up to 30 μA. No damage to the target holder or material was 
observed at 30 μA after a 30 min irradiation. 
4.3.2 Target Digestion 
The methods developed in this work were validated using non-radioactive TiO2 pressed disc 
targets and Ti foils that were prepared in quadruplicate. The samples were weighed, dissolved, and 
Ti ions in the digestant were precipitated using methods detailed in this work (Figure 4-4).  
 




Figure 4-4 indicates that the average (n = 4 ± 1σ) percent of dissolved TiO2 and Ti was (100 ± 
8)% and (96 ± 5)% of the initial masses. A typical digestion of an irradiated Ti foil and pressed 
TiO2 disc required 45 and 90 min, respectively. Titanium foils were digested at 160°C using a 
mixture of NH4HF2 and 12.1 M HCl. Trace metals analysis of the digestant via ICP-MS showed 
that the average (n = 3 ± 1σ) percentage of Ti foil dissolved in solution was (98 ± 3)%. Likewise, 
TiO2 discs were digested in two-steps and the average (n = 3 ± 1σ) percentage of TiO2 dissolved 
in solution was (95 ± 1)%. 
4.3.3 Radionuclide Yields 
The radionuclides measured by HPGe were 48V (γ1 = 944.1 keV, γ2 = 983.5 keV, γ3 = 1312.1 keV), 
43Sc (372.9 keV), 44gSc (1157.0 keV), 44mSc (271.2 keV) and 47Sc (159.4 keV). The sample 
counting time was varied to achieve a minimum photopeak area of 500 counts and dead time was 
kept below 5%. The average EOB production rate (n = 9 ± 1σ) and predicted rate for each 
radionuclide are shown in Table 4-1. 
Table 4-1. The average EOB production rate and predicted rate for each 
radionuclide6, 22, 25, 26 
Radionuclide Predicted rate(kBq·s-1·uA-1) Average Rate (kBq·s-1·uA-1) 
43Sc 1.1 1.1(0.2) 
44gSc 4.3 4.2(0.4) 
44mSc 0.20 0.11(0.01) 
47Sc 0.19 0.17(0.01) 
48V 0.23 0.25(0.01) 
 




4.3.4 BDGA Separation 
The digestant containing Ti ions, Sc radioisotopes, and 48V was loaded onto BDGA resin at a 1.0 
mL/min flow rate. The bulk Ti target material was eluted from the resin and resulted in an average 
(n = 6 ± 1σ) Ti recovery factor of (96 ± 5)% in 12 mL of the load eluate and 20 mL of eluate 1. In 
contrast, Sc radioisotopes were strongly adsorbed onto the resin in 7 to 8 M HCl. No Sc 
radioisotopes were detected in the eluate from the load, eluent 1 and eluent 2. The Sc radioisotopes 
were desorbed from the resin in 10 mL of eluent 3 (0.1 M HCl). The eluate containing the 
recovered Sc radioisotopes (eluate 3) was free of any radionuclidic impurities including 48V. These 
data are summarized in Table 4-2.  
Table 4-2. The initial 47Sc and 48V activity and its recovery in each eluate.  
Material Activity Initial (MBq) Load (MBq) E1 (MBq) E2 (MBq) E3 (MBq) 
Ti Foil 
47Sc 52.3(0.4) 5×10-5∗ 1×10-5∗ 1×10-5∗ 49.0(0.5) 
48V 66.2(0.6) 63.5(0.3) 2.5(0.3) 0.4(0.1) 1×10-5∗ 
TiO2 
47Sc 29.1(0.7) 3×10-5∗ 1×10-5∗ 1×10-5∗ 27.6(0.6) 
48V 38.4(0.8) 35.1(0.2) 3.1(0.3) 0.3(0.1) 1×10-5∗ 
*Minimum Detectable Radioactivity 
 
These data show an average (n = 3 ± 1σ) Sc recovery from Ti foil and TiO2 irradiated targets of 






Figure 4-4. Typical elution profile for the DGA separation 
Figure 4-5 indicates that the magnitude of the interaction between Ti and V ions and BDGA resin 
is small, and the majority of these ions are recovered in the eluate from the load fraction. The 
adsorbed 43Sc, 44Sc, and 47Sc are stripped from the BDGA in 0.1 M HCl over a broad elution band 
(10 mL of 0.1 M HCl).  
 Samples taken from the final Sc product after reconstitution showed the presence of different 
non-radioactive contaminants. After purification and evaporation, the identity and average (n = 3 
± 1σ) concentration of contaminants in 400 μL of 0.50 M CH3CO2NH4 was Fe (1.0 ± 0.3)mg/L, 
Cu (0.8 ± 0.3)mg/L, Zn (1.3 ± 0.3)mg/L, V (0.5 ± 0.3)mg/L, and Al (0.8 ± 0.3)mg/L. Scandium 
was not detected or was below the detection limits of the ICP-MS used in this work. The complete 
separation and concentration of Sc activities required approximately 180 min. 
4.3.5 Ti Recycling 
The combined eluate containing Ti was diluted and pH adjusted. Near pH 8 (verified by pH strip 




recovery of Ti was (103 ± 5)% and (108 ± 8)% from Ti foil and TiO2, respectively. 
4.4 Discussion 
Targets were created which allowed for the irradiation of TiO2 with a proton beam of 24 MeV at 
a beam current up to 40 μA. The SmCo magnets (Al target) did not lose their magnetism due to 
heat and could play a role in the design of compact cyclotron targets. The Ta target holder design 
was robust and future work will be carried out to define the maximum tolerated beam current on 
TiO2 in these target holders. These data show that 43Sc, 44Sc, and 47Sc production can occur at 
higher beam currents greater than those currently used for their cyclotron production via CaO or 
CaCO3 (approximately 20 μA). Moreover, in most cases the (p,n) and (p,xn) reaction cross sections 
on Ca nulcei have greater magnitudes; thus, it is important to focus on optimizing the design of 
TiO2 target holders to offset the lower yields by increasing their tolerance to high beam currents. 
 The yield of 43Sc, 44Sc, and 47Sc and co-produced 48V in Ti foils agreed with EOB yields 
predicted using published nuclear data sets for the natTi(p,x) reaction (Table 4-1). Using the same 
methodology, the EOB yield of 43Sc, 44Sc, and 47S from enriched TiO2 target material was 
predicted for the 46Ti(p,α)43Sc, 47Ti(p,α)44g,44mSc, 50Ti(p,α)47Sc and 48Ti(p,2p)47Sc nuclear 
reactions based on a 1 mm thick TiO2 target that drops the proton energy from 24 MeV to 15.5 




Table 4-3. The predicted Sc yields at 1, 2, and 24 h.6, 25-27 
Time 43Sc (GBq) 44gSc (GBq) 44mSc (GBq) 47Sc (MBq) 
























*Predicted yield from 50Ti(p,α)47Sc 
†Predicted yield from 48Ti(p,2p)47Sc 
 
These yields from enriched TiO2 show that tens of MBq to Gbq quantities of Sc radioisotopes 
could be produced based on this work. These quantities would be suitable for pre-clinical and in 
some cases clinical investigations. 
 Previously reported methods to digest TiO2 have used concentrated HF with some methods 
requiring hours or use of microwave/IR systems to reach completion.18, 28-32 These methods, in 
practice, could result in the loss of at least one 43Sc and 44Sc half-life. The methods developed in 
this work make use of pressure, heat, and the in situ generation of approximately 1.0 M HF via the 
reaction of NH4HF2 with 12.1 M HCl.33 These two methods have been confirmed to work with a 
mineral oil bath or convection oven and require no specialized equipment. The results show that 
greater than 95% of Ti foil and TiO2 could be dissolved in 45 and 90 min, respectively. Further, 
the closed PFA vessels used in this work were inexpensive and durable at temperatures up to 
250°C. These data support future efforts to characterize and optimize the digestion parameters to 
further decrease digestion times for Ti foil and TiO2. 
 Branched DGA and DGA resin have been used to separate Sc in multiple reports.7, 18, 34 The 




the method used in this work (Figure 4-6). 
 
Figure 4-5. Sc, V, and Ti equilibrium disassociation constants with BDGA 
Based on the measured Kd for Sc, Ti and V, the separation method detailed in this work was 
predicted to separate Sc from Ti and V at HCl concentrations greater than 4 M. This prediction 
was confirmed by determining the Sc decontamination factor relative to each contaminant. Based 
on quantities in Table 2, the decontamination factor for 47Sc relative to 48V was greater than 6x106 
and 3x106 for Sc isolated from Ti foil and TiO2, respectively. Similarly, Ti present in the recovered 
Sc fractions was below the ICP-MS detection limits (approximately 1 μg/L); thus, the data shows 
the decontamination factor of 47Sc relative to Ti was greater than 2.8x105 and 1.6x105 for Sc 
isolated from Ti foil and TiO2, respectively. These data show that this method isolates Sc with 




procedures using DGA resins.7, 18, 35 Trace metal analyses via ICP-MS of the Ti foil and TiO2 
digestants and recovered Sc fractions showed the presence of Fe, Cu, Z, V and Al. The average 
concentrations of these impurities were between 0.5-1.3 mg/L, which compared well to previously 
reported methods to produce Sc.18, 35 
 Historically and in recent reports, Ti was precipitated from an aqueous solution using ammonia 
solution at pH 8.7, 36, 37 In this work, a Ti precipitant was obtained using ammonia solution to adjust 
the bulk media to pH 8. After sufficient time for aggregation and sedimentation, the precipitate 
was filtered and combusted. The typical concentration of Ti in the filtrate was below 100 μg/L 
(approximately 50 μg) which indicated the percent loss of Ti after precipitation was less than 0.1%. 
The mass recovery of Ti exceeded 100% and may be attributed to two factors: (1) etching of glass 
wool by HF generated in situ and (2) the incomplete combustion of the filter paper and presence 
of water. These data show that the recovery of Ti in the oxide form using ammonia solution was 
an effective approach to recycling Ti nuclei. However, additional work will be carried out to reduce 
the introduction of external masses to avoid buildup of these contaminants during iterative use of 
this method. 
4.5 Conclusion 
In this study, we investigated the feasibility of producing the theranostic radioisotopes of Sc on a 
proton accelerator using a robust and unified process. Results from this work showed that routine 
production of 43Sc, 44Sc, and 47Sc could be accomplished using enriched TiO2. Importantly, our 
findings showed that TiO2 targets may tolerate beam currents greater than 30 μA using target 
holders designed in this work, TiO2 can be digested via a two-step process in 90 min, and digested 
Ti could be efficiently recovered via alkali precipitation with ammonia solution. Future work 




impact on downstream chemistry that may be caused by the increased heat deposition in the target 
material, which could lead to phase changes in the TiO2 that alter its physical characteristics. 
Additionally, these efforts should seek to better understand and optimize the digestion methods 
developed in this work to reduce digestion times. Finally, the method to precipitate Ti should be 
modified to remove sources of carbon and silicon. Ultimately, the results in this work showed the 
potential promise in using enriched Ti targets to produce these matched-pair theranostic 
radioisotopes of Sc. 
4.6 References 
1. Hennrich, U.; Kopka, K., Lutathera®: the first FDA- and EMA-approved 
radiopharmaceutical for peptide receptor radionuclide therapy. Pharmaceuticals 2019, 12 
(3). 
2. Maurer, T.;  Eiber, M.;  Schwaiger, M.; Gschwend, J. E., Current use of PSMA-PET in 
prostate cancer management. Nat Rev Urol 2016, 13 (4), 226-35. 
3. Wester, H.-J.; Schottelius, M., PSMA-Targeted radiopharmaceuticals for imaging and 
therapy. Semin Nucl Med 2019, 49 (4), 302-312. 
4. Muller, C.;  Domnanich, K. A.;  Umbricht, C. A.; van der Meulen, N. P., Scandium and 
terbium radionuclides for radiotheranostics: current state of development towards clinical 
application. Br J Radiol 2018, 91 (1091), 20180074. 
5. Eppard, E.;  de la Fuente, A.;  Benesova, M.;  Khawar, A.;  Bundschuh, R. A.;  Gartner, 
F. C.;  Kreppel, B.;  Kopka, K.;  Essler, M.; Rosch, F., Clinical translation and first in-
human use of [44Sc]Sc-PSMA-617 for PET imaging of metastasized castrate-resistant 
prostate cancer. Theranostics 2017, 7 (18), 4359-4369. 
6. Carzaniga, T. S.;  Auger, M.;  Braccini, S.;  Bunka, M.;  Ereditato, A.;  Nesteruk, K. P.;  




cross-section with an 18MeV medical PET cyclotron. Applied Radiation and Isotopes 
2017, 129, 96-102. 
7. Domnanich, K. A.;  Eichler, R.;  Müller, C.;  Jordi, S.;  Yakusheva, V.;  Braccini, S.;  
Behe, M.;  Schibli, R.;  Türler, A.; van der Meulen, N. P., Production and separation of 
(43)Sc for radiopharmaceutical purposes. EJNMMI radiopharmacy and chemistry 2017, 
2 (1), 14-14. 
8. Duchemin, C.;  Guertin, A.;  Haddad, F.;  Michel, N.; Metivier, V., Production of 
scandium-44m and scandium-44g with deuterons on calcium-44: cross section 
measurements and production yield calculations. Phys Med Biol 2015, 60 (17), 6847-64. 
9. Walczak, R.;  Krajewski, S.;  Szkliniarz, K.;  Sitarz, M.;  Abbas, K.;  Choiński, J.;  
Jakubowski, A.;  Jastrzębski, J.;  Majkowska, A.;  Simonelli, F.;  Stolarz, A.;  Trzcińska, 
A.;  Zipper, W.; Bilewicz, A., Cyclotron production of (43)Sc for PET imaging. EJNMMI 
Physics 2015, 2, 33. 
10. Krajewski, S.;  Cydzik, I.;  Abbas, K.;  Bulgheroni, A.;  Simonelli, F.;  Holzwarth, U.; 
Bilewicz, A., Cyclotron production of 44Sc for clinical application. Radiochimica Acta 
2013, 101 (5), 333-338. 
11. Severin, G. W.;  Engle, J. W.;  Valdovinos, H. F.;  Barnhart, T. E.; Nickles, R. J., 
Cyclotron produced 44gSc from natural calcium. Applied Radiation and Isotopes 2012, 
70 (8), 1526-1530. 
12. Szkliniarz, K.;  Sitarz, M.;  Walczak, R.;  Jastrzębski, J.;  Bilewicz, A.;  Choiński, J.;  
Jakubowski, A.;  Majkowska, A.;  Stolarz, A.;  Trzcińska, A.; Zipper, W., Production of 
medical Sc radioisotopes with an alpha particle beam. Appl Radiat Isotopes 2016, 118, 
182-189. 
13. Frank, R., Scandium-44: Benefits of a Long-Lived PET Radionuclide Available from the 




14. Pruszyński, M.;  Majkowska-Pilip, A.;  Loktionova, N. S.;  Eppard, E.; Roesch, F., 
Radiolabeling of DOTATOC with the long-lived positron emitter 44Sc. Applied 
Radiation and Isotopes 2012, 70 (6), 974-979. 
15. Radchenko, V.;  Engle, J. W.;  Medvedev, D. G.;  Maassen, J. M.;  Naranjo, C. M.;  Unc, 
G. A.;  Meyer, C. A. L.;  Mastren, T.;  Brugh, M.;  Mausner, L.;  Cutler, C. S.;  
Birnbaum, E. R.;  John, K. D.;  Nortier, F. M.; Fassbender, M. E., Proton-induced 
production and radiochemical isolation of (44)Ti from scandium metal targets for 
(44)Ti/(44)Sc generator development. Nucl Med Biol 2017, 50, 25-32. 
16. Domnanich, K. A.;  Müller, C.;  Benešová, M.;  Dressler, R.;  Haller, S.;  Köster, U.;  
Ponsard, B.;  Schibli, R.;  Türler, A.; van der Meulen, N. P., 47Sc as useful β–-emitter for 
the radiotheragnostic paradigm: a comparative study of feasible production routes. 
EJNMMI Radiopharmacy and Chemistry 2017, 2 (1), 5. 
17. Loveless, C. S.;  Radford, L. L.;  Ferran, S. J.;  Queern, S. L.;  Shepherd, M. R.; Lapi, S. 
E., Photonuclear production, chemistry, and in vitro evaluation of the theranostic 
radionuclide 47Sc. EJNMMI Research 2019, 9 (1), 42. 
18. Rotsch, D. A.;  Brown, M. A.;  Nolen, J. A.;  Brossard, T.;  Henning, W. F.;  Chemerisov, 
S. D.;  Gromov, R. G.; Greene, J., Electron linear accelerator production and purification 
of scandium-47 from titanium dioxide targets. Applied Radiation and Isotopes 2018, 131, 
77-82. 
19. Mamtimin, M.;  Harmon, F.; Starovoitova, V. N., Sc-47 production from titanium targets 
using electron linacs. Applied Radiation and Isotopes 2015, 102, 1-4. 
20. Carzaniga, T. S.;  van der Meulen, N. P.;  Hasler, R.;  Kottler, C.;  Peier, P.;  Türler, A.;  
Vermeulen, E.;  Vockenhuber, C.; Braccini, S., Measurement of the 43Sc production 




21. Zerkin, V. V.; Pritychenko, B., The experimental nuclear reaction data (EXFOR): 
Extended computer database and Web retrieval system. Nuclear Instruments and 
Methods in Physics Research Section A 2018, 888, 31-43. 
22. Khandaker, M. U.;  Kim, K.;  Lee, M. W.;  Kim, K. S.;  Kim, G. N.;  Cho, Y. S.; Lee, Y. 
O., Investigations of the natTi(p,x)43,44m,44g,46,47,48Sc,48V nuclear processes up to 
40MeV. Applied Radiation and Isotopes 2009, 67 (7), 1348-1354. 
23. Otuka, N.; Takács, S., Definitions of radioisotope thick target yields. In Radiochimica 
Acta, 2015; Vol. 103, p 1. 
24. Sandell, E. B., Meaning of the term "separation factor". Analytical Chemistry 1968, 40 
(4), 834-835. 
25. Levkovski, V. N., Middle mass nuclides activation cross-sections by medium energy 
protons and a particles. Inter-Vesi: Moscow, 1991. 
26. Gadioli, E.;  Gadioli Erba, E.;  Hogan, J. J.; Burns, K. I., Emission of alpha particles in 
the interaction of 10–85 MeV protons with48,50Ti. Zeitschrift für Physik A Atoms and 
Nuclei 1981, 301 (4), 289-300. 
27. Koning, A. J.; Rochman, D., Modern Nuclear Data Evaluation with the TALYS Code 
System. Nuclear Data Sheets 2012, 113 (12), 2841-2934. 
28. Krystek, P.;  Tentschert, J.;  Nia, Y.;  Trouiller, B.;  Noël, L.;  Goetz, M. E.;  Papin, A.;  
Luch, A.;  Guérin, T.; de Jong, W. H., Method development and inter-laboratory 
comparison about the determination of titanium from titanium dioxide nanoparticles in 
tissues by inductively coupled plasma mass spectrometry. Anal. Bioanal. Chem 2014, 
406 (16), 3853-3861. 
29. Vidmar, J.;  Milačič, R.;  Golja, V.;  Novak, S.; Ščančar, J., Optimization of the 
procedure for efficient dispersion of titanium dioxide nanoparticles in aqueous samples. 




30. Tsanaktsidou, E.; Zachariadis, G., Titanium and Chromium Determination in Feedstuffs 
Using ICP-AES Technique. Separations 2019, 7 (1), 1. 
31. Kolsky, K. L.;  Joshi, V.;  Mausner, L. F.; Srivastava, S. C., Radiochemical purification 
of no-carrier-added scandium-47 for radioimmunotherapy. Applied Radiation and 
Isotopes 1998, 49 (12), 1541-1549. 
32. Pawlak, D.;  Wojdowska, W.;  Parus, J.;  Cieszykowska, I.;  Żółtowska, M.;  Garnuszek, 
P.; Mikolajczak, R., Comparison of separation methods for 47Ca/47Sc radionuclide 
generator. Appl. Radiat. Isot. 2019, 151. 
33. Zhang, W.;  Hu, Z.;  Liu, Y.;  Chen, H.;  Gao, S.; Gaschnig, R. M., Total Rock 
Dissolution Using Ammonium Bifluoride (NH4HF2) in Screw-Top Teflon Vials: A New 
Development in Open-Vessel Digestion. Analytical Chemistry 2012, 84 (24), 10686-
10693. 
34. Valdovinos, H. F.;  Hernandez, R.;  Barnhart, T. E.;  Graves, S.;  Cai, W.; Nickles, R. J., 
Separation of cyclotron-produced (44)Sc from a natural calcium target using a dipentyl 
pentylphosphonate functionalized extraction resin. Applied Radiation and Isotopes 2015, 
95, 23-29. 
35. Alliot, C.;  Kerdjoudj, R.;  Michel, N.;  Haddad, F.; Huclier-Markai, S., Cyclotron 
production of high purity (44m,44)Sc with deuterons from (44)CaCO3 targets. Nucl Med 
Biol 2015, 42 (6), 524-9. 
36. Gooch, F. A., On the Separation of Titanium and Aluminum, with a Note on the 
Separation of Titanium and Iron. Proceedings of the American Academy of Arts and 
Sciences 1884, 20, 435-447. 
37. Murphy, T. J.;  Claubaugh, W. S.; Gilchrist, R., Method for the Separation of Titanium, 
Zirconium, Iron, and Aluminum from One Another and for their Subsequent 
Determination. Journal of Research of the National Bureau of Standards: A. Physics and 




Chapter 5: Radiochemistry and Investigation 




Pharmaceutical development is a complex and expensive process that involves many key aspects 
such as in vivo target identification , compound screening, secondary assays that investigate 
mechanism and selectivity, and in vivo analyses that investigate pharmacology, efficacy, safety, 
and toxicity.1 In most cases, the process begins by using high throughput screening assays to 
identify a lead compound that could be useful as a targeting vector based on its affinity for a 
biomarker. Post-screening, the pharmacokinetic profile of the lead compound is determined by 
studying its absorption, biodistribution, metabolism, and elimination or excretion.1, 2 Each of these 
physiological aspects can be studied using a radiotracer (i.e., a compound in which one or more 
atoms are radioactive).3 A lead compound can be turned into a radiotracer by directly incorporating 
a radionuclide or by conjugating the compound to a chelator capable of binding a radionuclide. In 
some cases, this radiotracer can be used as a radiopharmaceutical for diagnostic imaging or 
therapy.  
 Diagnostic radiopharmaceuticals can be detected at concentrations that range from fM to pM 
using highly sensitive nuclear detectors (see Section 1.4). Therefore, diagnostic 
radiopharmaceuticals (and radiotracers) can be used to study molecular function without 
perturbing the physiological system being probed.4 Additionally, because radiopharmaceuticals 




concentrations primarily due to the presence unlabeled nonradioactive molecule) , they can be used 
safely to determine dosimetry, efficacy and the biodistribution profile of a radiopharmaceutical.  
 The pre-clinical investigation of a new radiopharmaceutical often involves the study of its in 
vitro and in vivo properties. These properties can be evaluated using different assays (in vitro) to 
characterize radiopharmaceutical features such as IC50 (inhibitory concentration of 50%), 
partition coefficient, binding potential, Kd (dissociation constant), Bmax (maximum number of 
binding sites), and chemical stability. Likewise, its biological properties can be evaluated in vivo 
using small animal models to investigate stability, target specificity, pharmacokinetic profile, and 
dosimetry. Therapeutic radiopharmaceuticals typically undergo additional studies to evaluate their 
therapeutic efficacy. A radiopharmaceutical with favorable in vitro and in vivo properties may be 
a potential drug-candidate that warrants further investigation in initial human studies. For example, 
the clinically used radiopharmaceuticals [68Ga/177Lu]Ga/Lu-DOTA-(Tyr3)-octreotate 
(DOTATATE) underwent pre-clinical evaluation and the in vitro and in vivo properties of both 
compounds were published prior to clinical trials and FDA approval. These radiopharmaceuticals 
now play an important clinical role in detecting neuroendocrine tumors (NETs), monitoring NET 
progression, and determining patient response prior to targeted radionuclide therapy (TRNT). The 
use of [68Ga/177Lu]Ga/Lu-DOTATATE to diagnose and treat NETs was detailed earlier in this 
work  (see Section 1.6.1). 
 Recently, different radiopharmaceuticals labeled with the positron emitting radionuclides 43Sc 
and 44Sc have been investigated to assess the in vitro and in vivo properties of these compounds. 
For example, the in vitro and in vivo characteristics of DOTATATE, DOTATOC, and 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid–1-NaI3-octreotide (DOTANOC) radiolabeled 




irradiation of Ca target material.5-8 These studies involved the direct comparison of 68Ga-labeled 
compounds with their 43Sc- or 44Sc-labeled analogues. Unlike Y- or In-labeled analogues (e.g., Y-
DOTA-lanreotide and In-DTPA-octreotide) that have lower affinities (i.e., higher IC50 values) for 
SSTR2 receptors (see Section 1.6.1), the IC50 values for compounds labeled with 68Ga and 43Sc 
or 44Sc were comparable with (0.20 ± 0.18) nM and (0.70 ± 0.20) nM, respectively. These results 
indicate that the diagnostic capability of Sc-DOTATATE may be similar to the FDA-approved 
[68Ga]Ga-DOTATATE.9 Additionally, compounds labeled with 44Sc (cyclotron produced using 
Ca) with indications for diagnosing human glioblastoma (i.e., an aggressive type of brain cancer) 
and prostate cancer (see Section 1.6.2) have been investigated. For example, DOTA-functionalized 
integrin αvβ3 cyclic peptide RGD (cRGD) that targets glioblastomas was labeled with 44Sc and 
had a yield of 90% and an effective specific activity of greater than 7.1 MBq/nmol.10 A different 
DOTA-functionalized compound that targets prostate cancer, PSMA-617, was labeled with 44Sc 
and may have indications for diagnosing castration resistant prostate cancer. The [44Sc]Sc-PSMA-
617 bioconjugate had a yield of greater than 97% and an effective specific activity of up to 10 
MBq/nmol. The effective specific activity describes the amount of radioactivity per unit mass of 
PSMA-617. Subsequent studies indicated that the in vitro properties of [44Sc]Sc-PSMA-617 were 
similar to those of PSMA-617 labeled with 68Ga and 177Lu, and the biodistribution profile (i.e., 
distribution kinetics) of [44Sc]Sc-PSMA-617 was more similar to [177Lu]Lu-PSMA-617; than 
[68Ga]Ga-PSMA-617. These results indicate that [43Sc/44Sc]Sc-PSMA-617 could provide a truer 
picture of the in vivo pharmacokinetics (compared to [68Ga]Ga-PSMA-617). The use of PSMA-
617 labeled with 43Sc or 44Sc could better inform TRNT of prostate cancer and improve therapeutic 
efficacy.  




applications, few reports exist on 47Sc, their therapeutic analogue. Recently, DOTA-cm10 (cm10) 
was labeled with 47Sc to target folate receptors (FR) that are expressed on a variety of tumor types, 
including ovarian and lung cancers.11 The [47Sc]Sc-cm10 bioconjugate had a yield of greater than 
96%, an effective specific activity of up to 13 MBq/nmol, and receptor-specific binding and uptake 
in FR+ human cervical cancer cells (KB cells) was demonstrated. Its therapeutic efficacy was then 
evaluated in vivo using two groups of KB tumor-bearing mice where the control and treatment 
groups were given saline and [47Sc]Sc-cm10 (10 MBq, 10 Gy), respectively. The treatment group 
had a 50% increase in survival time, compared to the control group. In order to increase the 
availability of 47Sc, multiple groups are investigating novel methods to produce and supply this 
theranostic radionuclide for preclinical studies. For example, in our work, 47Sc produced by 
bremsstrahlung radiation using natural Ti foil targets was used to label DOTATOC and show cell-
mediated uptake in SSTR2 expressing AR42J cells (see Section 3.3.3 and Section 3.3.4). 
 The findings reported in Chapter 3 and Chapter 4 showed that useful quantities of 43Sc, 44Sc, 
and 47Sc could be produced using Ti as a target material on a 24 MeV cyclotron and used for pre-
clinical evaluation of 47Sc-labeled radiopharmaceuticals that have clinical potential. Using the 
methods reported in Chapter 4, a purified mixture of 43Sc, 44Sc, and 47Sc was obtained and used to 
prepare and characterize [43,44,47Sc]Sc-PSMA-617. The in vitro properties of PSMA-617 labeled 
with Sc radionuclides (43Sc, 44Sc, and 47Sc), 68Ga, and 177Lu were evaluated in LNCaP cells, a 
PSMA+ human prostate adenocarcinoma cell line. 
5.2 Materials & Methods 
Reagents 
All chemicals were analytical or trace metals grade. Deionized 18.2 MΩ⋅cm water (Milli-Q 




(NH4HF2, 99.999%), hydrochloric acid (HCl, 37% wt. in water, 99.999%), 25% ammonia solution 
(NH4OH, EMSURE), TiO2 (anatase form, 99.8%), periodic table analytical standards (Mix 1, 
10-mg/L, TraceCERT), ammonium acetate (CH3CO2NH4, 99.999%) and nitric acid (HNO3, 70% 
wt. in water, 99.999%) were purchased from Sigma-Aldrich (St. Louis, Missouri). Analytical 
grade branched N,N,N’,N’-tetra-2-ethylhexyldiglycolamide (BDGA) resin was purchased from 
Eichrom Technologies (Lisle, IL). Cell culture media, Gibco RPMI 1640 and DMEM, and Gibco 
fetal bovine serum were purchased from Fischer Scientific (Waltham, MA). Cell culture media, 
Gibco RPMI 1640 and DMEM, Gibco fetal bovine serum, and Gibco trypsin-EDTA (0.25% 
trypsin/0.53 mM EDTA) were purchased from Fischer Scientific (Waltham, MA). Glass 
microfiber chromatography paper impregnated with silica-gel (iTLC-SG) was purchased from 
Agilent Technologies (Santa Clara, California). All glassware was acid washed in a 50% HNO3 
bath overnight.  
Radionuclides 
A mixture of Sc radionuclides 43Sc, 44Sc, and 47Sc were obtained by the proton irradiation of 
naturally isotopic Ti foil. The Ti targets was bombarded with 24 MeV protons for 3 hours at 30 
µA. Post-irradiation, the targets were dissolved, and the Sc radionuclides were purified using 
BDGA, a chromatographic resin (see Section 4.3.2 and Section 4.3.4). The Sc radionuclides were 
recovered in 5 to 10 mL of 0.1 M HCl. The eluate was concentrated to a wet salt by vacuum 
evaporation at 95°C for approximately 2 to 3 hours. A final stock solution was obtained by 
dissolving the wet salt in 100 to 200 µL of 0.5 M ammonium acetate (pH 4.7) and was used directly 
for labeling reactions. Gallium-68 was obtained from a 68Ge/68Ga generator obtained from Eckert 
& Ziegler (Santa Clarita, CA). The 68Ga was eluted from the generator in 0.1 M HCl with a 




than 80% of the 68Ga in 3 to 4 mL. The stock solution was used directly for labeling reactions. 
Lutetium-177-chloride solution (0.05 M HCl) with a specific activity greater than 740 GBq/mg 
and radionuclidic purity greater than 99% was obtained from the Missouri University Research 
Reactor (Columbia, MO). A small aliquot (0.5 to 2 µL) of the 177Lu stock solution was diluted in 
0.5 M ammonium acetate (pH 4.7) and was used directly for labeling reactions. 
Radiolabeling of PSMA-617 
The PSMA ligand PSMA-617 was obtained from Medkoo Biosciences (Morrisville, NC) and 
stored at -20°C. Prior to use, PSMA-617 was reconstituted in 100 to 200 uL of water at a 
concentration of 1 mg/mL to 5 mg/mL. The conditions to label PSMA-617 with a mixture of Sc 
radionuclides, 177Lu, and 68Ga was tested at a small scale prior to batch labeling. [43,44,47Sc]Sc-
PSMA-617 was prepared in a 50 µL mixture of 0.5 M ammonium acetate (pH 4.7) containing 43Sc, 
44Sc, and 47Sc and aqueous PSMA-617 and incubated at 95°C for 30 min. [177Lu]Lu-PSMA-617 
was prepared in a 50 µL mixture of 0.5 ammonium acetate (pH 4.7) and 0.05 M HCl containing 
177Lu and aqueous PSMA-617 and incubated at 95°C for 30 min. [68Ga]Ga-PSMA-617 was 
prepared in a 1 mL mixture of 0.1 M HCl and aqueous PSMA-617 at a volume ratio of 1:1000 
(unless otherwise stated) and incubated at 95°C for 30 min. For batch labeling of [43,44,47Sc]Sc-
PSMA-617 and [177Lu]Lu-PSMA-617, a typical reaction labeled 1 nmol of PSMA-617 in 100 µL 
of 0.5 M ammonium acetate (pH 4.7) containing 43Sc, 44Sc, and 47Sc or 177Lu. For batch labeling 
of [68Ga]Ga-PSMA-617, a typical reaction labeled 10 nmol of PSMA-617 in 3 mL of 0.1 M HCl 
containing 68Ga. These reactions were incubated at 95°C for 30 min. 
Radiochemical Analyses 
The radiochemical yields of [43,44,47Sc]Sc-PSMA-617, [177Lu]Lu-PSMA-617, and [68Ga]Ga-




pressure liquid chromatography (radio-HPLC). Radio-TLC was carried out using an Eckert & 
Ziegler AR-2000 radio-TLC imaging scanner (Hopkinton, MA) and instant TLC paper developed 
using a 1:1 ratio of 1.0 M ammonium acetate and methanol and 0.1 M citrate buffer (pH 4.0). 
Radio-HPLC was carried out using an Agilent 1200 series HPLC (Lexington, MA) and an in-line 
NaI(Tl) radiation detector. For all HPLC analyses, a Waters Xterra C18 reversed-phase column (5 
μm, 150 × 4.6 mm, Milford, MA) was used with a binary mobile phase composed of (A) water 
containing 0.1% trifluoracetic acid (TFA) and (B) acetonitrile containing 0.1% TFA with a 
gradient of 95% A and 5% B to 20% A and 80% B over a period of 15 mins at a flow rate of 0.7 
mL/min. 
Cell Culture 
Tumorigenic cell lines LNCaP (CRL-1704) and PC-3 (CRL-1435) were obtained from American 
Type Culture Collection (Manassas, VA). LNCaP cells were maintained in RPMI 1640 containing 
10% FBS (RPMI+) and grown at 37°C with 5% CO2. PC3 cells were maintained in DMEM 
containing 10% FBS (DMEM+) and grown at 37°C with 5% CO2. LNCaP and PC3 cells were 
cultured in poly-l-lysine coated cell culture flasks and passaged when approximately 70-90% 
confluent. 
EC50 Cell Titration 
LNCaP cells were seeded in 24-well plates in 0.5 mL/well of RPMI+ at a concentration of 1 x 105 
cells/well and incubated for 48 hours at 37°C in 5% CO2 atmosphere. The supernatant was 
removed, and the cells were washed once with PBS before addition of 0.5 mL of RPMI+ containing 
0.1 to 200 nM of [43,44,47Sc]Sc-PSMA-617. The sample size for each concentration was four. The 
cells were incubated for 2 hours at 37° C, washed twice with 1 mL of ice-cold PBS, and lysed with 
200 uL 0.2 N NaOH. The lysate was transferred into a 1.5 mL centrifuge tube and was measured 




percentage of added dose per milligram of protein (% AD/mg protein). A one site dose response 
curve was used to fit the data and determine the EC50 using GraphPad Prism software (v. 7.0). 
Specific Uptake 
LNCaP and PC3 cells were seeded in 24-well plates in 0.5 mL/well of RPMI+ and DMEM+ and 
incubated for 48 h at 37°C in 5% CO2 at a concentration of 1 x 105 cells/well and 0.5 x 105 
cells/well, respectively. The supernatant was removed and the cells were washed once with warm 
PBS before addition of 0.5 mL of RPMI+ (or DMEM+) containing up to 20 nM of each radioligand 
or 0.5 mL of RPMI+ (or DMEM+) containing a mixture of up to 20 nM of each radioligand and 
100 uM of 2-PMPA. The sample size for each blocking and non-blocking cell line was six. The 
cells were incubated for 2 and 4 hours at 37° C in a 5% CO2 atmosphere, washed twice with 0.5 
mL of ice-cold PBS, and lysed with 200 uL 0.2 M NaOH. The lysate was transferred into a 1.5 
mL centrifuge tube. Each tube was measured in a gamma counter. To determine the percent of 
initial activity per mg, the cell protein mass was determined with a Thermo Scientific Pierce BCA 
protein assay kit (Waltham, MA) using Bovine Serum Albumin (BSA) as a standard. Samples 
were measured in triplicate on a BioTek microplate reader (Winooski, VT). The results were 
expressed as the percentage of the ratio of cell-associated activity to activity added to each well 
per mg cell protein. 
Cell Internalization 
LNCaP cells were seeded in 24-well plates in 0.5 mL/well of RPMI+ at a concentration of 1 x 105 
cells/well and incubated for 48 h at 37°C in 5% CO2 atmosphere. The supernatant was removed, 
and the cells were washed once with warm PBS before addition of 0.5 mL of RPMI+ containing 
up to 20 nM of each radioligand (10 MBq/nmol). The sample size for each blocking and non-
blocking cell line was six. For 43,44,47Sc and 177Lu, the cells were incubated for 10 min, 30 min, 1 




for 10 min, 20 min, 30 min, 45 min, 1 h, and 2 h in a 5% CO2 atmosphere. At the same time points, 
an additional set of reactions were carried out at 4° C (to prevent internalization) as a control. 
Following incubation, the cells were washed once with 1 mL of ice-cold PBS. To determine the 
receptor associated fraction of radioligand, the cells were washed with 0.2 mL of stripping buffer 
(0.15 M NaCl in 0.1 M acetic acid at pH 3) which was transferred to 1.5 mL centrifuge tube and 
centrifuged at 5000 rpm for 5 min to pelletize any LNCaP cells in the sample. The supernatant was 
transferred to a new 1.5 mL centrifuge tube. To determine the internalized radioligand, the cells 
were lysed with 200 uL 0.2 N NaOH. The lysate was transferred into the previous 1.5 mL 
centrifuged tube containing any pelletized cells from the stripping buffer. Each tube (receptor 
associated and internalized) was measured in a gamma counter. The results were expressed as 
percentage of total internalized radioligand and percentage of total receptor associated radioligand. 
High Purity Germanium Spectroscopy 
Radioactive samples were characterized by gamma-ray spectroscopy using a Canberra GC2018 
HPGe detector with a relative efficiency of 24.5% (Meriden, CT). Canberra Genie 2000 software 
was used for data acquisition and analysis. Energy and efficiency calibrations were performed 
using a mixed nuclide source in a sealed 1.5 mL microcentrifuge vial prepared by Eckert & Ziegler 
Analytics (Atlanta, GA). Efficiency-calibration spectra with a minimum photopeak area of 2 x 105 
counts were collected and fit to determine the detector efficiency. For all measurements, aliquots 
of sample material were transferred into a 1.5 mL vial, diluted to 1 mL, and suspended in a fixed 
acrylic holder at a distance of 5 or 25 mm from the HPGe detector. This geometry was maintained 





5.3.1 Production of Sc Radionuclides 
The Nb target holder was used to irradiate 250 μm thick metallic Ti foils (ρ = 4.506 g/cm3) at 
approximately 24 MeV for 3 hours. The average (n = 3 ± 1σ) mass of a Ti foil was (91.5 ± 0.3) 
mg. Post-irradiation, the targets were allowed to sit and decay for 4 to 5 hours due to the co-
production of tens of GBqs of 47V (see Figure 2-11). The irradiated targets were digested at 250°C 
in a closed PFA vessel containing 3 mL of 1.0 M ammonium bifluoride digested in 12.1 M HCl. 
The complete digestion took 30 min and the digestant was dark-violet. The 43Sc, 44Sc, and 47Sc in 
the digestant was separated from contaminants using BDGA resin. The recovery efficiency of the 
Sc radionuclides was greater than 90%. After separation, the recovered 43Sc, 44Sc, and 47Sc was 
concentrated by vacuum evaporation at 95°C. Typically, the digestion, purification, and 
concentration of Sc radionuclides took 3-4 hr. 
5.3.2 PSMA-617 Radiochemistry 
[43,44,47Sc]Sc-PSMA-617 
The purified 43Sc, 44Sc, and 47Sc digested in 0.5 M ammonium acetate (pH 4.7) was used to label 
different quantities of aqueous PSMA-617 (0.5 to 20 nmol) in 50 µL of the ammonium acetate 





Figure 5-1. The average (n = 3, 1σ) radiochemical yield of [43,44,47Sc]Sc-PSMA-617 as a 
function of PSMA-617 mass 
Figure 5-1 shows the average (n = 3, 1σ) radiochemical yield of [43,44,47Sc]Sc-PSMA-617 
determined by radio-TLC under these conditions was greater than 99% at PSMA-617 
concentrations as low as 20 uM (1 nmol). Different incubation times at 95°C were investigated by 
labeling 20 uM PSMA-617 in 50 µL of 0.5 M ammonium acetate (pH 4.7) containing 43Sc, 44Sc, 





Figure 5-2. The average (n = 3, 1σ) radiochemical yield of [43,44,47Sc]Sc-PSMA-617 as a 
function of incubation time 
Figure 5-2 indicates the average (n = 3, 1σ) radiochemical yield of [43,44,47Sc]Sc-PSMA-617 
determined by radio-TLC varied at incubation times less than 30 min (10 min, 15 min, and 20 min) 
but was consistently greater than 99% when the reaction was incubated for at least 30 min. The 
batch radiochemical synthesis of [43,44,47Sc]Sc-PSMA-617 for in vitro experiments typically 
involved labeling 1 nmol of aqueous PSMA-617 (1 g/L) in 100 µL of 0.5 ammonium acetate (pH 





Figure 5-3. A representative chromatogram showing the radiochemical purity of [43,44,47Sc]Sc-
PSMA-617 measured by radio-HPLC 
Figure 5-3 indicates that the radiochemical purity of [43,44,47Sc]Sc-PSMA-617 measured by radio-
HPLC was greater than 99%. 
[177Lu]Lu-PSMA-617 
The high specific activity 177Lu digested in 0.05 M HCl (0.5 to 2 µL) was used to label different 
quantities of aqueous PSMA-617 (0.5 to 20 nmol) at 95°C for 30 min in 50 µL of the ammonium 





Figure 5-4. The average (n = 3, 1σ) radiochemical yield of [177Lu]Lu-PSMA-617 as a function 
of PSMA-617 mass 
The specific activity for these reactions, depending upon ligand mass, varied from approximately 
0.5 to 20 MBq/nmol and an average (n = 3, 1σ) radiochemical yield greater than 99% was observed 
at a specific activity of 10 MBq/nmol using 1 nmol of PSMA-617. The batch radiochemical 
synthesis of [177Lu]Lu-PSMA-617 for in vitro experiments typically involved labeling 2 nmol of 
aqueous PSMA-617 (1 g/L) in 100 µL of 0.5 ammonium acetate (pH 4.7) containing 37 MBq of 





Figure 5-5. A representative chromatogram showing the radiochemical purity of [43,44,47Sc]Sc-
PSMA-617 measured by radio-HPLC 
Figure 5-5 indicates that the radiochemical purity of [177Lu]Lu-PSMA-617 measured by radio-
HPLC was greater than 99%. 
[68Ga]Ga-PSMA-617 
The 68Ga obtained from a 68Ge/68Ga generator in 0.1 M HCl at a concentration of approximately 
100 MBq/mL was used to label aqueous PSMA-617 (20 nmol) in 3 mL. The bulk volume required 
an acid clean 5 mL glass v-vial and stir bar, and the generator eluate containing 68Ga was heated 





Figure 5-6. The average (n = 4, 1σ) radiochemical purity of [68Ga]Ga-PSMA-617 measured by 
radio-HPLC 
Figure 5-6 indicates that the radiochemical purity of [68Ga]Ga-PSMA-617 was greater than 97% 
(n = 3, 1σ) and the specific activity was approximately 10 MBq/nmol. 
5.3.3 In Vitro Properties of [43,44,47Sc]Sc-PSMA-617 
EC50 Cell Titration 
Titration  studies of [43,44,47Sc]Sc-PSMA-617 and LNCaP cells showed the average (n = 4, 1σ) 





Figure 5-7. Competitive binding of [43,44,47Sc]Sc-PSMA-617 on LNCaP cells 
Specific Uptake 
Cell uptake studies of [43,44,47Sc]Sc-PSMA-617, [177Lu]Lu-PSMA-617, and [68Ga]Ga-PSMA-617 
were carried out on LNCaP (PSMA+) and PC3 (PSMA-) cells. Table 5-1 shows the average (n = 
4, 1σ) cell uptake values of  [43,44,47Sc]Sc-PSMA-617 and [177Lu]Lu-PSMA-617 at 2 hr and 4 hr, 
and [68Ga]Ga-PSMA-617 at 1 hr and 2 hr. 
Table 5-1. The average (n = 4, 1σ) cell uptake values of different PSMA-617 radioligands to 
LNCaP cells. 
Time [43,44,47Sc]Sc-PSMA-617 [177Lu]Lu-PSMA-617 [68Ga]Ga-PSMA-617 
[PSMA-617] 2 nM 20 nM 20 nM 
2 hr (LNCaP) (16.6 ± 1.6)% (20.8 ± 1.1)% *(10.8 ± 1.1)% 
2 hr (PC3) (0.42 ± 0.03 )% (1.02 ± 0.3)% *(0.7 ± 0.4)% 
4 hr (LNCaP) (21.9 ± 1.7)% (27.0 ± 1.2 )% †(15.5 ± 1.2)% 
4 hr (PC3) (0.31 ± 0.03)% (1.04 ± 0.11)% †(2.2 ± 0.3)% 





Specific uptake was confirmed by co-incubating each radioligand with 100 µM of the known 
PSMA inhibitor 2-PMPA. Table 5-2 shows the average (n = 4, 1σ) cell uptake values of 
[43,44,47Sc]Sc-PSMA-617 and [177Lu]Lu-PSMA-617 at 2 hr and 4 hr, and [68Ga]Ga-PSMA-617 at 
1 hr and 2 hr (co-incubated with 2-PMPA). 
Table 5-2. The average (n = 4, 1σ) cell uptake values of different PSMA-617 radioligands to 
LNCaP cells. 
Time [43,44,47Sc]Sc-PSMA-617 [177Lu]Lu-PSMA-617 [68Ga]Ga-PSMA-617 
[PSMA-617] 2 nM 20 nM 20 nM 
2 hr (LNCaP) (0.3 ± 0.1)% (1.3 ± 0.4)% *(0.5 ± 0.1)% 
2 hr (PC3) (0.33 ± 0.04)%  (1.0 ± 0.2)% *(0.3 ± 0.2)% 
4 hr (LNCaP) (0.3 ± 0.1)% (1.2 ± 0.3)% †(1.5 ± 0.2)% 
4 hr (PC3) (0.27 ± 0.03)% (0.9 ± 0.1)% †(1.6 ± 0.3)% 
*1 hr, †2 hr    
 
The cell uptake values for each radioligand under both conditions (no-inhibitor and inhibitor) at 
both time points were than plotted to show the specific uptake of PSMA-617 labeled with Sc 
radionuclides, 68Ga, and 177Lu (Figure 5-8). 
 
Figure 5-8. The average cell uptake of [43,44,47Sc]Sc-PSMA-617, [177Lu]Lu-PSMA-617, and 





The internalization of receptor-bound [43,44,47Sc]Sc-PSMA-617 and [177Lu]Lu-PSMA-617 into 
LNCaP cells was investigated. Table 5-3 shows the percent of membrane-bound [43,44,47Sc]Sc-
PSMA-617 and internalized [43,44,47Sc]Sc-PSMA-617 on LNCaP cells at time points out to 24 hr.  
Table 5-3. The average (n = 6, 1σ) percent of membrane-bound or internalized [43,44,47Sc]Sc-
PSMA-617 and [177Lu]Lu-PSMA-617 
 [43,44,47Sc]Sc-PSMA-617 [177Lu]Lu-PSMA-617 
Times (h) Internalized Receptor-bound Internalized Receptor-bound 
0.167 (37.3 ± 2.8)% (62.7 ± 2.8)% (66.8 ± 3.2)% (33.2 ± 3.2)% 
0.5 (82.0 ± 2.1)% (18.0 ± 2.1)% (80.5 ± 0.8)% (19.5 ± 0.8)% 
0.8 (79.1 ± 1.7)% (20.9 ± 1.7)% (85.5 ± 2.0)% (14.5 ± 2.0)% 
1.0 (82.4 ± 2.1)% (17.6 ± 0.7)% (85.5 ± 2.0)% (14.5 ± 2.0)% 
2.0 (91.5 ± 1.3)% (9.0 ± 1.3)% (91.2 ± 0.4)% (8.8 ± 0.4)% 
4.0 (94.8 ± 0.7)% (5.2 ± 0.7)% (92.8 ± 1.0)% (7.2 ± 1.0)% 
8.0 (95.2 ± 1.7)% (4.8 ± 1.7)% (93.2 ± 0.8)% (6.8 ± 0.8)% 
24.0 (95.6 ± 1.6)% (4.4 ± 1.6)% (95.0 ± 2.1)% (5.0 ± 2.1)% 
 
Figure 5-9 shows the fraction of membrane-bound [43,44,47Sc]Sc-PSMA-617 and [177Lu]Lu-





Figure 5-9. The rate of internalized (◊) PSMA-617 labeled with Sc radionuclides and 177Lu  
5.4 Discussion 
PSMA-617 was labeled with 43Sc, 44Sc, and 47Sc produced via proton irradiation of Ti target 
material using methods detailed in Chapter 4. The [43,44,47Sc]Sc-PSMA-617 yield, based on 
radiolabeling conditions employed in this work, was greater than 99% measured by radio-TLC 
and radio-HPLC at ligand masses as low as 1 nmol in 50 µL of 0.5 M ammonium acetate (pH 4.7). 
Similar to other published methods to label DOTA-functionalized compounds, all synthesis 
reactions were carried out at 95°C. The effect of time on radiochemical yield was studied and  
reproducible yields greater than 99% were obtained at incubation times greater than or equal to 30 
min. At shorter reaction times, 10 min, 15 min, and 20 min, reaction yields less than 90% were 
obtained. PSMA-617 was labeled with 177Lu using similar conditions by dissolving 177Lu-chloride 
solution (0.05 M HCl) in 0.5 M ammonium acetate (pH 4.7). The [177Lu]Lu-PSMA-617 yield was 
greater than 99% measured by radio-TLC and radio-HPLC at ligand masses low as 1 nmol in 50 
µL of 0.5 M ammonium acetate (pH 4.7).  




43Sc, 44Sc, and 47Sc, and 177Lu. The reaction volume and PSMA ligand mass was increased from 
50 µL to 100 µL and 1 nmol to 2 nmol, respectively. At these conditions, the radiochemical yield 
of [43,44,47Sc]Sc-PSMA-617 and [177Lu]Lu-PSMA-617 was greater than 99%. A specific activity 
for [43,44,47Sc]Sc-PSMA-617 was not measured due to the mixture of Sc radionuclides with 
different half-lives; however, the [177Lu]Lu-PSMA-617 specific activity was between 10-20 
MBq/nmol for all reactions. The [177Lu]Lu-PSMA-617 specific activity was similar to or greater 
than specific activities (approximately 10 MBq/nmol) reported using similar labeling conditions.  
PSMA-617 was labeled with 68Ga by adding 25 nmol of aqueous PSMA-617 to 3 mL of 0.1 M 
HCl containing 259-296 MBq 68Ga obtained by fractionating the eluate from a 68Ge/68Ga 
generator. The [68Ga]Ga-PSMA-617 yield and specific activity were greater than 98% and  
approximately 10 MBq/nmol, respectively. For each radioligand, the radiochemical purity, 
confirmed by radio-HPLC, was greater than 99% and each trivalent radiometal was chelated by 
DOTA at acidic pH. Unlike the mixture of 43Sc, 44Sc, and 47Sc and 177Lu, which labeled PSMA-
617 in low molarity ammonium acetate buffer with an approximate pH of 4.7, 68Ga was directly 
labeled in 0.1 M HCl; however, previously published methods exist to concentrate 68Ga onto a 
strong cation exchange cartridge followed by collection of purified 68Ga in a small solvent volume. 
Once concentrated, purified 68Ga could be used to label PSMA-617 under conditions identical to 
the 43Sc, 44Sc, and 47Sc, and 177Lu in 0.5 M ammonium acetate (pH 4.7).  
 The affinity of PSMA-617 for PSMA receptors on LNCaP cells was studied to determine the 
ligand concentration that minimized self-competition for available receptor sites. The experimental 
EC50 for [43,44,47Sc]Sc-PSMA-617 associated with LNCaP cells was 2.0 ± 0.1 nM. This ligand 
concentration was used to investigate the specific targeting of PSMA receptors on LNCaP cells by 




used to show specific targeting of PSMA receptors on LNCaP cells by [177Lu]Lu-PSMA-617 and 
[68Ga]Ga-PSMA-617 and the known PSMA inhibitor 2-PMPA was used to block PSMA receptors 
and confirm specific targeting by PSMA-617. At 2 hr and 4 hr, after addition of [43,44,47Sc]Sc-
PSMA-617 to LNCaP cells, the cell uptake was (16.6 ± 1.6)% and (21.9 ± 1.7)%, respectively. 
The [43,44,47Sc]Sc-PSMA-617 cell uptake values were similar to the experimental uptake of 
[177Lu]Lu-PSMA-617 and [68Ga]Ga-PSMA-617 (Table 5-1 and Table 5-2) to LNCaP cells at 2 hr 
and 4 hr (1 hr and 2 hr for PSMA-617 labeled with 68Ga). These results confirmed that 
[43,44,47Sc]Sc-PSMA-617 was selectively associated with PSMA receptors on LNCaP cells. 
Moreover, [43,44,47Sc]Sc-PSMA-617 had cell uptake values similar to those of [177Lu]Lu-PSMA-
617. However, increased non-specific uptake was observed in PSMA-617 labeled with 177Lu and 
68Ga (20 nM); thus, the cell uptake values of both compounds should be measured at 2 nM.   
 The rates at which [43,44,47Sc]Sc-PSMA-617 and [177Lu]Lu-PSMA-617 was internalized into 
LNCaP cells were studied at different time points up to 24 hours. These data may predict the in 
vivo characteristics of PSMA-617. Figure 5-9 showed that within 4 h the fraction of receptor-
bound [43,44,47Sc]Sc-PSMA-617 and [177Lu]Lu-PSMA-617 internalized into LNCaP cells was 
approximately 95% and 93%, respectively. At 24 hr, the fraction internalized into LNCaP cells 
was (95.6 ± 1.6)% and (95.0 ± 2.1)%. This in vitro model using LNCaP cells indicated successful 
targeting of PSMA receptors with [43,44,47Sc]Sc-PSMA-617, [177Lu]Lu-PSMA-617, and [68Ga]Ga-
PSMA-617.  
 The cell uptake studies indicated that a significant fraction of PSMA-617 labeled with Sc 
radionuclides will target PSMA receptors. After receptor mediated uptake to LNCaP cells, up to 
93% of PSMA-617 was then transported into the cell within 4 h. These preliminary data may 




time-points up to 24 hr and the continuation of the work described herein will include studies that 
investigate the in vivo properties of PSMA-617 labeled with the matched-pair radionuclides of Sc. 
5.5 Conclusion 
Scandium-43, 44Sc, and 47Sc were produced using natTiO2 and the in vitro properties of PSMA-617 
labeled with these radionuclides was investigated. The radiochemical yield of [43,44,47Sc]Sc-
PSMA-617 was greater than 99%. The in vitro properties of [43,44,47Sc]Sc-PSMA-617 were 
investigated and the radioligand was used to show cell associated uptake to LNCaP prostate cancer 
cells. These data were directly compared to the cell associated uptake of [177Lu]Lu-PSMA-617 
and [68Ga]Ga-PSMA-617 in the same prostate cancer cell line. These findings showed that PSMA-
617 labeled with Sc radionuclides has similar in vitro properties to PSMA-617 labeled with 177Lu 
and 68Ga. Future work should repeat these studies using radioisotopically pure 43Sc and 47Sc 
(produced using enriched 46,50TiO2) to assess the in vivo biodistribution of [43Sc]Sc-PSMA-617 
and [47Sc]Sc-PSMA-617. Additionally, the in vitro and in vivo therapeutic efficacy of [47Sc]Sc-
PSMA-617 should be investigated along with the in vivo imaging of LNCaP tumors in tumor-
bearing animal models. Overall, these results in this work show that cyclotron produced 43Sc and 
47Sc obtained using enriched TiO2 targets can be used in future preclinical investigations to study 
the in vitro and in vivo characteristics of PSMA-617 labeled with the matched-pair theranostic 
radionuclides 43Sc and 47Sc. 
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Chapter 6: Conclusion 
6.1 Research Summary 
This work investigated the production, purification, and potential medical applications of 43Sc, 
44Sc, and 47Sc. These radionuclides of Sc have properties that can be used for molecular imaging 
and targeted radionuclide therapy (TRNT) in nuclear medicine. The diagnostic radionuclides, 43Sc 
and 44Sc (see Figure 2-2 and Figure 2-3), undergo positron decay and emit annihilation photons 
that can be detected by a positron emission tomography (PET) scanner. The third radionuclide, 
47Sc (see Figure 2-7), undergoes beta decay and emits a beta particle which deposits ionizing 
radiation in tissue that can kill cells. When these radionuclides are incorporated into a molecular 
compound that targets a disease, they can be used as a pair (i.e., 43Sc/47Sc and 44Sc/47Sc). In this 
case, 43Sc or 44Sc can be used for diagnostic imaging followed by 47Sc for TRNT. These matched-
pair Sc radionuclides enable a theranostic strategy that uses a diagnostic compound to identify and 
profile disease and a therapeutic compound to provide patient specific treatment. An example of 
this personalized approach in nuclear medicine is the FDA-approved compound DOTATE labeled 
with 68Ga and 177Lu. The diagnostic, [68Ga]Ga-DOTATATE is clinically used to detect 
neuroendocrine tumors (NETs), monitor NETs progression, and profile patient response to 
targeted radionuclide therapy (TRNT) with [177Lu]Lu-DOTATATE. The aim of this work was to 
identify and develop methods to produce these matched-pair radionuclides of Sc for pre-clinical 
investigation of novel theranostic agents at the University of Alabama at Birmingham (UAB). 
 Unlike many FDA-approved radiopharmaceuticals that use radionuclides of different elements 
(e.g. 68Ga and 177Lu) that require different instruments and infrastructure (e.g. particle accelerator 




induced nuclear reactions on enriched Ti in the oxide form (i.e. TiO2) would represent a robust 
and unified production route that uses similar target material and target processing methods to 
supply 43Sc, 44Sc, and 47Sc. The findings detailed in Chapter 3 and Chapter 4, taken together, show 
that methods developed in this work can provide useful quantities of these Sc radionuclides for 
pre-clinical studies. However, these methods will require further optimization and development of 
additional steps to reduce the time required to process irradiated targets and isolate 43Sc, 44Sc, and 
47Sc in a small volume suitable for direct radiolabeling of theranostic compounds. As optimization 
continues at UAB, the processes detailed in this work will allow onsite production of 43Sc/47Sc or 
44Sc/47Sc. A reliable source of these radionuclides will enable future studies that investigate the 
diagnostic efficacy of 43Sc and 44Sc and the therapeutic efficacy of 47Sc. The key findings detailed 
in this work are summarized below. 
Scandium-43, 44Sc, and 47Sc Production  
Naturally isotopic Ti foils were irradiated to produce a mixture of Sc radionuclides (including co-
produced 46Sc and 48Sc). These targets were digested, and the experimental yield of each 
radioactive product (43Sc, 44Sc, and 47Sc) was measured using gamma-ray spectroscopy. The 
experimental end-of-bombardment (EOB) yield was compared to theoretical EOB yields for each 
Sc radionuclide. The theoretical EOB yields were calculated using published cross-section data or 
theoretical cross-section data obtained from the TENDL database.1 The experimental and 
theoretical EOB yields agreed, and the modeling methodology was used to predict EOB yields for 
43Sc, 44Sc, and 47Sc using enriched 46,47,48,50TiO2. These data showed that hundreds of MBqs of 
47Sc and tens of GBqs of 43Sc and 44Sc could be produced using 24 MeV protons at low beam 
currents (20-30 µA) to irradiate enriched Ti targets (46Ti, 47Ti, 48Ti, and 50Ti). 
Target Processing 




its oxide form at beam currents up to 30 µA to produce 43Sc, 44Sc, and 47Sc. Firstly, durable Ta 
target holders were developed and tested that held pressed natTiO2 targets. The Ta target holder was 
designed to enclose the powdery oxide target material to prevent radiological contamination during 
irradiation and transfer of irradiated targets. These Ta target holders were durable under all 
conditions tested and tolerated heat buildup in the natTiO2 due to its poor thermal conductivity. 
Further, no radiological contamination was detected after EOB or during transfer of the irradiated 
targets. Next, a method to digest natTiO2, known for its resistance to attack by acids, was developed 
since previously reported methods required hours to achieve total digestion of this target material. 
The digestion method developed in this work used inexpensive and widely available PFA vials 
(threaded with caps) that contained natTiO2 in a mixture of ammonium bifluoride digested in 12.1 
M HCl (see Figure 4-2). The vial was tightly capped and heated at 255°C for approximately 60 
min to completely digest natTiO2. Last, a method to chemically separate and purify 43Sc, 44Sc, and 
47Sc from co-produced radionuclides (like 47V and 48V, see Figure 2-11 and Figure 2-12) using 
the cation exchange resin BDGA was developed. The average (n = 3, 1σ) percent recovery of Sc 
using the separation method was greater than 90%. Typically, the separation (see Figure 4-3), 
included a vacuum evaporation step to concentrate the Sc radionuclides collected in 10 mL of the 
eluate. The complete digestion and processing of an irradiated natTiO2 target and concentration of 
the 43Sc, 44Sc, and 47Sc in the separation column eluate required approximately 4 h.   
Target Material Recycling 
Non-radioactive TiO2 was used to develop an alkali-based precipitation of Ti collected in 20 mL 
of 7.0 M HCl. This method was needed to recycle costly enriched TiO2 after reach irradiation to 
produce 43Sc, 44Sc, and 47Sc using enriched TiO2 targets and represents an important element of 




the digestion method. For each sample, the digestant was diluted to 20 mL with HCl to reach a 
final concentration of 7.0 M HCl. These samples were then diluted to 500 mL with water and the 
alkali precipitation was carried out by dropwise addition of ammonia solution (see Section 4.3.5). 
The Ti precipitate that formed at pH 8 was isolated by gravity filtration onto ashless filter paper 
and thoroughly rinsed with ethanol to dry each sample. The dried precipitate was combusted and 
the initial mass and final mass of target material (measured via mass balance) were compared to 
determine the percent recovery of TiO2. The average (n = 4, 1σ) recovery of TiO2 was equal to or 
greater than 100% and these data suggest added mass in the precipitate may be due to contributions 
from incomplete ashing. Additionally, the concentration of Ti in the final filtrate was measured 
via ICP-MS and no Ti was detected (n = 4, 1σ). This result indicated that Ti in the filtrate was 
below the ICP-MS detection limit (approximately 100 µg/L). Therefore, the Ti mass would be less 
than 50 µg which shows that the alkali precipitation is effective. 
Preliminary Study of the In Vitro Properties of [43,44,47Sc]Sc-PSMA-617 
Radionuclides of Sc were produced using natTi targets irradiated with 24 MeV and 30 µA of beam 
current. Irradiated targets were processed using the methods described in this work. The 43Sc, 44Sc, 
and 47Sc collected in the final purified Sc product was used to investigate conditions to radiolabel 
PSMA-617. A radiochemical yield of greater than 99% (measured via radio-TLC) was obtained 
for [43,44,47Sc]Sc-PSMA-617 when aqueous PSMA-617 was labeled with Sc radionuclides in 0.5 
M ammonium acetate (pH 4.7). Additionally, a radiochemical purity greater than 99% was 
confirmed by radio-HPLC. PSMA-617 was also labeled with 68Ga and 177Lu (see Section 5.3.2). 
The PSMA-617 labeled with Sc radionuclides, 68Ga, and 177Lu was then used in cell uptake studies 
to show specific uptake to LNCaP cells for each radioligand. At 4 h (2 h for 68Ga) after each 




cells for [43,44,47Sc]Sc-PSMA-617, [177Lu]Lu-PSMA-617, and [68Ga]Ga-PSMA-617 was (21.9 ± 
1.7)%, (27.0 ± 1.2 )%, and (15.5 ± 1.2)%, respectively. These results indicated that Sc 
radionuclides produced and purified using the methods in this work can be used to label PSMA-
617 to investigate its in vitro properties. Furthermore, results from the proof-of-concept cell uptake 
study (see Section 5.3.3) showed agreement in cell uptake values between PSMA labeled with Sc 
radionuclides produced in this work, 68Ga obtained from a 68Ge/68Ga generator, and 177Lu produced 
in a nuclear reactor. 
6.2 Future Work 
Continuation of studies detailed in this work should focus on two areas: (1) optimization of the 
existing methods and development of methods to improve the production and chemical separation 
of 43Sc, 44Sc, and 47Sc, and (2) development of a 44Ti/44Sc generator. 
 The methods described herein demonstrated that relevant quantities of Sc radionuclides were 
prepared for pre-clinical evaluations of [43,44,47Sc]Sc-PSMA-617; however, optimization of 
processing steps (e.g. target digestion) should be investigated to improve overall yields. 
Suggestions for optimization (or improvement) to the existing methods are detailed below. 
TiO2 Target Material 
The Ta-backed targets developed in this work allowed irradiation of natTiO2 with 24 MeV protons 
at beam currents up to 40 µA; however, the temperature increase in the target material (due to heat 
deposition and poor thermal conductivity of the target material) resulted in a distinct change in 
color (white to gray-blue) of the pressed natTiO2 targets between 30 and 40 µA. Upon digestion 
(see Figure 4-2), these targets (n = 2) did not fully dissolve, and it was hypothesized that the 
natTiO2 may have undergone a phase change from the anatase to rutile form (600 to 700°C) during 




this effect was either not observed or the change in color was faint. To better understand the 
downstream process effects caused by the color change, multiple pressed TiO2 targets should be 
subject to different temperatures using a furnace and processed using the methods in this work. 
The TiO2 targets should be divided into at least three groups (control, low-heat, and high-heat). 
The low-heat and high-heat groups should be heated at 400°C and 1000°C, and the control group 
kept at room temperature. Each target should then be digested, purified as if it had been 
bombarded, and the Ti target material recovered via alkali precipitation (see Section 4.3.5). 
Measurements of the initial and recovered masses of Ti can be performed using a mass balance, 
and the mass of Ti measured in the digestant can be determined using an inductively-coupled mass 
spectrometer (ICP-MS). The phase and morphology of the natTiO2 can be characterized before 
digestion and after combustion by surface analysis with a scanning electron microscope (SEM). 
The proposed experiment may be helpful in determining how to modify the digestion method to 
fully dissolve targets irradiated at beam currents greater than 25 µA. An emphasis on irradiating 
Ti targets at higher beam currents would increase the EOB yields of 43Sc, 44Sc, and 47Sc. 
Additionally, the current targetry could be modified to decrease the amount of energy (i.e., heat) 
deposited in the natTiO2 by modifying the target holder design to promote better thermal 
conductivity throughout the target-target holder, improving the cooling efficiency of the target 
station, or by irradiating targets using the 20° target station to spread the beam over a greater 
region. 
Target Digestion 
The method to digest TiO2 developed herein uses a mixture of ammonium bifluoride and HCl and 
requires approximately 60 min for full dissolution. During development of the dissolution method, 




times was investigated but the sample size was limited (n = 1 or n = 2). Additional experiments to 
assess the effects that the volume of 12.1 M HCl have on dissolution may be beneficial. Results 
from these studies were reproducible and showed that TiO2 could be dissolved in two 30 min steps 
(see Section 4.3.2). In some cases, total digestion was observed after heating for 15 to 20 min per 
step; however, faster dissolution times caused more variable results. Therefore, the impact of each 
parameter should be systematically investigated to ascertain whether total digestion of TiO2 can 
be reliably performed in less than 60 min. Optimizing the time required to digest irradiated targets 
will reduce the amount of 43Sc, 44Sc, or 47Sc that is lost to decay during target processing. These 
optimization studies could be carried out with non-radioactive TiO2. The degree of dissolution can 
be determined by measuring the ratio of dissolved Ti in the digestant (via ICP-MS analysis) to the 
initial Ti mass (via mass balance measurement). 
BDGA Separation 
The Ti/Sc separation method using BDGA resin used 10 mL of 0.1 M HCl to collect the purified 
Sc material. The volume of the Sc fraction was reduced by heating the fraction at 95°C under 
vacuum to remove the eluant. The remaining radioactive Sc was reconstituted in 0.5 M ammonium 
acetate (pH 4.7). While this approach was successful, the steps required to evaporate the eluate 
could be a potential source of chemical contamination. 
 Two studies could be conducted to investigate improvements in the separation process. First, 
data from a preliminary investigation of the disassociation constant (e.g., kD) for the adsorption of 
Sc onto BDGA resin at different concentrations of HNO3 showed that Sc ions have a similar 
affinity for the resin at 7 M and 2 M HNO3. Based on this observation, the HNO3 fraction (collected 
just prior to the Sc fraction) was adjusted to 2 M HNO3. This modification reduced the 




of 0.1 M HCl (instead of 10 mL). This modification will need further validation to prove that 43Sc, 
44Sc, and 47Sc purified using the modified method is of comparable or better quality to that 
prepared using the original method (i.e., 7 M HNO3 followed by 10 mL of 0.1 M HCl). Secondly, 
an alternative concentration method could be explored. The purified Sc fraction in 0.1 M HCl 
could be absorbed onto a cartridge containing strong cation exchange resin cartridge and eluted by 
a small volume (hundreds of µLs) of suitable solvent or buffer. This approach could be pursued 
by identifying multiple chromatographic resin cartridges that have affinity for Sc in 0.1 M HCl. 
Each cartridge could be systematically investigated using different eluents buffered to an 
approximate pH of 4.0 to 4.7. These experiments could be carried out with radiotracer quantities 
of 43Sc, 44Sc, and 47Sc produced using natTi targets, and the fate of radioactive Sc could be 
quantitatively determined via gamma-ray spectroscopy using an HPGe detector. 
Ti Recycling 
The Ti/Sc separation method using BDGA resin used 10 mL of 0.1 M HCl to collect the purified 
Sc material. The volume of the Sc fraction was reduced by heating the fraction at 95°C under 
vacuum to remove the eluant. The remaining radioactive Sc was reconstituted in 0.5 M ammonium 
acetate (pH 4.7). While this approach was successful, the steps required to evaporate the eluate 
could be a potential source of chemical contamination. 
 Two studies could be conducted to investigate improvements in the separation process. First, 
data from a preliminary investigation of the disassociation constant (e.g., kD) for the adsorption of 
Sc onto BDGA resin at different concentrations of HNO3 showed that Sc ions have a similar 
affinity for the resin at 7 M and 2 M HNO3. Based on this observation, the HNO3 fraction (collected 
just prior to the Sc fraction) was adjusted to 2 M HNO3. This modification reduced the 




of 0.1 M HCl (instead of 10 mL). This modification will need further validation to prove that 43Sc, 
44Sc, and 47Sc purified using the modified method is of comparable or better quality to that 
prepared using the original method (i.e., 7 M HNO3 followed by 10 mL of 0.1 M HCl). Secondly, 
an alternative concentration method could be explored. The purified Sc fraction in 0.1 M HCl 
could be absorbed onto a cartridge containing strong cation exchange resin cartridge and eluted by 
a small volume (hundreds of µLs) of suitable solvent or buffer. This approach could be pursued 
by identifying multiple chromatographic resin cartridges that have affinity for Sc in 0.1 M HCl. 
Each cartridge could be systematically investigated using different eluents buffered to an 
approximate pH of 4.0 to 4.7. These experiments could be carried out with radiotracer quantities 
of 43Sc, 44Sc, and 47Sc produced using natTi targets, and the fate of radioactive Sc could be 
quantitatively determined via gamma-ray spectroscopy using an HPGe detector. 
Ti-44 Production 
Unlike 43Sc and 47Sc, which can be produced in their ground states via proton bombardment on 
enriched Ti nuclei, 44Sc produced via proton-induced reactions on 47Ti will always result in a 
mixture of 44mSc and 44Sc (see Figure 2-3 and Figure 2-4). Due to the relatively long half-life of 
44mSc (in comparison to 44Sc), using a mixture of these two radionuclides would complicate patient 
dosimetry and adoption into a clinical setting. Therefore, the more desirable method for producing 
44Sc is indirectly via the 45Sc(p,2n)44Ti  44Sc reaction pathway. The decay of the 44Ti parent 
offers an alternative production route where 44Sc can be obtained from a 44Ti/44Sc generator as the 
radiopure ground state isomer. 
 Previous investigations have shown that a 44Ti/44Sc generator capable of supplying 
approximately 185 MBq of 44Sc can be produced.2-5 The generator operated by adsorbing 44Ti in 




44Ti to reach secular equilibrium with the 44Sc daughter, approximately 185 MBq was eluted in 20 
mL of 0.005 M H2C2O4 in 0.07 M HCl (aq) at a flow rate of 1 mL/min. The reported generator 
design resulted in 97% recovery of 44Sc with 44Ti breakthrough of (5 x 10-5)%. An additional step 
to concentrate and further purify the 44Sc eluate was also reported.5 The 44Sc generator fraction 
was loaded onto 53 mg of AG 50W-X8, a strong cation exchange resin, and the resin was rinsed 
with water, dried with air, and 44Sc was collected in 3 mL of 0.25 M ammonium acetate (pH 4.0). 
A flow rate of 1 mL/min was used for each step in this process. The quantity of 44Ti in the final 
recovered product was further reduced by a factor of 10 with a final 44Ti breakthrough of less than 
(2 x 10-7)%. 
 In the future, a well-designed commercial 44Ti/44Sc generator capable of supplying clinical 
quantities of 44Sc could potentially be used for several years due to the approximately 60 y half-
life of 44Ti. Furthermore, a 44Ti/44Sc generator that incorporated 700-800 MBq of 44Ti could 
provide as much as 370 MBq of 44Sc every 4 hrs, which indicates multiple patient doses could be 
eluted per day to support clinical imaging with 44Sc-labeled compounds. However, multiple 
technical challenges exist that must be addressed in order to make these generators widely 
available. Firstly, few published studies exist that investigate alternative 44Ti/44Sc generator 
designs to the Rosch generator described earlier; thus, a method to produce and supply 44Ti isolated 
from irradiated 45Sc targets should be developed.3, 4 Next, the magnitude of the cross section for 
the 45Sc(p,2n)44Ti reaction is small (tens of mb) between proton energies of 13 and 24 MeV, and 
due to the half-life of 44Ti, production of useful quantities of 44Ti may require months of dedicated 
beam time at high beam currents. The resource cost (i.e., beam time), can be reduced by developing 
targetry that allows bombardment of 45Sc at currents of up to 300 µA and by utilizing the dual-




ability to continuously irradiate Sc targets concurrent with routine production of clinical 
radionuclides presents opportunities for production of significant quantities of 44Ti that could be 
used to investigate alternative generator designs and supply isomerically pure 44Sc at UAB and at 
other institutions. Lastly, long-lived 44Ti represents a hazard with respect to radiological 
contamination. All experiments that involve cyclotron produced 44Ti should be carefully planned 
and executed to avoid contamination of equipment and surfaces. 
 As part of this initial work, calculations were performed to predict the theoretical 44Ti 
production rate using 24 MeV protons at different beam currents up to 200 µA. The predicted 
production rate was approximately 0.05 MBq/µA⸱d and a thick Sc target was assumed for this 
model. At this rate, 185 MBq of 44Ti could be produced in 39 days using 24 MeV protons and a 
beam current of 100 µA. Further,  small quantities (up to 10 MBq) of 44Ti could be produced within 
a reasonable timeframe of 2 to 3 months using beam currents of up to 60 to 80 µA and a thick Sc 
target periodically. 
 To produce quantities greater than 10 MBq it is more feasible to design targetry capable of 
withstanding much higher beam currents. Therefore, an additional focus of this preliminary work 
was target design. To bombard thick Sc targets at high-current, two target holders were proposed 
that could be used to bombard targets at a grazing angle of either 7° or 20°. The target stations can 
mount each Sc target-target holder assemblies and were described in Chapter 2 (see Section 2.4.5). 
By using a slant angle, the profile of the beam elongates and adopts an oval-shape. Thus, the slant 
angle targets will have an increased region where the beam deposits energy in the target material 
and can therefore be cooled more efficiently, increasing the amount of beam current the target can 
withstand. The angle also means that thick target yields can be achieved with a thin layer of 45Sc 





 Phase one would involve developing production of 44Ti using the 20° target station. This station 
mounts an oval shaped Ta target holder with a maximum thickness of 3 mm. For 44Ti production, 
a 650 µm thick 45Sc foil could be heat-pressed into an oval shaped inset centered on a Ta base 
(Figure 6-1).  
 
Figure 6-1. The 20° target holder and a carton illustrating the heat-pressing of a Sc foil 
Figure 6-1 demonstrates the straightforward design of this proposed target holder. For this design, 
the 45Sc foil can be machined to achieve a tight-fit with the oval shaped inset. The 45Sc foil can be 
mounted into the Ta target holder by heating the Ta base with an acetylene torch to induce thermal 
expansion. At this point, the 45Sc foil can be pressed into oval shaped inset by using a machined 
punch with geometry similar to the oval shaped inset. The feasibility of this proposed method was 
confirmed by heat-pressing a circular 250 µm 45Sc foil into a circular bore (∅ = 260 to 265 µm) 
centered in a 2 mm thick Ta disc (∅ = 24 mm). This proof-of-concept experiment validated the 




small quantities (less than 10 MBq) of 44Ti using 24 MeV protons and beam currents up to 35 µA. 
These results suggest that the proposed design for the 20° target holder could be implemented for 
production of greater quantities of 44Ti using 60 to 80 µA of beam current. The predicted EOB 
yield of 44Ti as a function of time are shown in Figure 6-2 for those conditions (24 MeV protons 
at 60 and 80 µA of beam current). 
  
Figure 6-2. The predicted EOB yield of 44Ti as a function of time at 60 and 80 µA of beam 
current. 
 Phase two would involve developing production of 44Ti using the 7° target station. This station 
was specifically designed for high-current irradiations of solid targets at beam currents up to 300 





Figure 6-3. A drawing of the stock high-current solid target geometry.. Not shown in this 
cartoon is a top plate that is secured by six fasteners. It can be removed and imaged to profile the 
proton beam strike. Alternatively, target material can be electrodeposited onto the top plate for 
radionuclide production. 
Figure 6-3 shows a stock Al target holder, designed for the 7° station, which has a specific 
geometry that must be maintained to achieve a vacuum seal (via a gasket seal that sits upon the 
gasket base) in the beam line and proper cooling of the target material (via the cooling ports which 
circulate water across the bottom of the top plate) during irradiation. The proposed modifications 





Figure 6-4. A drawing of the unmodified target holder base and a modified top plate. The top 
plate contains an oval-shaped inset for the 45Sc foil 
The modifications shown in Figure 6-4 include an oval-shaped inset and a thinner top plate, which 
was adjusted to reduce the material thickness between the 45Sc foil and the water cooling fins. The 
reduction in thickness is expected to promote better conductive cooling of the Sc target during 
irradiation. Moreover, the top plate material was changed to Nb, which was selected as a 
machinable corrosion-resistant alternative to Ta. Similarly, to preparing the target for the 20° target 
station, a 45Sc foil can be machined to achieve a tight-fit with the oval-shaped inset in the Nb top 
plate and heat-pressed into the target holder. After development and preparation of a proof-of-
concept target-target holder assembly, the target should be tested by increasing beam current 
incrementally over a series of irradiations to determine the maximum tolerated beam current. The 
proposed design for the 7° 45Sc target holder may tolerate 24 MeV protons at beam currents up to 






Figure 6-5. The predicted EOB yield of 44Ti as a function of time at 100, 200, and 300 µA of 
beam current. 
Figure 6-5 indicates that 370 MBq of 44Ti could be produced at 300 µA in approximately 20 days 
of beam time.  
 To prepare 45Sc targets using the target holder designs proposed in this work, the 45Sc foil will 
need to be mechanically fixed into the oval-shaped inset, and the irradiated targets must be digested 
while fixed in the target holder. Therefore, an apparatus for achieving dissolution of the 45Sc foil 
was designed. 
  
Figure 6-6. The proposed design for a perfluoroalkoxy alkane (PFA) collar 
Figure 6-6 illustrates the proposed design for a corrosion resistant addition to the target holder 
that creates a reservoir. An irradiated Sc target could be digested while mounted into the target 
holder.  that allows acid digestion of a Sc target. The PFA reservoir could be secured with c-
clamps. This apparatus will allow testing of different mineral acids to determine the best method 
to digest irradiated Sc targets. The proposed designs may enable 44Ti production at beam currents 





This work investigated the production and supply of 43Sc, 44Sc, and 47Sc using proton-induced 
reactions on titanium nuclei. Compounds can be labeled with these Sc radionuclides to allow a 
theranostic approach using the diagnostic and therapeutic matched-pairs, 43Sc/47Sc and 44Sc/47Sc.  
The theranostic approach uses a diagnostic compound to identify and profile disease followed by 
treatment with a therapeutic compound. Unlike other common diagnostic and therapeutic pairs 
(e.g., 68Ga and 177Lu), a compound labeled with a Sc matched-pair could be prepared using 
identical methods and would be expected to have an identical pharmacokinetic profile. This work 
showed, based on the use of naturally isotopic TiO2, that enriched TiO2 targets (i.e., 46Ti, 47Ti, 48Ti, 
and 50Ti) could be used to produce small quantities of radiopure 43Sc, 44Sc, and 47Sc. 
 Production of these Sc radionuclides was carried out at 24 MeV and at beam currents up to 40 
µA using naturally isotopic Ti foil and Ti in the oxide form (TiO2). Irradiated targets were digested 
in less than 60 min. and separated from non-radioactive target material via cation-exchange 
chromatography using BDGA resin. The eluate containing 43Sc, 44Sc, and 47Sc was evaporated and 
reconstituted in 0.5 M ammonium acetate (pH 4.7). The Sc radionuclides were then used to label 
PSMA-617, a compound that targets PSMA receptors on prostate cancer cells. The in vitro 
properties of [43,44,47Sc]Sc-PSMA-617 were then evaluated and compared to the in vitro properties 
of PSMA-617 labeled with 68Ga and 177Lu. These studies were carried out using the LNCaP cell 
line (PSMA+) and PC3 cell line (PSMA-). Cell uptake studies that used the known PSMA inhibitor 
2-PMPA were carried out using [43,44,47Sc]Sc-PSMA-617, [177Lu]Lu-PSMA-617, and [68Ga]Ga-
PSMA-617, and these studies showed specific uptake of each radioligand to LNCaP cells.  
 Collectively, the results in this work show that small quantities of these matched-pair Sc 




and used to supply radiopure 43Sc, 44Sc, and 47Sc using a combination of enriched Ti target material 
and a future 44Ti/44Sc generator. A reliable supply of each radionuclide will support future 
preclinical investigations of different compounds that enable theranostic strategies in nuclear 
medicine.  
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